Bispecific CAR T-cells for solid tumor targeting

ABSTRACT

Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.

INCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS

This application is a division of U.S. application Ser. No. 15/750,708filed Feb. 6, 2018, which is the U.S. National Phase of Int. App. No.PCT/US2016/045360 filed Aug. 3, 2016, which designated the United Statesand was published in English and, which claims the benefit of priorityto U.S. Prov. No. 62/202,698, filed Aug. 7, 2015, which are eachincorporated herein by reference in its entirety.

REFERENCE TO SEQUENCE LISTING

The present application is being filed along with a Sequence Listing inelectronic format. The Sequence Listing is provided as a file entitledSCRI.95D1.TXT, created Oct. 13, 2020, which is 45 kb in size. Theinformation is the electronic format of the Sequence Listing isincorporated herein by reference in its entirety.

FIELD OF THE INVENTION

Aspects of the present invention described herein, include methods,cells and compositions for augmenting the therapeutic potency ofadoptively transferred chimeric antigen receptor (CAR) bearing T-cellsagainst solid tumors. In particular, methods, cells and compositions forCAR T-cell products that co-express two CARs in individual T-cells, suchas a B cell targeting “driver” CAR for promoting in vivo expansion andactivation of an effector cell, and a CAR or T-cell receptor (TcR) of adesired specificity for targeting a solid tumor (passenger CAR/TcR), areprovided herein.

BACKGROUND OF THE INVENTION

A variety of cellular therapies have been integrated into the standardmethods used in the treatment of cancer. The cellular therapy forpatients suffering from cancer or disease is the injection of cellularmaterial, such as living cells into a patient in need. This can includethe infusion of polyclonal or antigen specific T-cells, lymphokineactivated killer cells, natural killer cells, dendritic cells as well asmacrophages. Advancements have been made in the development of chimericantigen receptor (CAR) bearing T-cells for adoptive T-cell therapies forcancer therapy, which are a promising therapeutic route for cancerimmunotherapy and viral therapy.

CAR T-cell therapy is an immunotherapy in which the patient's ownT-cells are isolated in a laboratory, genetically manipulated to expressa synthetic receptor to recognize a particular antigen or protein, andreinfused into the patient. A CAR can be comprised of several domains.Without being limiting, the CAR can have 1) an antigen-binding region,typically derived from an antibody, (2) a transmembrane domain to anchorthe CAR into the T-cells, and/or (3) 1 or more intracellular T-cellsignaling domains. First-generation CARs commonly incorporated a singlechain variable fragment (scFv) that is derived from a monoclonalantibody (mAb) plus a signaling motif from a TCR chain. The second- andthird-generation CARs are an improvement over the first-generation CARswith co-stimulatory activating motifs, which can lead to the enhancedproliferation, cytotoxicity and persistence of the CAR bearing cells invivo. Clinical trials have shown some evidence of anti-tumor activity,with insufficient activation, persistence and homing to cancer tissue.Some anti-tumor responses have been reported in patients with B celllymphoma, for example, and some neuroblastoma patients have reportedpartial response, stable disease and remission. Second- andthird-generation CAR-modified T-cells have been shown to be able toprovide enhanced activation signals, proliferation, production ofcytokines and effector function of CAR-modified T-cells in pre-clinicaltrials. Initial clinical trials have been shown to exhibit somepromising results.

Unfortunately, the field of immunotherapy is unable to adequatelyaddress the problems associated with CAR bearing T-cells. Problems caninclude the suboptimal expansion and activation cells as well as toxiceffects that occur upon infusion of cells. There are several types oftoxicities that can occur with the administration of CAR T-cells.Adverse reactions can include B cell aplasia, cytokine release syndrome(CRS) and tumor lysis syndrome upon infusion of CAR bearing T-cells. Bcell aplasia can occur due to effective targeting of antigens on aB-cell. However, B cells are not a life sustaining type of tissue andcan be an initial target for CAR T-cells.

Expanding the CAR T-Cells in the body can be associated with CRS. Thesymptoms of CRS can include fever, hypotension, hypoxia, and neurologicchanges. Neurologic changes can include seizures, aphasia, and mentalstatus changes. Additional clinical and biochemical changes may occur,such as disseminated intravascular coagulation and/or transaminitisassociated with marked elevations in ferritin and C-reactive protein,which are found to be similar to macrophage activation syndrome orhemophagocytic lymphohistiocytosis (HLH).

Adverse effects can also include failure to exhibit engraftment, whichmay be due to the limited migration of infused T-cells to the sites oftumor metastasis, and the limited immunostimulatory activity of solidtumors and their immunosuppressive environment. As the development forCARs is still in its infancy, advancements in the field of CAR T-celltherapy are much needed to circumvent the adverse effects that ariseduring therapy.

SUMMARY

In a first aspect, a nucleic acid encoding a chimeric antigen receptoris provided. The nucleic acid comprises a first nucleic acid comprisinga sequence encoding a leader sequence, a second nucleic acid comprisinga sequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora B cell specific cell surface molecule, and wherein the first nucleicacid is covalently attached to a 5′ end of the second nucleic acid, athird nucleic acid comprising a sequence encoding a de-immunizedextracellular spacer, wherein the third nucleic acid is covalentlyattached to a 3′ end of the second nucleic acid, a fourth nucleic acidcomprising a sequence encoding a transmembrane domain, wherein thefourth nucleic acid is covalently attached to a 3′ end of the thirdnucleic acid, a fifth nucleic acid comprising a sequence encoding asignaling domain, wherein the signaling domain comprises a 4-1BB domainand/or CD3-zeta domain, and wherein the fifth nucleic acid is covalentlyattached to a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a linker, wherein the sixth nucleic acidis covalently attached to a 3′ end of the fifth nucleic acid and aseventh nucleic acid comprising a sequence encoding a marker domain,wherein the seventh nucleic acid is covalently attached to a 3′ end ofthe sixth nucleic acid, thereby having said nucleic acid encoding achimeric antigen receptor. In some alternatives, the linker is aribosome skip sequence or an IRES sequence. In some alternatives, theribosome skip sequence is a P2A, T2A, E2A or F2A sequence. In somealternatives, the ribosome skip sequence is T2A. In some alternatives,the T2A sequence comprises an amino acid sequence set forth in SEQ IDNO: 33 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:34. In some alternatives, the linker further comprises an IRES sequenceat the 5′ end of the linker. In some alternatives, the sequence encodingthe transmembrane domain further comprises an IRES sequence at the 3′end of the sequence encoding the transmembrane domain. In somealternatives, the B-cell specific cell surface molecule is CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the nucleic acidfurther comprises a polynucleotide encoding a suicide gene system. Insome alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the spacer is an IgG4 hinge spacer. In some alternatives,the spacer comprises an amino acid sequence set forth in SEQ ID NO: 1and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 2. Insome alternatives, the spacer comprises an amino acid sequence set forthin SEQ ID NO: 3 and is encoded by a nucleic acid sequence set forth inSEQ ID NO: 4. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 39 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 40. In some alternatives, the CD28-zetadomain comprises an amino acid sequence set forth in SEQ ID NO: 5 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 6. In somealternatives, the 4-1BB domain comprises an amino acid sequence setforth in SEQ ID NO: 7 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 8. In some alternatives, the CD3-zeta domaincomprises an amino acid sequence set forth in SEQ ID NO: 9 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 10. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule is specific for CD19. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12. In some alternatives, theantibody or binding fragment thereof or scFv specific for the B cellspecific cell surface molecule is specific for CD20. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule comprises an aminosequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. In some alternatives, the leadersequence comprises a Granulocyte-macrophage colony-stimulating factorsignal sequence. In some alternatives, the Granulocyte-macrophagecolony-stimulating factor signal sequence comprises an amino acidsequence set forth in SEQ ID NO: 29 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 30. In some alternatives, the leadersequence comprises an amino acid sequence set forth in SEQ ID NO: 31 andis encoded by a nucleic acid sequence set forth in SEQ ID NO: 32. Insome alternatives, the marker domain comprises Her2tG. In somealternatives, Her2tG comprises an amino acid sequence set forth in SEQID NO: 35 and is encoded by a nucleic acid sequence set forth in SEQ IDNO: 36. In some alternatives, the marker domain comprises EGFRt. In somealternatives, EGFRt comprises an amino acid sequence set forth in SEQ IDNO: 37 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:38.

In a second aspect, a nucleic acid encoding a chimeric antigen receptoris provided. The nucleic acid comprises a first nucleic acid comprisinga sequence encoding a leader sequence, a second nucleic acid comprisinga sequence encoding a first promoter inducible by a drug, wherein thefirst nucleic acid is covalently attached to a 5′ end of the secondnucleic acid, a third nucleic acid comprising a sequence encoding anantibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B cell specific cellsurface molecule, and wherein the third nucleic acid is covalentlyattached to a 3′ end of the second nucleic acid, a fourth nucleic acidcomprising a sequence encoding a de-immunized extracellular spacer,wherein the fourth nucleic acid is covalently attached to a 3′ end ofthe third nucleic acid, a fifth nucleic acid comprising a sequenceencoding a transmembrane domain, wherein the fifth nucleic acid iscovalently attached to a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a signaling domain, whereinthe signaling domain comprises a 4-1BB domain and/or CD3-zeta domain,and wherein the sixth nucleic acid is covalently attached to a 3′ end ofthe fifth nucleic acid, a seventh nucleic acid comprising a sequenceencoding a linker, wherein the seventh nucleic acid is covalentlyattached to a 3′ end of the sixth nucleic acid; and an eighth nucleicacid comprising a sequence encoding a marker domain, wherein the eighthnucleic acid is covalently attached to a 3′ end of the seventh nucleicacid, thereby having said nucleic acid encoding a chimeric antigenreceptor. In some alternatives, the linker is a ribosome skip sequenceor an IRES sequence. In some alternatives, the ribosome skip sequence isa P2A, T2A, E2A or F2A sequence. In some alternatives, the ribosome skipsequence is T2A. In some alternatives, the T2A sequence comprises anamino acid sequence set forth in SEQ ID NO: 33 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 34. In some alternatives,the linker further comprises an IRES sequence at the 5′ end of thelinker. In some alternatives, the first promoter is inducible bytamoxifen and/or its metabolites. In some alternatives, the firstpromoter is inducible by a drug. In some alternatives, the sequenceencoding the transmembrane domain further comprises an IRES sequence atthe 3′ end of the sequence encoding the transmembrane domain. In somealternatives, the B-cell specific cell surface molecule is CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the nucleic acidfurther comprises a polynucleotide encoding a suicide gene system. Insome alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the spacer is an IgG4 hinge spacer. In some alternatives,the spacer comprises an amino acid sequence set forth in SEQ ID NO: 1and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 2. Insome alternatives, the spacer comprises an amino acid sequence set forthin SEQ ID NO: 3 and is encoded by a nucleic acid sequence set forth inSEQ ID NO: 4. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 39 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 40. In some alternatives, the CD28-zetadomain comprises an amino acid sequence set forth in SEQ ID NO: 5 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 6. In somealternatives, the 4-1BB domain comprises an amino acid sequence setforth in SEQ ID NO: 7 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 8. In some alternatives, the CD3-zeta domaincomprises an amino acid sequence set forth in SEQ ID NO: 9 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 10. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule is specific for CD19. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12. In some alternatives, theantibody or binding fragment thereof or scFv specific for the B cellspecific cell surface molecule is specific for CD20. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule comprises an aminosequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. In some alternatives, the leadersequence comprises a Granulocyte-macrophage colony-stimulating factorsignal sequence. In some alternatives, the Granulocyte-macrophagecolony-stimulating factor signal sequence comprises an amino acidsequence set forth in SEQ ID NO: 29 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 30. In some alternatives, the leadersequence comprises an amino acid sequence set forth in SEQ ID NO: 31 andis encoded by a nucleic acid sequence set forth in SEQ ID NO: 32. Insome alternatives, the marker domain comprises Her2tG. In somealternatives, Her2tG comprises an amino acid sequence set forth in SEQID NO: 35 and is encoded by a nucleic acid sequence set forth in SEQ IDNO: 36. In some alternatives, the marker domain comprises EGFRt. In somealternatives, EGFRt comprises an amino acid sequence set forth in SEQ IDNO: 37 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:38.

In a third aspect, a nucleic acid encoding a chimeric antigen receptoris provided. The nucleic acid comprises a first nucleic acid comprisinga sequence encoding a leader sequence, a second nucleic acid comprisinga sequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora cell surface tumor specific molecule, and wherein the first nucleicacid is covalently attached at a 5′ end of the second nucleic acid, athird nucleic acid comprising a sequence encoding a de-immunizedextracellular spacer, wherein the third nucleic acid sequence iscovalently attached at a 3′ end of the second nucleic acid, a fourthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the fourth nucleic acid is covalently attached at a 3′ end ofthe third nucleic acid, a fifth nucleic acid comprising a sequenceencoding a signaling domain sequence, wherein the signaling domaincomprises a 4-1BB domain, CD3-zeta domain and/or CD28-zeta domain, andwherein the fifth nucleic acid is covalently attached at a 3′ end of thefourth nucleic acid, a sixth nucleic acid comprising a sequence encodinga linker, wherein the sixth nucleic acid is covalently attached at a 3′end of the fifth nucleic acid and a seventh nucleic acid comprising asequence encoding a marker domain, wherein the seventh nucleic acid iscovalently attached at a 3′ end of the sixth nucleic acid, therebyhaving said nucleic acid encoding a chimeric antigen receptor. In somealternatives, the linker is a ribosome skip sequence or an IRESsequence. In some alternatives, the ribosome skip sequence is a P2A,T2A, E2A or F2A sequence. In some alternatives, the ribosome skipsequence is T2A. In some alternatives, the T2A sequence comprises anamino acid sequence set forth in SEQ ID NO: 33 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 34. In some alternatives,the linker further comprises an IRES sequence at the 5′ end of thelinker. In some alternatives, the sequence encoding the transmembranedomain further comprises an IRES sequence at the 3′ end of the sequenceencoding the transmembrane domain. In some alternatives, the nucleicacid further comprises a polynucleotide encoding a suicide gene system.In some alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the cell surface tumor specific molecule is a cancerantigen. In some alternatives, the cell surface tumor specific moleculeis EGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylatedGD2, GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5,RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin,telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In some alternatives, thecancer antigen is L1CAM. In some alternatives, the cancer antigen isROR1. In some alternatives, the spacer is an IgG4 hinge spacer. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 1 and is encoded by a nucleic acid sequence set forth in SEQID NO: 2. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 3 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 4. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 39 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 40. In somealternatives, the CD28-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 5 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 6. In some alternatives, the 4-1BB domain comprisesan amino acid sequence set forth in SEQ ID NO: 7 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 8. In some alternatives,the CD3-zeta domain comprises an amino acid sequence set forth in SEQ IDNO: 9 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:10. In some alternatives, the antibody or binding fragment thereof orscFv specific for a cell surface tumor specific molecule is specific forL1CAM. In some alternatives, the antibody or binding fragment thereof orscFv specific for a cell surface tumor specific molecule is specific fora CE7 epitope on L1CAM. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 15 and is encoded by a nucleic acid sequence set forth in SEQID NO: 16. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for ROR1. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 17 and is encoded by a nucleic acid sequence set forth in SEQID NO: 18. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for EGFR 806. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 19 and is encoded by a nucleic acid sequence set forth in SEQID NO: 20. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for Her2. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 21 and is encoded by a nucleic acid sequence set forth in SEQID NO: 22. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for GD2. In some alternatives, the antibody or binding fragmentthereof or scFv comprises an amino acid sequence set forth in SEQ ID NO:23 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 24.In some alternatives, the antibody or binding fragment thereof or scFvspecific for a cell surface tumor specific molecule is specific forEphA2 (2H4). In some alternatives, the antibody or binding fragmentthereof or scFv comprises an amino acid sequence set forth in SEQ ID NO:25 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 26.In some alternatives, the antibody or binding fragment thereof or scFvspecific for a cell surface tumor specific molecule is specific forEphA2 (4H5). In some alternatives, the antibody or binding fragmentthereof or scFv comprises an amino acid sequence set forth in SEQ ID NO:27 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 28.In some alternatives, the leader sequence comprises aGranulocyte-macrophage colony-stimulating factor signal sequence. Insome alternatives, the Granulocyte-macrophage colony-stimulating factorsignal sequence comprises an amino acid sequence set forth in SEQ ID NO:29 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 30.In some alternatives, the leader sequence comprises an amino acidsequence set forth in SEQ ID NO: 31 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 32. In some alternatives, the markerdomain comprises Her2tG. In some alternatives, Her2tG comprises an aminoacid sequence set forth in SEQ ID NO: 35 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 36. In some alternatives, themarker domain comprises EGFRt. In some alternatives, EGFRt comprises anamino acid sequence set forth in SEQ ID NO: 37 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 38.

In a fourth aspect, a nucleic acid encoding a chimeric antigen receptoris provided. The nucleic acid comprises a first nucleic acid comprisinga sequence encoding a leader sequence, a second nucleic acid comprisinga sequence encoding a first promoter inducible by a drug, wherein thefirst nucleic acid is covalently attached to a 5′ end of the secondnucleic acid, a third nucleic acid comprising a sequence encoding anantibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a cell surface tumorspecific molecule, and wherein the third nucleic acid is covalentlyattached at a 3′ end of the second nucleic acid, a fourth nucleic acidcomprising a sequence encoding a de-immunized extracellular spacer,wherein the fourth nucleic acid sequence is covalently attached at a 3′end of the third nucleic acid, a fifth nucleic acid comprising asequence encoding a transmembrane domain, wherein the fifth nucleic acidis covalently attached at a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a signaling domain sequence,wherein the signaling domain comprises a 4-1BB domain, CD3-zeta domainand/or CD28-zeta domain, and wherein the sixth nucleic acid iscovalently attached at a 3′ end of the fifth nucleic acid, a seventhnucleic acid comprising a sequence encoding a linker, wherein theseventh nucleic acid is covalently attached at a 3′ end of the sixthnucleic acid and an eighth nucleic acid comprising a sequence encoding amarker domain, wherein the eighth nucleic acid is covalently attached ata 3′ end of the seventh nucleic acid, thereby having said nucleic acidencoding a chimeric antigen receptor. In some alternatives, the linkeris a ribosome skip sequence or an IRES sequence. In some alternatives,the ribosome skip sequence is a P2A, T2A, E2A or F2A sequence. In somealternatives, the ribosome skip sequence is T2A. In some alternatives,the T2A sequence comprises an amino acid sequence set forth in SEQ IDNO: 33 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:34. In some alternatives, the linker further comprises an IRES sequenceat the 5′ end of the linker. In some alternatives, the first promoter isinducible by tamoxifen and/or its metabolites. In some alternatives, thefirst promoter is inducible by a drug. In some alternatives, thesequence encoding the transmembrane domain further comprises an IRESsequence at the 3′ end of the sequence encoding the transmembranedomain. In some alternatives, the nucleic acid further comprises apolynucleotide encoding a suicide gene system. In some alternatives, thesuicide gene system is a Herpes Simplex Virus Thymidine Kinase(HSVTK)/Ganciclovir (GCV) suicide gene system or an inducible Caspasesuicide gene system. In some alternatives, the drug is a steroid, suchas a ligand for the estrogen receptor. In some alternatives, the steroidis tamoxifen and/or its metabolites. In some alternatives, the cellsurface tumor specific molecule is a cancer antigen. In somealternatives, the cell surface tumor specific molecule is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the spacer is an IgG4hinge spacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for a cell surface tumor specificmolecule is specific for L1CAM. In some alternatives, the antibody orbinding fragment thereof or scFv specific for a cell surface tumorspecific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38.

In a fifth aspect, a nucleic acid encoding a bi-specific chimericantigen receptor is provided. The nucleic acid encoding the bi-specificchimeric antigen receptor comprises a first nucleic acid sequencecomprising a sequence encoding a leader sequence, a second nucleic acidcomprising a sequence encoding an antibody or binding fragment thereofor scFv, wherein the antibody or binding fragment thereof or scFv isspecific for a B cell specific cell surface molecule or is specific fora cell surface tumor specific molecule, and wherein the first nucleicacid is covalently attached at a 5′ end of the second nucleic acid, athird nucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface moleculeor is specific for a cell surface tumor specific molecule, and whereinthe third nucleic acid is covalently attached at a 3′ end of the secondnucleic acid, a fourth nucleic acid comprising a sequence encoding ade-immunized extracellular spacer, wherein the fourth nucleic acid iscovalently attached at a 3′ end of the third nucleic acid, a fifthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the fifth nucleic acid is covalently attached at a 3′ end of thefourth nucleic acid, a sixth nucleic acid comprising a sequence encodinga signaling domain sequence, wherein the signaling domain comprises aco-stimulatory domain, wherein the co-stimulatory domain comprises a4-1BB domain, CD3-zeta domain and/or CD28-zeta domain and wherein thesixth nucleic acid is covalently attached at a 3′ end of the fifthnucleic acid, a seventh nucleic acid comprising a sequence encoding alinker, wherein the seventh nucleic acid is covalently attached at a 3′end of the sixth nucleic acid and an eighth nucleic acid comprising asequence encoding a marker domain, wherein the eighth nucleic acid iscovalently attached at a 3′ end of the seventh nucleic acid, therebyhaving said nucleic acid encoding a bi-specific chimeric antigenreceptor. In some alternatives, the linker is a ribosome skip sequenceor an IRES sequence. In some alternatives, the ribosome skip sequence isa P2A, T2A, E2A or F2A sequence. In some alternatives, the ribosome skipsequence is T2A. In some alternatives, the T2A sequence comprises anamino acid sequence set forth in SEQ ID NO: 33 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 34. In some alternatives,the linker further comprises an IRES sequence at the 5′ end of thelinker. In some alternatives, the sequence encoding the transmembranedomain further comprises an IRES sequence at the 3′ end of the sequenceencoding the transmembrane domain. In some alternatives, the B-cellspecific cell surface molecule is CD1d, CD5, CD19, CD20, CD21, CD22,CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32, CD34,CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54 (ICAM-1),CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA, B-cell receptor(BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5, BAFFR/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1,HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, or EMMPRIN/CD147. Insome alternatives, the nucleic acid further comprises a polynucleotideencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the drug is a steroid, such as a ligand for theestrogen receptor. In some alternatives, the steroid is tamoxifen and/orits metabolites. In some alternatives, the cell surface tumor specificmolecule is a cancer antigen. In some alternatives, the cell surfacetumor specific molecule is EGFR, HER2, Mesothelin, cancer testisantigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2, glypican-2(GPC2), HPV antigens, alphafetoprotein, carcinoembryonic antigen,CA-125, MUC-1, epithelial tumor antigen, abnormal products of ras orp53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin, AIM2,ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3,EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In some alternatives, the cancerantigen is L1CAM. In some alternatives, the cancer antigen is ROR1. Insome alternatives, the spacer is an IgG4 hinge spacer. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 1 and is encoded by a nucleic acid sequence set forth in SEQID NO: 2. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 3 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 4. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 39 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 40. In somealternatives, the CD28-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 5 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 6. In some alternatives, the 4-1BB domain comprisesan amino acid sequence set forth in SEQ ID NO: 7 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 8. In some alternatives,the CD3-zeta domain comprises an amino acid sequence set forth in SEQ IDNO: 9 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:10. In some alternatives, the antibody or binding fragment thereof orscFv specific for the B cell specific cell surface molecule is specificfor CD19. In some alternatives, the antibody or binding fragment thereofor scFv specific for the B cell specific cell surface molecule comprisesan amino sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12. In some alternatives, theantibody or binding fragment thereof or scFv specific for the B cellspecific cell surface molecule is specific for CD20. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule comprises an aminosequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. In some alternatives, the antibodyor binding fragment thereof or scFv specific for a cell surface tumorspecific molecule is specific for L1CAM. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38.

In a sixth aspect, a nucleic acid encoding a bi-specific chimericantigen receptor is provided. The nucleic acid comprises a first nucleicacid comprising a sequence encoding a leader sequence, a second nucleicacid comprising a sequence encoding a first promoter inducible by adrug, wherein the first nucleic acid is covalently attached to a 5′ endof the second nucleic acid, a third nucleic acid comprising a sequenceencoding an antibody or binding fragment thereof or scFv, wherein theantibody or binding fragment thereof or scFv is specific for a B cellspecific cell surface molecule or is specific for a cell surface tumorspecific molecule, and wherein the third nucleic acid is covalentlyattached at a 3′ end of the second nucleic acid, a fourth nucleic acidcomprising a sequence encoding an antibody or binding fragment thereofor scFv, wherein the antibody or binding fragment thereof or scFv isspecific for a B cell specific cell surface molecule or is specific fora cell surface tumor specific molecule, and wherein the fourth nucleicacid is covalently attached at a 3′ end of the third nucleic acid, afifth nucleic acid comprising a sequence encoding a de-immunizedextracellular spacer, wherein the fifth nucleic acid is covalentlyattached at a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a transmembrane domain, wherein the sixthnucleic acid is covalently attached at a 3′ end of the fifth nucleicacid, a seventh nucleic acid comprising a sequence encoding a signalingdomain sequence, wherein the signaling domain comprises a co-stimulatorydomain, wherein the co-stimulatory domain comprises a 4-1BB domain,CD3-zeta domain and/or CD28-zeta domain and wherein the seventh nucleicacid is covalently attached at a 3′ end of the sixth nucleic acid, aneighth nucleic acid comprising a sequence encoding a linker, wherein theeighth nucleic acid is covalently attached at a 3′ end of the seventhnucleic acid, and a ninth nucleic acid comprising a sequence encoding amarker domain, wherein the ninth nucleic acid is covalently attached ata 3′ end of the eighth nucleic acid, thereby having said nucleic acidencoding a bi-specific chimeric antigen receptor. In some alternatives,the linker is a ribosome skip sequence or an IRES sequence. In somealternatives, the ribosome skip sequence is a P2A, T2A, E2A or F2Asequence. In some alternatives, the ribosome skip sequence is T2A. Insome alternatives, the T2A sequence comprises an amino acid sequence setforth in SEQ ID NO: 33 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 34. In some alternatives, the linker furthercomprises an IRES sequence at the 5′ end of the linker. In somealternatives, the first promoter is inducible by tamoxifen and/or itsmetabolites. In some alternatives, the first promoter is inducible by adrug. In some alternatives, the sequence encoding the transmembranedomain further comprises an IRES sequence at the 3′ end of the sequenceencoding the transmembrane domain. In some alternatives, the B-cellspecific cell surface molecule is CD1d, CD5, CD19, CD20, CD21, CD22,CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32, CD34,CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54 (ICAM-1),CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA, B-cell receptor(BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5, BAFFR/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1,HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, or EMMPRIN/CD147. Insome alternatives, the nucleic acid further comprises a polynucleotideencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the drug is a steroid, such as a ligand for theestrogen receptor. In some alternatives, the steroid is tamoxifen and/orits metabolites. In some alternatives, the cell surface tumor specificmolecule is a cancer antigen. In some alternatives, the cell surfacetumor specific molecule is EGFR, HER2, Mesothelin, cancer testisantigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2, glypican-2(GPC2), HPV antigens, alphafetoprotein, carcinoembryonic antigen,CA-125, MUC-1, epithelial tumor antigen, abnormal products of ras orp53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin, AIM2,ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3,EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In some alternatives, the cancerantigen is L1CAM. In some alternatives, the cancer antigen is ROR1. Insome alternatives, the spacer is an IgG4 hinge spacer. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 1 and is encoded by a nucleic acid sequence set forth in SEQID NO: 2. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 3 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 4. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 39 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 40. In somealternatives, the CD28-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 5 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 6. In some alternatives, the 4-1BB domain comprisesan amino acid sequence set forth in SEQ ID NO: 7 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 8. In some alternatives,the CD3-zeta domain comprises an amino acid sequence set forth in SEQ IDNO: 9 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:10. In some alternatives, the antibody or binding fragment thereof orscFv specific for the B cell specific cell surface molecule is specificfor CD19. In some alternatives, the antibody or binding fragment thereofor scFv specific for the B cell specific cell surface molecule comprisesan amino sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12. In some alternatives, theantibody or binding fragment thereof or scFv specific for the B cellspecific cell surface molecule is specific for CD20. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule comprises an aminosequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. In some alternatives, the antibodyor binding fragment thereof or scFv specific for a cell surface tumorspecific molecule is specific for L1CAM. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38.

In a seventh aspect, a vector for expression of a chimeric antigenreceptor specific for promoting in vivo expansion and activation of Bcells is provided. The vector can comprise the nucleic acid of any oneof the alternatives described herein. In some alternatives, the nucleicacid comprises a first nucleic acid comprising a sequence encoding aleader sequence, a second nucleic acid comprising a sequence encoding anantibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B cell specific cellsurface molecule, and wherein the first nucleic acid is covalentlyattached to a 5′ end of the second nucleic acid, a third nucleic acidcomprising a sequence encoding a de-immunized extracellular spacer,wherein the third nucleic acid is covalently attached to a 3′ end of thesecond nucleic acid, a fourth nucleic acid comprising a sequenceencoding a transmembrane domain, wherein the fourth nucleic acid iscovalently attached to a 3′ end of the third nucleic acid, a fifthnucleic acid comprising a sequence encoding a signaling domain, whereinthe signaling domain comprises a 4-1BB domain and/or CD3-zeta domain,and wherein the fifth nucleic acid is covalently attached to a 3′ end ofthe fourth nucleic acid, a sixth nucleic acid comprising a sequenceencoding a linker, wherein the sixth nucleic acid is covalently attachedto a 3′ end of the fifth nucleic acid and a seventh nucleic acidcomprising a sequence encoding a marker domain, wherein the seventhnucleic acid is covalently attached to a 3′ end of the sixth nucleicacid, thereby having said nucleic acid encoding a chimeric antigenreceptor. In some alternatives, the nucleic acid comprises a firstnucleic acid comprising a sequence encoding a leader sequence, a secondnucleic acid comprising a sequence encoding a first promoter inducibleby a drug, wherein the first nucleic acid is covalently attached to a 5′end of the second nucleic acid, a third nucleic acid comprising asequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora B cell specific cell surface molecule, and wherein the third nucleicacid is covalently attached to a 3′ end of the second nucleic acid, afourth nucleic acid comprising a sequence encoding a de-immunizedextracellular spacer, wherein the fourth nucleic acid is covalentlyattached to a 3′ end of the third nucleic acid, a fifth nucleic acidcomprising a sequence encoding a transmembrane domain, wherein the fifthnucleic acid is covalently attached to a 3′ end of the fourth nucleicacid, a sixth nucleic acid comprising a sequence encoding a signalingdomain, wherein the signaling domain comprises a 4-1BB domain and/orCD3-zeta domain, and wherein the sixth nucleic acid is covalentlyattached to a 3′ end of the fifth nucleic acid, a seventh nucleic acidcomprising a sequence encoding a linker, wherein the seventh nucleicacid is covalently attached to a 3′ end of the sixth nucleic acid; andan eighth nucleic acid comprising a sequence encoding a marker domain,wherein the eighth nucleic acid is covalently attached to a 3′ end ofthe seventh nucleic acid, thereby having said nucleic acid encoding achimeric antigen receptor. In some alternatives, the linker is aribosome skip sequence or an IRES sequence. In some alternatives, theribosome skip sequence is a P2A, T2A, E2A or F2A sequence. In somealternatives, the ribosome skip sequence is T2A. In some alternatives,the T2A sequence comprises an amino acid sequence set forth in SEQ IDNO: 33 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:34. In some alternatives, the linker further comprises an IRES sequenceat the 5′ end of the linker. In some alternatives, the first promoter isinducible by tamoxifen and/or its metabolites. In some alternatives, thefirst promoter is inducible by a drug. In some alternatives, thesequence encoding the transmembrane domain further comprises an IRESsequence at the 3′ end of the sequence encoding the transmembranedomain. In some alternatives, the B-cell specific cell surface moleculeis CD1d, CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24,CD25/IL-2 R alphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5),CD44, CD45, CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80,CD84/SLAMF5, LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD,B220/CD45R, C1q R1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R,B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14,BLIMP1/PRDM1, CXCR4, DEP-1/CD148, or EMMPRIN/CD147. In somealternatives, the nucleic acid further comprises a polynucleotideencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the drug is a steroid, such as a ligand for theestrogen receptor. In some alternatives, the steroid is tamoxifen and/orits metabolites. In some alternatives, the spacer is an IgG4 hingespacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for the B cell specific cell surfacemolecule is specific for CD19. In some alternatives, the antibody orbinding fragment thereof or scFv specific for the B cell specific cellsurface molecule comprises an amino sequence set forth in SEQ ID NO: 11and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 12. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule is specific forCD20. In some alternatives, the antibody or binding fragment thereof orscFv specific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 13 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 14. The leader sequence cancomprise a Granulocyte-macrophage colony-stimulating factor signalsequence. In some alternatives, the Granulocyte-macrophagecolony-stimulating factor signal sequence comprises an amino acidsequence set forth in SEQ ID NO: 29 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 30. In some alternatives, the leadersequence comprises an amino acid sequence set forth in SEQ ID NO: 31 andis encoded by a nucleic acid sequence set forth in SEQ ID NO: 32. Insome alternatives, the marker domain comprises Her2tG. In somealternatives, Her2tG comprises an amino acid sequence set forth in SEQID NO: 35 and is encoded by a nucleic acid sequence set forth in SEQ IDNO: 36. In some alternatives, the marker domain comprises EGFRt. In somealternatives, EGFRt comprises an amino acid sequence set forth in SEQ IDNO: 37 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:38. The vector can be a viral vector in some alternatives. In somealternatives, the vector is a lentiviral vector, retroviral vector,gammaretroviral vectors or a foamy viral vector. In some alternatives,the vector is a transposon, integrase vector system, or an mRNA vector.

In an eighth aspect, a vector for expression of a chimeric antigenreceptor or TcR specific for targeting a solid tumor is provided. Thevector can comprise the nucleic acid of any one of the alternativesdescribed herein. In some alternatives, the nucleic acid comprises afirst nucleic acid comprising a sequence encoding a leader sequence, asecond nucleic acid comprising a sequence encoding an antibody orbinding fragment thereof or scFv, wherein the antibody or bindingfragment thereof or scFv is specific for a cell surface tumor specificmolecule, and wherein the first nucleic acid is covalently attached at a5′ end of the second nucleic acid, a third nucleic acid comprising asequence encoding a de-immunized extracellular spacer, wherein the thirdnucleic acid sequence is covalently attached at a 3′ end of the secondnucleic acid, a fourth nucleic acid comprising a sequence encoding atransmembrane domain, wherein the fourth nucleic acid is covalentlyattached at a 3′ end of the third nucleic acid, a fifth nucleic acidcomprising a sequence encoding a signaling domain sequence, wherein thesignaling domain comprises a 4-1BB domain, CD3-zeta domain and/orCD28-zeta domain, and wherein the fifth nucleic acid is covalentlyattached at a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a linker, wherein the sixth nucleic acidis covalently attached at a 3′ end of the fifth nucleic acid and aseventh nucleic acid comprising a sequence encoding a marker domain,wherein the seventh nucleic acid is covalently attached at a 3′ end ofthe sixth nucleic acid, thereby having said nucleic acid encoding achimeric antigen receptor. In some alternatives, the nucleic acidcomprises a first nucleic acid comprising a sequence encoding a leadersequence, a second nucleic acid comprising a sequence encoding a firstpromoter inducible by a drug, wherein the first nucleic acid iscovalently attached to a 5′ end of the second nucleic acid, a thirdnucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a cell surface tumor specific molecule,and wherein the third nucleic acid is covalently attached at a 3′ end ofthe second nucleic acid, a fourth nucleic acid comprising a sequenceencoding a de-immunized extracellular spacer, wherein the fourth nucleicacid sequence is covalently attached at a 3′ end of the third nucleicacid, a fifth nucleic acid comprising a sequence encoding atransmembrane domain, wherein the fifth nucleic acid is covalentlyattached at a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a signaling domain sequence, wherein thesignaling domain comprises a 4-1BB domain, CD3-zeta domain and/orCD28-zeta domain, and wherein the sixth nucleic acid is covalentlyattached at a 3′ end of the fifth nucleic acid, a seventh nucleic acidcomprising a sequence encoding a linker, wherein the seventh nucleicacid is covalently attached at a 3′ end of the sixth nucleic acid and aneighth nucleic acid comprising a sequence encoding a marker domain,wherein the eighth nucleic acid is covalently attached at a 3′ end ofthe seventh nucleic acid, thereby having said nucleic acid encoding achimeric antigen receptor. In some alternatives, the linker is aribosome skip sequence or an IRES sequence. In some alternatives, theribosome skip sequence is a P2A, T2A, E2A or F2A sequence. In somealternatives, the ribosome skip sequence is T2A. In some alternatives,the T2A sequence comprises an amino acid sequence set forth in SEQ IDNO: 33 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:34. In some alternatives, the linker further comprises an IRES sequenceat the 5′ end of the linker. In some alternatives, the first promoter isinducible by tamoxifen and/or its metabolites. In some alternatives, thefirst promoter is inducible by a drug. In some alternatives, thesequence encoding the transmembrane domain further comprises an IRESsequence at the 3′ end of the sequence encoding the transmembranedomain. In some alternatives, the nucleic acid further comprises apolynucleotide encoding a suicide gene system. In some alternatives, thesuicide gene system is a Herpes Simplex Virus Thymidine Kinase(HSVTK)/Ganciclovir (GCV) suicide gene system or an inducible Caspasesuicide gene system. In some alternatives, the drug is a steroid, suchas a ligand for the estrogen receptor. In some alternatives, the steroidis tamoxifen and/or its metabolites. In some alternatives, the cellsurface tumor specific molecule is a cancer antigen. In somealternatives, the cell surface tumor specific molecule is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the spacer is an IgG4hinge spacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for a cell surface tumor specificmolecule is specific for L1CAM. In some alternatives, the antibody orbinding fragment thereof or scFv specific for a cell surface tumorspecific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives,Granulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38. The vector can be a viralvector in some alternatives. In some alternatives, the vector is alentiviral vector, retroviral vector, gammaretroviral vectors or a foamyviral vector. In some alternatives, the vector is a transposon,integrase vector system, or an mRNA vector.

In a ninth aspect, a vector for expression of a bi-specific chimericantigen receptor is provided. The bi-specific chimeric antigen receptoris specific for a B cell specific cell surface molecule and is specificfor a cell surface tumor specific molecule. The vector can comprise thenucleic acid of any one of the alternatives described herein. In somealternatives, the nucleic acid encoding the bi-specific chimeric antigenreceptor comprises a first nucleic acid sequence comprising a sequenceencoding a leader sequence, a second nucleic acid comprising a sequenceencoding an antibody or binding fragment thereof or scFv, wherein theantibody or binding fragment thereof or scFv is specific for a B cellspecific cell surface molecule or is specific for a cell surface tumorspecific molecule, and wherein the first nucleic acid is covalentlyattached at a 5′ end of the second nucleic acid, a third nucleic acidcomprising a sequence encoding an antibody or binding fragment thereofor scFv, wherein the antibody or binding fragment thereof or scFv isspecific for a B cell specific cell surface molecule or is specific fora cell surface tumor specific molecule, and wherein the third nucleicacid is covalently attached at a 3′ end of the second nucleic acid, afourth nucleic acid comprising a sequence encoding a de-immunizedextracellular spacer, wherein the fourth nucleic acid is covalentlyattached at a 3′ end of the third nucleic acid, a fifth nucleic acidcomprising a sequence encoding a transmembrane domain, wherein the fifthnucleic acid is covalently attached at a 3′ end of the fourth nucleicacid, a sixth nucleic acid comprising a sequence encoding a signalingdomain sequence, wherein the signaling domain comprises a co-stimulatorydomain, wherein the co-stimulatory domain comprises a 4-1BB domain,CD3-zeta domain and/or CD28-zeta domain and wherein the sixth nucleicacid is covalently attached at a 3′ end of the fifth nucleic acid, aseventh nucleic acid comprising a sequence encoding a linker, whereinthe seventh nucleic acid is covalently attached at a 3′ end of the sixthnucleic acid and an eighth nucleic acid comprising a sequence encoding amarker domain, wherein the eighth nucleic acid is covalently attached ata 3′ end of the seventh nucleic acid, thereby having said nucleic acidencoding a bi-specific chimeric antigen receptor. In some alternatives,the nucleic acid comprises a first nucleic acid comprising a sequenceencoding a leader sequence, a second nucleic acid comprising a sequenceencoding a first promoter inducible by a drug, wherein the first nucleicacid is covalently attached to a 5′ end of the second nucleic acid, athird nucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface moleculeor is specific for a cell surface tumor specific molecule, and whereinthe third nucleic acid is covalently attached at a 3′ end of the secondnucleic acid, a fourth nucleic acid comprising a sequence encoding anantibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B cell specific cellsurface molecule or is specific for a cell surface tumor specificmolecule, and wherein the fourth nucleic acid is covalently attached ata 3′ end of the third nucleic acid, a fifth nucleic acid comprising asequence encoding a de-immunized extracellular spacer, wherein the fifthnucleic acid is covalently attached at a 3′ end of the fourth nucleicacid, a sixth nucleic acid comprising a sequence encoding atransmembrane domain, wherein the sixth nucleic acid is covalentlyattached at a 3′ end of the fifth nucleic acid, a seventh nucleic acidcomprising a sequence encoding a signaling domain sequence, wherein thesignaling domain comprises a co-stimulatory domain, wherein theco-stimulatory domain comprises a 4-1BB domain, CD3-zeta domain and/orCD28-zeta domain and wherein the seventh nucleic acid is covalentlyattached at a 3′ end of the sixth nucleic acid, an eighth nucleic acidcomprising a sequence encoding a linker, wherein the eighth nucleic acidis covalently attached at a 3′ end of the seventh nucleic acid, and aninth nucleic acid comprising a sequence encoding a marker domain,wherein the ninth nucleic acid is covalently attached at a 3′ end of theeighth nucleic acid, thereby having said nucleic acid encoding abi-specific chimeric antigen receptor. In some alternatives, the linkeris a ribosome skip sequence or an IRES sequence. In some alternatives,the ribosome skip sequence is a P2A, T2A, E2A or F2A sequence. In somealternatives, the ribosome skip sequence is T2A. In some alternatives,the T2A sequence comprises an amino acid sequence set forth in SEQ IDNO: 33 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:34. In some alternatives, the linker further comprises an IRES sequenceat the 5′ end of the linker. In some alternatives, the first promoter isinducible by tamoxifen and/or its metabolites. In some alternatives, thefirst promoter is inducible by a drug. In some alternatives, thesequence encoding the transmembrane domain further comprises an IRESsequence at the 3′ end of the sequence encoding the transmembranedomain. In some alternatives, the B-cell specific cell surface moleculeis CD1d, CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24,CD25/IL-2 R alphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5),CD44, CD45, CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80,CD84/SLAMF5, LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD,B220/CD45R, C1q R1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R,B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14,BLIMP1/PRDM1, CXCR4, DEP-1/CD148, or EMMPRIN/CD147. In somealternatives, the nucleic acid further comprises a polynucleotideencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the drug is a steroid, such as a ligand for theestrogen receptor. In some alternatives, the steroid is tamoxifen and/orits metabolites. In some alternatives, the cell surface tumor specificmolecule is a cancer antigen. In some alternatives, the cell surfacetumor specific molecule is EGFR, HER2, Mesothelin, cancer testisantigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2, glypican-2(GPC2), HPV antigens, alphafetoprotein, carcinoembryonic antigen,CA-125, MUC-1, epithelial tumor antigen, abnormal products of ras orp53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin, AIM2,ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3,EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In some alternatives, the cancerantigen is L1CAM. In some alternatives, the cancer antigen is ROR1. Insome alternatives, the spacer is an IgG4 hinge spacer. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 1 and is encoded by a nucleic acid sequence set forth in SEQID NO: 2. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 3 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 4. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 39 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 40. In somealternatives, the CD28-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 5 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 6. In some alternatives, the 4-1BB domain comprisesan amino acid sequence set forth in SEQ ID NO: 7 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 8. In some alternatives,the CD3-zeta domain comprises an amino acid sequence set forth in SEQ IDNO: 9 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:10. In some alternatives, the antibody or binding fragment thereof orscFv specific for the B cell specific cell surface molecule is specificfor CD19. In some alternatives, the antibody or binding fragment thereofor scFv specific for the B cell specific cell surface molecule comprisesan amino sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12. In some alternatives, theantibody or binding fragment thereof or scFv specific for the B cellspecific cell surface molecule is specific for CD20. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule comprises an aminosequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. In some alternatives, the antibodyor binding fragment thereof or scFv specific for a cell surface tumorspecific molecule is specific for L1CAM. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38. In some alternatives, thevector is a viral vector. In some alternatives, the vector is alentiviral vector, retroviral vector, gammaretroviral vectors or a foamyviral vector. In some alternatives, the vector is a transposon,integrase vector system, or an mRNA vector.

In a tenth aspect, a chimeric antigen receptor or TcR specific for aB-cell specific cell surface molecule encoded by a nucleic acid orvector of any one of the alternatives described herein is provided. Thevector can comprise the nucleic acid of any one of the alternativesdescribed herein. In some alternatives, the nucleic acid comprises afirst nucleic acid comprising a sequence encoding a leader sequence, asecond nucleic acid comprising a sequence encoding an antibody orbinding fragment thereof or scFv, wherein the antibody or bindingfragment thereof or scFv is specific for a B cell specific cell surfacemolecule, and wherein the first nucleic acid is covalently attached to a5′ end of the second nucleic acid, a third nucleic acid comprising asequence encoding a de-immunized extracellular spacer, wherein the thirdnucleic acid is covalently attached to a 3′ end of the second nucleicacid, a fourth nucleic acid comprising a sequence encoding atransmembrane domain, wherein the fourth nucleic acid is covalentlyattached to a 3′ end of the third nucleic acid, a fifth nucleic acidcomprising a sequence encoding a signaling domain, wherein the signalingdomain comprises a 4-1BB domain and/or CD3-zeta domain, and wherein thefifth nucleic acid is covalently attached to a 3′ end of the fourthnucleic acid, a sixth nucleic acid comprising a sequence encoding alinker, wherein the sixth nucleic acid is covalently attached to a 3′end of the fifth nucleic acid and a seventh nucleic acid comprising asequence encoding a marker domain, wherein the seventh nucleic acid iscovalently attached to a 3′ end of the sixth nucleic acid, therebyhaving said nucleic acid encoding a chimeric antigen receptor. In somealternatives, the nucleic acid comprises a first nucleic acid comprisinga sequence encoding a leader sequence, a second nucleic acid comprisinga sequence encoding a first promoter inducible by a drug, wherein thefirst nucleic acid is covalently attached to a 5′ end of the secondnucleic acid, a third nucleic acid comprising a sequence encoding anantibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B cell specific cellsurface molecule, and wherein the third nucleic acid is covalentlyattached to a 3′ end of the second nucleic acid, a fourth nucleic acidcomprising a sequence encoding a de-immunized extracellular spacer,wherein the fourth nucleic acid is covalently attached to a 3′ end ofthe third nucleic acid, a fifth nucleic acid comprising a sequenceencoding a transmembrane domain, wherein the fifth nucleic acid iscovalently attached to a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a signaling domain, whereinthe signaling domain comprises a 4-1BB domain and/or CD3-zeta domain,and wherein the sixth nucleic acid is covalently attached to a 3′ end ofthe fifth nucleic acid, a seventh nucleic acid comprising a sequenceencoding a linker, wherein the seventh nucleic acid is covalentlyattached to a 3′ end of the sixth nucleic acid; and an eighth nucleicacid comprising a sequence encoding a marker domain, wherein the eighthnucleic acid is covalently attached to a 3′ end of the seventh nucleicacid, thereby having said nucleic acid encoding a chimeric antigenreceptor. In some alternatives, the linker is a ribosome skip sequenceor an IRES sequence. In some alternatives, the ribosome skip sequence isa P2A, T2A, E2A or F2A sequence. In some alternatives, the ribosome skipsequence is T2A. In some alternatives, the T2A sequence comprises anamino acid sequence set forth in SEQ ID NO: 33 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 34. In some alternatives,the linker further comprises an IRES sequence at the 5′ end of thelinker. In some alternatives, the first promoter is inducible bytamoxifen and/or its metabolites. In some alternatives, the firstpromoter is inducible by a drug. In some alternatives, the sequenceencoding the transmembrane domain further comprises an IRES sequence atthe 3′ end of the sequence encoding the transmembrane domain. In somealternatives, the B-cell specific cell surface molecule is CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the nucleic acidfurther comprises a polynucleotide encoding a suicide gene system. Insome alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the spacer is an IgG4 hinge spacer. In some alternatives,the spacer comprises an amino acid sequence set forth in SEQ ID NO: 1and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 2. Insome alternatives, the spacer comprises an amino acid sequence set forthin SEQ ID NO: 3 and is encoded by a nucleic acid sequence set forth inSEQ ID NO: 4. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 39 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 40. In some alternatives, the CD28-zetadomain comprises an amino acid sequence set forth in SEQ ID NO: 5 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 6. In somealternatives, the 4-1BB domain comprises an amino acid sequence setforth in SEQ ID NO: 7 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 8. In some alternatives, the CD3-zeta domaincomprises an amino acid sequence set forth in SEQ ID NO: 9 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 10. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule is specific for CD19. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12. In some alternatives, theantibody or binding fragment thereof or scFv specific for the B cellspecific cell surface molecule is specific for CD20. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule comprises an aminosequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. The leader sequence comprises aGranulocyte-macrophage colony-stimulating factor signal sequence in somealternatives. In some alternatives, the Granulocyte-macrophagecolony-stimulating factor signal sequence comprises an amino acidsequence set forth in SEQ ID NO: 29 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 30. In some alternatives, the leadersequence comprises an amino acid sequence set forth in SEQ ID NO: 31 andis encoded by a nucleic acid sequence set forth in SEQ ID NO: 32. Insome alternatives, the marker domain comprises Her2tG. In somealternatives, Her2tG comprises an amino acid sequence set forth in SEQID NO: 35 and is encoded by a nucleic acid sequence set forth in SEQ IDNO: 36. In some alternatives, the marker domain comprises EGFRt. In somealternatives, EGFRt comprises an amino acid sequence set forth in SEQ IDNO: 37 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:38. In some alternatives, the vector is a viral vector. In somealternatives, the vector is a lentiviral vector, retroviral vector,gammaretroviral vectors or a foamy viral vector. In some alternatives,the vector is a transposon, integrase vector system, or an mRNA vector.

In an eleventh aspect, a chimeric antigen receptor or TcR specific fortargeting a solid tumor, encoded by a nucleic acid or vector of any oneof the alternatives described herein, is provided. The vector cancomprise the nucleic acid of any one of the alternatives describedherein. In some alternatives, the nucleic acid comprises a first nucleicacid comprising a sequence encoding a leader sequence, a second nucleicacid comprising a sequence encoding an antibody or binding fragmentthereof or scFv, wherein the antibody or binding fragment thereof orscFv is specific for a cell surface tumor specific molecule, and whereinthe first nucleic acid is covalently attached at a 5′ end of the secondnucleic acid, a third nucleic acid comprising a sequence encoding ade-immunized extracellular spacer, wherein the third nucleic acidsequence is covalently attached at a 3′ end of the second nucleic acid,a fourth nucleic acid comprising a sequence encoding a transmembranedomain, wherein the fourth nucleic acid is covalently attached at a 3′end of the third nucleic acid, a fifth nucleic acid comprising asequence encoding a signaling domain sequence, wherein the signalingdomain comprises a 4-1BB domain, CD3-zeta domain and/or CD28-zetadomain, and wherein the fifth nucleic acid is covalently attached at a3′ end of the fourth nucleic acid, a sixth nucleic acid comprising asequence encoding a linker, wherein the sixth nucleic acid is covalentlyattached at a 3′ end of the fifth nucleic acid and a seventh nucleicacid comprising a sequence encoding a marker domain, wherein the seventhnucleic acid is covalently attached at a 3′ end of the sixth nucleicacid, thereby having said nucleic acid encoding a chimeric antigenreceptor. In some alternatives, the nucleic acid comprises a firstnucleic acid comprising a sequence encoding a leader sequence, a secondnucleic acid comprising a sequence encoding a first promoter inducibleby a drug, wherein the first nucleic acid is covalently attached to a 5′end of the second nucleic acid, a third nucleic acid comprising asequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora cell surface tumor specific molecule, and wherein the third nucleicacid is covalently attached at a 3′ end of the second nucleic acid, afourth nucleic acid comprising a sequence encoding a de-immunizedextracellular spacer, wherein the fourth nucleic acid sequence iscovalently attached at a 3′ end of the third nucleic acid, a fifthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the fifth nucleic acid is covalently attached at a 3′ end of thefourth nucleic acid, a sixth nucleic acid comprising a sequence encodinga signaling domain sequence, wherein the signaling domain comprises a4-1BB domain, CD3-zeta domain and/or CD28-zeta domain, and wherein thesixth nucleic acid is covalently attached at a 3′ end of the fifthnucleic acid, a seventh nucleic acid comprising a sequence encoding alinker, wherein the seventh nucleic acid is covalently attached at a 3′end of the sixth nucleic acid and an eighth nucleic acid comprising asequence encoding a marker domain, wherein the eighth nucleic acid iscovalently attached at a 3′ end of the seventh nucleic acid, therebyhaving said nucleic acid encoding a chimeric antigen receptor. In somealternatives, the linker is a ribosome skip sequence or an IRESsequence. In some alternatives, the ribosome skip sequence is a P2A,T2A, E2A or F2A sequence. In some alternatives, the ribosome skipsequence is T2A. In some alternatives, the T2A sequence comprises anamino acid sequence set forth in SEQ ID NO: 33 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 34. In some alternatives,the linker further comprises an IRES sequence at the 5′ end of thelinker. In some alternatives, the first promoter is inducible bytamoxifen and/or its metabolites. In some alternatives, the firstpromoter is inducible by a drug. In some alternatives, the sequenceencoding the transmembrane domain further comprises an IRES sequence atthe 3′ end of the sequence encoding the transmembrane domain. In somealternatives, the nucleic acid further comprises a polynucleotideencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the drug is a steroid, such as a ligand for theestrogen receptor. In some alternatives, the steroid is tamoxifen and/orits metabolites. In some alternatives, the cell surface tumor specificmolecule is a cancer antigen. In some alternatives, the cell surfacetumor specific molecule is EGFR, HER2, Mesothelin, cancer testisantigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2, glypican-2(GPC2), HPV antigens, alphafetoprotein, carcinoembryonic antigen,CA-125, MUC-1, epithelial tumor antigen, abnormal products of ras orp53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin, AIM2,ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3,EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In some alternatives, the cancerantigen is L1CAM. In some alternatives, the cancer antigen is ROR1. Insome alternatives, the spacer is an IgG4 hinge spacer. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 1 and is encoded by a nucleic acid sequence set forth in SEQID NO: 2. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 3 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 4. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 39 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 40. In somealternatives, the CD28-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 5 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 6. In some alternatives, the 4-1BB domain comprisesan amino acid sequence set forth in SEQ ID NO: 7 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 8. In some alternatives,the CD3-zeta domain comprises an amino acid sequence set forth in SEQ IDNO: 9 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:10. In some alternatives, the antibody or binding fragment thereof orscFv specific for a cell surface tumor specific molecule is specific forL1CAM. In some alternatives, the antibody or binding fragment thereof orscFv specific for a cell surface tumor specific molecule is specific fora CE7 epitope on L1CAM. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 15 and is encoded by a nucleic acid sequence set forth in SEQID NO: 16. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for ROR1. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 17 and is encoded by a nucleic acid sequence set forth in SEQID NO: 18. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for EGFR 806. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 19 and is encoded by a nucleic acid sequence set forth in SEQID NO: 20. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for Her2. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 21 and is encoded by a nucleic acid sequence set forth in SEQID NO: 22. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for GD2. In some alternatives, the antibody or binding fragmentthereof or scFv comprises an amino acid sequence set forth in SEQ ID NO:23 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 24.In some alternatives, the antibody or binding fragment thereof or scFvspecific for a cell surface tumor specific molecule is specific forEphA2 (2H4). In some alternatives, the antibody or binding fragmentthereof or scFv comprises an amino acid sequence set forth in SEQ ID NO:25 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 26.In some alternatives, the antibody or binding fragment thereof or scFvspecific for a cell surface tumor specific molecule is specific forEphA2 (4H5). In some alternatives, the antibody or binding fragmentthereof or scFv comprises an amino acid sequence set forth in SEQ ID NO:27 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 28.In some alternatives, the leader sequence comprises aGranulocyte-macrophage colony-stimulating factor signal sequence. Insome alternatives, Granulocyte-macrophage colony-stimulating factorsignal sequence comprises an amino acid sequence set forth in SEQ ID NO:29 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 30.In some alternatives, the leader sequence comprises an amino acidsequence set forth in SEQ ID NO: 31 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 32. In some alternatives, the markerdomain comprises Her2tG. In some alternatives, Her2tG comprises an aminoacid sequence set forth in SEQ ID NO: 35 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 36. In some alternatives, themarker domain comprises EGFRt. In some alternatives, EGFRt comprises anamino acid sequence set forth in SEQ ID NO: 37 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 38. The vector is a viralvector in some alternatives. In some alternatives, the vector is alentiviral vector, retroviral vector, gammaretroviral vectors or a foamyviral vector. In some alternatives, the vector is a transposon,integrase vector system, or an mRNA vector.

In a twelfth aspect, a bi-specific chimeric antigen receptor specificfor a B cell specific cell surface molecule and specific for a cellsurface tumor specific molecule, encoded by a nucleic acid or vector ofany one of the alternatives described herein is provided. The vector cancomprise the nucleic acid of any one of the alternatives describedherein. In some alternatives, the nucleic acid encoding the bi-specificchimeric antigen receptor comprises a first nucleic acid sequencecomprising a sequence encoding a leader sequence, a second nucleic acidcomprising a sequence encoding an antibody or binding fragment thereofor scFv, wherein the antibody or binding fragment thereof or scFv isspecific for a B cell specific cell surface molecule or is specific fora cell surface tumor specific molecule, and wherein the first nucleicacid is covalently attached at a 5′ end of the second nucleic acid, athird nucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface moleculeor is specific for a cell surface tumor specific molecule, and whereinthe third nucleic acid is covalently attached at a 3′ end of the secondnucleic acid, a fourth nucleic acid comprising a sequence encoding ade-immunized extracellular spacer, wherein the fourth nucleic acid iscovalently attached at a 3′ end of the third nucleic acid, a fifthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the fifth nucleic acid is covalently attached at a 3′ end of thefourth nucleic acid, a sixth nucleic acid comprising a sequence encodinga signaling domain sequence, wherein the signaling domain comprises aco-stimulatory domain, wherein the co-stimulatory domain comprises a4-1BB domain, CD3-zeta domain and/or CD28-zeta domain and wherein thesixth nucleic acid is covalently attached at a 3′ end of the fifthnucleic acid, a seventh nucleic acid comprising a sequence encoding alinker, wherein the seventh nucleic acid is covalently attached at a 3′end of the sixth nucleic acid and an eighth nucleic acid comprising asequence encoding a marker domain, wherein the eighth nucleic acid iscovalently attached at a 3′ end of the seventh nucleic acid, therebyhaving said nucleic acid encoding a bi-specific chimeric antigenreceptor. In some alternatives, the nucleic acid comprises a firstnucleic acid comprising a sequence encoding a leader sequence, a secondnucleic acid comprising a sequence encoding a first promoter inducibleby a drug, wherein the first nucleic acid is covalently attached to a 5′end of the second nucleic acid, a third nucleic acid comprising asequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora B cell specific cell surface molecule or is specific for a cellsurface tumor specific molecule, and wherein the third nucleic acid iscovalently attached at a 3′ end of the second nucleic acid, a fourthnucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface moleculeor is specific for a cell surface tumor specific molecule, and whereinthe fourth nucleic acid is covalently attached at a 3′ end of the thirdnucleic acid, a fifth nucleic acid comprising a sequence encoding ade-immunized extracellular spacer, wherein the fifth nucleic acid iscovalently attached at a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the sixth nucleic acid is covalently attached at a 3′ end of thefifth nucleic acid, a seventh nucleic acid comprising a sequenceencoding a signaling domain sequence, wherein the signaling domaincomprises a co-stimulatory domain, wherein the co-stimulatory domaincomprises a 4-1BB domain, CD3-zeta domain and/or CD28-zeta domain andwherein the seventh nucleic acid is covalently attached at a 3′ end ofthe sixth nucleic acid, an eighth nucleic acid comprising a sequenceencoding a linker, wherein the eighth nucleic acid is covalentlyattached at a 3′ end of the seventh nucleic acid, and a ninth nucleicacid comprising a sequence encoding a marker domain, wherein the ninthnucleic acid is covalently attached at a 3′ end of the eighth nucleicacid, thereby having said nucleic acid encoding a bi-specific chimericantigen receptor. In some alternatives, the linker is a ribosome skipsequence or an IRES sequence. In some alternatives, the ribosome skipsequence is a P2A, T2A, E2A or F2A sequence. In some alternatives, theribosome skip sequence is T2A. In some alternatives, the T2A sequencecomprises an amino acid sequence set forth in SEQ ID NO: 33 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 34. In somealternatives, the linker further comprises an IRES sequence at the 5′end of the linker. In some alternatives, the first promoter is inducibleby tamoxifen and/or its metabolites. In some alternatives, the firstpromoter is inducible by a drug. In some alternatives, the sequenceencoding the transmembrane domain further comprises an IRES sequence atthe 3′ end of the sequence encoding the transmembrane domain. In somealternatives, the B-cell specific cell surface molecule is CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the nucleic acidfurther comprises a polynucleotide encoding a suicide gene system. Insome alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the cell surface tumor specific molecule is a cancerantigen. In some alternatives, the cell surface tumor specific moleculeis EGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylatedGD2, GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the spacer is an IgG4hinge spacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for the B cell specific cell surfacemolecule is specific for CD19. In some alternatives, the antibody orbinding fragment thereof or scFv specific for the B cell specific cellsurface molecule comprises an amino sequence set forth in SEQ ID NO: 11and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 12. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule is specific forCD20. In some alternatives, the antibody or binding fragment thereof orscFv specific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 13 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 14. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for L1CAM. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38. In some alternatives, thevector is a viral vector. In some alternatives, the vector is alentiviral vector, retroviral vector, gammaretroviral vectors or a foamyviral vector. In some alternatives, the vector is a transposon,integrase vector system, or an mRNA vector.

In a thirteenth aspect, a cell comprising a first and second chimericantigen receptor or TcR is provided. In some alternatives, the firstchimeric antigen receptor is specific for a ligand on a B cell, whichpromotes the in vivo expansion and activation of an effector cell and,wherein the second chimeric antigen receptor or TcR is specific for aligand on a tumor. In some alternatives, the ligand on a B cell is CD1d,CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the ligand on thetumor is a cancer antigen. In some alternatives, the cancer antigen isEGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2,GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the first chimeric antigenreceptor and/or the second chimeric antigen receptor or TcR areinducibly expressed in said cell. In some alternatives, expression ofthe first chimeric antigen receptor and/or the second chimeric antigenreceptor or TcR is under the control of a regulatory element. In somealternatives, the first chimeric antigen receptor comprises an antibodyor binding fragment thereof or scFv, a receptor ligand or mutantthereof, peptide, and/or polypeptide affinity molecule or bindingpartner. In some alternatives, the second chimeric antigen receptor orTcR comprises an antibody or binding fragment thereof or scFv, areceptor ligand or mutant thereof, peptide, and/or polypeptide affinitymolecule or binding partner. In some alternatives, a first markerprotein is co-expressed with the first chimeric antigen receptor and asecond marker protein is co-expressed with the second chimeric antigenreceptor or TcR. In some alternatives, the first marker proteinco-expressed with the first chimeric antigen receptor is EGFRt and thesecond marker protein co-expressed with the second chimeric antigenreceptor or TcR is Her2tg or first marker protein co-expressed with thefirst chimeric antigen receptor is Her2tg and the second marker proteinco-expressed with the second chimeric antigen receptor or TcR is EGFRt.In some alternatives, the cell further comprises a nucleic acid encodinga suicide gene system. In some alternatives, the suicide gene system isa Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir (GCV)suicide gene system or an inducible Caspase suicide gene system. In somealternatives, the cell expresses a soluble protein for therapy. In somealternatives, the soluble protein is a homeostatic cytokine, wherein thehomeostatic cytokine is IL2, IL7, IL12 or IL15. In some alternatives,the cell is a CD8+ T cytotoxic lymphocyte cell selected from the groupconsisting of naïve CD8+ T-cells, CD8+ memory T-cells, central memoryCD8+ T-cells, regulatory CD8+ T-cells, IPS derived CD8+ T-cells,effector memory CD8+ T-cells and bulk CD8+ T-cells. In somealternatives, the cell is a CD4+ T helper lymphocyte cell that isselected from the group consisting of naïve CD4+ T-cells, CD4+ memoryT-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells, IPSderived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the first chimeric antigen receptor isspecific for a ligand on a B cell, wherein the ligand on the B cell isCD19, and wherein the second chimeric antigen receptor is specific forL1CAM, and wherein the chimeric antigen receptors further comprises a4-1 BB and CD3-zeta signaling domain. In some alternatives, the firstchimeric antigen receptor is specific for a ligand on a B cell, whereinthe ligand on the B cell is CD19, and wherein the second chimericantigen receptor is specific for ROR1, and wherein the chimeric antigenreceptors further comprises a 4-1 BB and CD3-zeta signaling domain.

In a fourteenth aspect, a cell comprising a bi-specific chimeric antigenreceptor is provided, wherein the bi-specific chimeric antigen receptorcomprises two binding domains, wherein a first binding domain isspecific for a ligand on a B cell, which promotes the in vivo expansionand activation of the B cell and a second binding domain, wherein thesecond binding domain is specific for a ligand on a tumor. In somealternatives, the ligand on a B cell is CD1d, CD5, CD19, CD20, CD21,CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32,CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54(ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA,B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5,BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5,ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, orEMMPRIN/CD147. In some alternatives, the ligand on the tumor is a cancerantigen. In some alternatives, the cancer antigen is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the first and secondbinding domain comprises an antibody or portion thereof, a receptorligand or mutant thereof, peptide, and/or polypeptide affinity moleculeor binding partner. In some alternatives, the cell further comprises anucleic acid encoding a suicide gene system. In some alternatives, thesuicide gene system is a Herpes Simplex Virus Thymidine Kinase(HSVTK)/Ganciclovir (GCV) suicide gene system or an inducible Caspasesuicide gene system. In some alternatives, the cell expresses a solubleprotein for therapy. In some alternatives, the soluble protein is ahomeostatic cytokine, wherein the homeostatic cytokine is IL2, IL7, IL12or IL15. In some alternatives, the cell is a CD8+ T cytotoxic lymphocytecell selected from the group consisting of naïve CD8+ T-cells, CD8+memory T-cells, central memory CD8+ T-cells, regulatory CD8+ T-cells,IPS derived CD8+ T-cells, effector memory CD8+ T-cells and bulk CD8+T-cells. In some alternatives, the cell is a CD4+T helper lymphocytecell that is selected from the group consisting of naïve CD4+ T-cells,CD4+ memory T-cells, central memory CD4+ T-cells, regulatory CD4+T-cells, IPS derived CD4+ T-cells, effector memory CD4+ T-cells and bulkCD4+ T-cells. In some alternatives, the first chimeric antigen receptoris specific for a ligand on a B cell, wherein the ligand on the B cellis CD19, and wherein the second chimeric antigen receptor is specificfor L1 CAM, and wherein the chimeric antigen receptors further comprisesa 4-1 BB and CD3-zeta signaling domain. In some alternatives, the firstchimeric antigen receptor is specific for a ligand on a B cell, whereinthe ligand on the B cell is CD19, and wherein the second chimericantigen receptor is specific for ROR1, and wherein the chimeric antigenreceptors further comprises a 4-1 BB and CD3-zeta signaling domain. Insome alternatives, the first binding domain is specific for a ligand ona B cell, wherein the ligand on the B cell is CD19, and wherein thesecond binding domain is specific for L1CAM. In some alternatives, thefirst binding domain is specific for a ligand on a B cell, wherein theligand on the B cell is CD19, and wherein the second binding domain isspecific for ROR1.

In a fifteenth aspect, a method of making a cell having a chimericantigen receptor is provided. The method can comprise the followingsteps: introducing into a cell a first nucleic acid or a first vectorcomprising a polynucleotide sequence encoding a first chimeric antigenreceptor that comprises a binding domain specific for a ligand on a Bcell, which promotes the in vivo expansion and activation of the B cell,introducing into the cell a second nucleic acid or a second vectorcomprising a polynucleotide sequence encoding a second chimeric antigenreceptor or TcR that comprises a binding domain specific for a ligand ona solid tumor, expanding the cell and isolating the cell. In somealternatives, the first nucleic acid and the second nucleic acid resideon separate viral vectors. In some alternatives, the viral vectors areretroviral vectors, gammaretroviral vectors, foamy viral vector and/orlentiviral vectors. In some alternatives, the viral vectors areco-introduced into the cell as a composition comprising the viralvectors. In some alternatives, the vectors are a transposon, integrasevector system, and/or an mRNA vector. In some alternatives, expressionof the first chimeric antigen receptor is linked to co-expression ofEGFRt and expression of the second chimeric antigen receptor is linkedto co-expression of Her2tg, or wherein expression of the first chimericantigen receptor is linked to co-expression of Her2tg, and expression ofthe second chimeric antigen receptor is linked to co-expression ofEGFRt. In some alternatives, the method further comprises introducing avector comprising a sequence encoding a soluble protein into said cell.In some alternatives, the soluble protein is a homeostatic cytokine. Insome alternatives, the homeostatic cytokine is IL2, IL7, IL12 or IL15.In some alternatives, the viral vectors further comprise a nucleic acidencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the method further comprises introducing a vectorcomprising a sequence encoding a suicide gene system. In somealternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system.

In a sixteenth aspect, a method of making a cell having a chimericantigen receptor is provided, wherein the method comprises co-deliveringinto a cell two vectors, wherein the first vector comprises a firstnucleic acid sequence encoding a first chimeric antigen receptor thatcomprises a binding domain specific for a ligand on a B cell, whichpromotes the in vivo expansion and activation of the B cell, and asecond vector wherein the second vector comprises a secondpolynucleotide sequence encoding a second chimeric antigen receptor orTcR that comprises a binding domain specific for a ligand on a solidtumor, expanding the cell and isolating the cell. In some alternatives,the vectors are plasmids and/or minicircle transposons. In somealternatives, the first nucleic acid and the second nucleic acid residebetween a first inverted terminal repeat gene sequence and a secondinverted terminal repeat gene sequence. In some alternatives, theinverted terminal repeat gene sequences are inverted repeats of aSleeping Beauty transposon or PiggyBac transposons. In somealternatives, the method further comprises introducing a vector encodingthe Sleeping Beauty transposase or PiggyBac transposase into the cell.

In a seventeenth aspect, a method of making a cell having a bi-specificchimeric antigen receptor is provided, wherein the method comprisesintroducing into a cell a nucleic acid comprising a polynucleotidesequence encoding a bi-specific chimeric antigen receptor that comprisesa first binding domain specific for a ligand on a B cell, which promotesthe in vivo expansion and activation of the B cell, and a second bindingdomain specific for a ligand on a solid tumor, expanding the cells andisolating the cells. In some alternatives, the polynucleotide resides ona viral vector. In some alternatives, the viral vector is a lentiviral,retroviral vector, foamy viral vector or a gammaretroviral vector. Insome alternatives, the bi-specific chimeric antigen receptor isco-expressed with a marker protein. In some alternatives, the markerprotein is EGFRt or Her2tg. In some alternatives, the method furthercomprises introducing a vector comprising a sequence encoding a solubleprotein into said cell. In some alternatives, the soluble protein is ahomeostatic cytokine. In some alternatives, the homeostatic cytokine isIL2, IL7, IL12 or IL15. In some alternatives, the viral vector furthercomprises a nucleic acid encoding a suicide gene system. In somealternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the methodfurther comprises introducing a vector comprising a sequence encoding asuicide gene system. In some alternatives, the suicide gene system is aHerpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir (GCV) suicidegene system or an inducible Caspase suicide gene system.

In an eighteenth aspect, a method of making a cell having a bi-specificchimeric antigen receptor is provided, wherein the method comprisesintroducing into a cell a vector, wherein the vector comprises a firstnucleic acid encoding a bi-specific chimeric antigen receptor thatcomprises a first binding domain specific for a ligand on a B cell,which promotes the in vivo expansion and activation of the B cell, and asecond binding domain wherein the second binding domain comprises abinding domain specific for a ligand on a solid tumor, expanding thecell and isolating the cell. In some alternatives, the vector is aplasmid or minicircle transposon. In some alternatives, the firstnucleic acid resides between a first inverted terminal repeat genesequence and a second inverted terminal repeat gene sequence. In somealternatives, the inverted terminal repeat gene sequences are invertedrepeats of a Sleeping Beauty transposon or PiggyBac transposons. In somealternatives, the method further comprises introducing a vector encodinga Sleeping Beauty transposase or PiggyBac transposase into the cell.

In a nineteenth aspect, a composition is provided, wherein thecomposition comprises any one or more of the cells of any of thealternatives described herein. In some alternatives, the cell comprisesa first and second chimeric antigen receptor or TcR. In somealternatives, the cell comprises a bi-specific chimeric antigenreceptor, wherein the bi-specific chimeric antigen receptor comprisestwo binding domains, wherein a first binding domain is specific for aligand on a B cell, which promotes the in vivo expansion and activationof the B cell and a second binding domain, wherein the second bindingdomain is specific for a ligand on a tumor. In some alternatives, thefirst chimeric antigen receptor is specific for a ligand on a B cell,which promotes the in vivo expansion and activation of an effector celland, wherein the second chimeric antigen receptor or TcR is specific fora ligand on a tumor. In some alternatives, the ligand on a B cell isCD1d, CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2R alphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the ligand on thetumor is a cancer antigen. In some alternatives, the cancer antigen isEGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2,GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the first chimeric antigenreceptor and/or the second chimeric antigen receptor or TcR areinducibly expressed in said cell. In some alternatives, expression ofthe first chimeric antigen receptor and/or the second chimeric antigenreceptor or TcR is under the control of a regulatory element. In somealternatives, the first chimeric antigen receptor comprises an antibodyor binding fragment thereof or scFv, a receptor ligand or mutantthereof, peptide, and/or polypeptide affinity molecule or bindingpartner. In some alternatives, the second chimeric antigen receptor orTcR comprises an antibody or binding fragment thereof or scFv, areceptor ligand or mutant thereof, peptide, and/or polypeptide affinitymolecule or binding partner. In some alternatives, a first markerprotein is co-expressed with the first chimeric antigen receptor and asecond marker protein is co-expressed with the second chimeric antigenreceptor or TcR. In some alternatives, the first marker proteinco-expressed with the first chimeric antigen receptor is EGFRt and thesecond marker protein co-expressed with the second chimeric antigenreceptor or TcR is Her2tg or first marker protein co-expressed with thefirst chimeric antigen receptor is Her2tg and the second marker proteinco-expressed with the second chimeric antigen receptor or TcR is EGFRt.In some alternatives, the cell further comprises a nucleic acid encodinga suicide gene system. In some alternatives, the suicide gene system isa Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir (GCV)suicide gene system or an inducible Caspase suicide gene system. In somealternatives, the cell expresses a soluble protein for therapy. In somealternatives, the soluble protein is a homeostatic cytokine, wherein thehomeostatic cytokine is IL2, IL7, IL12 or IL15. In some alternatives,the cell is a CD8+ T cytotoxic lymphocyte cell selected from the groupconsisting of naïve CD8+ T-cells, CD8+ memory T-cells, central memoryCD8+ T-cells, regulatory CD8+ T-cells, IPS derived CD8+ T-cells,effector memory CD8+ T-cells and bulk CD8+ T-cells. In somealternatives, the cell is a CD4+ T helper lymphocyte cell that isselected from the group consisting of naïve CD4+ T-cells, CD4+ memoryT-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells, IPSderived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the first chimeric antigen receptor isspecific for a ligand on a B cell, wherein the ligand on the B cell isCD19, and wherein the second chimeric antigen receptor is specific forL1CAM, and wherein the chimeric antigen receptors further comprises a4-1 BB and CD3-zeta signaling domain. In some alternatives, the firstchimeric antigen receptor is specific for a ligand on a B cell, whereinthe ligand on the B cell is CD19, and wherein the second chimericantigen receptor is specific for ROR1, and wherein the chimeric antigenreceptors further comprises a 4-1 BB and CD3-zeta signaling domain. Insome alternatives, the ligand on a B cell is CD1d, CD5, CD19, CD20,CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7,CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54(ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA,B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5,BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5,ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, orEMMPRIN/CD147. In some alternatives, the ligand on the tumor is a cancerantigen. In some alternatives, the cancer antigen is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the first and secondbinding domain comprises an antibody or portion thereof, a receptorligand or mutant thereof, peptide, and/or polypeptide affinity moleculeor binding partner. In some alternatives, the cell further comprises anucleic acid encoding a suicide gene system. In some alternatives, thesuicide gene system is a Herpes Simplex Virus Thymidine Kinase(HSVTK)/Ganciclovir (GCV) suicide gene system or an inducible Caspasesuicide gene system. In some alternatives, the cell expresses a solubleprotein for therapy. In some alternatives, the soluble protein is ahomeostatic cytokine, wherein the homeostatic cytokine is IL2, IL7, IL12or IL15. In some alternatives, the cell is a CD8+ T cytotoxic lymphocytecell selected from the group consisting of naïve CD8+ T-cells, CD8+memory T-cells, central memory CD8+ T-cells, regulatory CD8+ T-cells,IPS derived CD8+ T-cells, effector memory CD8+ T-cells and bulk CD8+T-cells. In some alternatives, the cell is a CD4+ T helper lymphocytecell that is selected from the group consisting of naïve CD4+ T-cells,CD4+ memory T-cells, central memory CD4+ T-cells, regulatory CD4+T-cells, IPS derived CD4+ T-cells, effector memory CD4+ T-cells and bulkCD4+ T-cells. In some alternatives, the first chimeric antigen receptoris specific for a ligand on a B cell, wherein the ligand on the B cellis CD19, and wherein the second chimeric antigen receptor is specificfor L1CAM, and wherein the chimeric antigen receptors further comprisesa 4-1 BB and CD3-zeta signaling domain. In some alternatives, the firstchimeric antigen receptor is specific for a ligand on a B cell, whereinthe ligand on the B cell is CD19, and wherein the second chimericantigen receptor is specific for ROR1, and wherein the chimeric antigenreceptors further comprises a 4-1 BB and CD3-zeta signaling domain. Insome alternatives, the first binding domain is specific for a ligand ona B cell, wherein the ligand on the B cell is CD19, and wherein thesecond binding domain is specific for L1CAM. In some alternatives, thefirst binding domain is specific for a ligand on a B cell, wherein theligand on the B cell is CD19, and wherein the second binding domain isspecific for ROR1.

In a twentieth aspect, a method of treating, ameliorating, or inhibitinga non-B cell related disease in a subject is provided. The method cancomprise identifying a subject that does not have a B-cell relateddisease for therapy, introducing, providing, or administering any one ormore of the cells of any of the alternatives provided herein or thecells made by any one or more of any of the alternatives provided hereinor a composition of any of the alternatives described herein into asubject for therapy. In some alternatives, the method comprisesintroducing into a cell a vector, wherein the vector comprises a firstnucleic acid encoding a bi-specific chimeric antigen receptor thatcomprises a first binding domain specific for a ligand on a B cell,which promotes the in vivo expansion and activation of the B cell, and asecond binding domain wherein the second binding domain comprises abinding domain specific for a ligand on a solid tumor, expanding thecell and isolating the cell. In some alternatives, the vector is aplasmid or minicircle transposon. In some alternatives, the firstnucleic acid resides between a first inverted terminal repeat genesequence and a second inverted terminal repeat gene sequence. In somealternatives, the inverted terminal repeat gene sequences are invertedrepeats of a Sleeping Beauty transposon or PiggyBac transposons. In somealternatives, the method further comprises introducing a vector encodinga Sleeping Beauty transposase or PiggyBac transposase into the cell. Insome alternatives, the composition comprises any one or more of thecells of any of the alternatives described herein. In some alternatives,the cell comprises a first and second chimeric antigen receptor or TcR.In some alternatives, the cell comprises a bi-specific chimeric antigenreceptor, wherein the bi-specific chimeric antigen receptor comprisestwo binding domains, wherein a first binding domain is specific for aligand on a B cell, which promotes the in vivo expansion and activationof the B cell and a second binding domain, wherein the second bindingdomain is specific for a ligand on a tumor. In some alternatives, thefirst chimeric antigen receptor is specific for a ligand on a B cell,which promotes the in vivo expansion and activation of an effector celland, wherein the second chimeric antigen receptor or TcR is specific fora ligand on a tumor. In some alternatives, the ligand on a B cell isCD1d, CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2R alphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the ligand on thetumor is a cancer antigen. In some alternatives, the cancer antigen isEGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2,GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the first chimeric antigenreceptor and/or the second chimeric antigen receptor or TcR areinducibly expressed in said cell. In some alternatives, expression ofthe first chimeric antigen receptor and/or the second chimeric antigenreceptor or TcR is under the control of a regulatory element. In somealternatives, the first chimeric antigen receptor comprises an antibodyor binding fragment thereof or scFv, a receptor ligand or mutantthereof, peptide, and/or polypeptide affinity molecule or bindingpartner. In some alternatives, the second chimeric antigen receptor orTcR comprises an antibody or binding fragment thereof or scFv, areceptor ligand or mutant thereof, peptide, and/or polypeptide affinitymolecule or binding partner. In some alternatives, a first markerprotein is co-expressed with the first chimeric antigen receptor and asecond marker protein is co-expressed with the second chimeric antigenreceptor or TcR. In some alternatives, the first marker proteinco-expressed with the first chimeric antigen receptor is EGFRt and thesecond marker protein co-expressed with the second chimeric antigenreceptor or TcR is Her2tg or first marker protein co-expressed with thefirst chimeric antigen receptor is Her2tg and the second marker proteinco-expressed with the second chimeric antigen receptor or TcR is EGFRt.In some alternatives, the cell further comprises a nucleic acid encodinga suicide gene system. In some alternatives, the suicide gene system isa Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir (GCV)suicide gene system or an inducible Caspase suicide gene system. In somealternatives, the cell expresses a soluble protein for therapy. In somealternatives, the soluble protein is a homeostatic cytokine, wherein thehomeostatic cytokine is IL2, IL7, IL12 or IL15. In some alternatives,the cell is a CD8+ T cytotoxic lymphocyte cell selected from the groupconsisting of naïve CD8+ T-cells, CD8+ memory T-cells, central memoryCD8+ T-cells, regulatory CD8+ T-cells, IPS derived CD8+ T-cells,effector memory CD8+ T-cells and bulk CD8+ T-cells. In somealternatives, the cell is a CD4+ T helper lymphocyte cell that isselected from the group consisting of naïve CD4+ T-cells, CD4+ memoryT-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells, IPSderived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the first chimeric antigen receptor isspecific for a ligand on a B cell, wherein the ligand on the B cell isCD19, and wherein the second chimeric antigen receptor is specific forL1CAM, and wherein the chimeric antigen receptors further comprises a4-1 BB and CD3-zeta signaling domain. In some alternatives, the firstchimeric antigen receptor is specific for a ligand on a B cell, whereinthe ligand on the B cell is CD19, and wherein the second chimericantigen receptor is specific for ROR1, and wherein the chimeric antigenreceptors further comprises a 4-1 BB and CD3-zeta signaling domain. Insome alternatives, the ligand on a B cell is CD1d, CD5, CD19, CD20,CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7,CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54(ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA,B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5,BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5,ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, orEMMPRIN/CD147. In some alternatives, the ligand on the tumor is a cancerantigen. In some alternatives, the cancer antigen is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1 CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the first and secondbinding domain comprises an antibody or portion thereof, a receptorligand or mutant thereof, peptide, and/or polypeptide affinity moleculeor binding partner. In some alternatives, the cell further comprises anucleic acid encoding a suicide gene system. In some alternatives, thesuicide gene system is a Herpes Simplex Virus Thymidine Kinase(HSVTK)/Ganciclovir (GCV) suicide gene system or an inducible Caspasesuicide gene system. In some alternatives, the cell expresses a solubleprotein for therapy. In some alternatives, the soluble protein is ahomeostatic cytokine, wherein the homeostatic cytokine is IL2, IL7, IL12or IL15. In some alternatives, the cell is a CD8+ T cytotoxic lymphocytecell selected from the group consisting of naïve CD8+ T-cells, CD8+memory T-cells, central memory CD8+ T-cells, regulatory CD8+ T-cells,IPS derived CD8+ T-cells, effector memory CD8+ T-cells and bulk CD8+T-cells. In some alternatives, the cell is a CD4+T helper lymphocytecell that is selected from the group consisting of naïve CD4+ T-cells,CD4+ memory T-cells, central memory CD4+ T-cells, regulatory CD4+T-cells, IPS derived CD4+ T-cells, effector memory CD4+ T-cells and bulkCD4+ T-cells. In some alternatives, the first chimeric antigen receptoris specific for a ligand on a B cell, wherein the ligand on the B cellis CD19, and wherein the second chimeric antigen receptor is specificfor L1 CAM, and wherein the chimeric antigen receptors further comprisesa 4-1 BB and CD3-zeta signaling domain. In some alternatives, the firstchimeric antigen receptor is specific for a ligand on a B cell, whereinthe ligand on the B cell is CD19, and wherein the second chimericantigen receptor is specific for ROR1, and wherein the chimeric antigenreceptors further comprises a 4-1 BB and CD3-zeta signaling domain. Insome alternatives, the first binding domain is specific for a ligand ona B cell, wherein the ligand on the B cell is CD19, and wherein thesecond binding domain is specific for L1CAM. In some alternatives, thefirst binding domain is specific for a ligand on a B cell, wherein theligand on the B cell is CD19, and wherein the second binding domain isspecific for ROR1. In some alternatives, the composition comprises anyone or more of the cells of any of the alternatives described herein orthe cells made by any one or more of the alternative methods describedherein. In some alternatives, the composition comprises CD8+ T cytotoxiclymphocyte cells and/or CD4+ T helper lymphocyte cells, wherein the CD8+T cytotoxic lymphocyte cells are selected from the group consisting ofnaïve CD8+ T-cells, CD8+ memory T-cells, central memory CD8+ T-cells,regulatory CD8+ T-cells, IPS derived CD8+ T-cells, effector memory CD8+T-cells and bulk CD8+ T-cells and, wherein the CD4+ T helper lymphocytecells are selected from the group consisting of naïve CD4+ T-cells, CD4+memory T-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells,IPS derived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the composition has a ratio of CD4+ Thelper lymphocyte cells to CD8+ T lymphocytes of 1:10 to 10:1. In somealternatives, the ratio of CD4+ T helper lymphocyte cells to CD8+ Tlymphocytes is 1:1. In some alternatives, the subject does not have aB-cell related disease. In some alternatives, the subject does not haveB-cell lymphoma, Hodgkin's lymphomas, non-Hodgkins lymphomas, Diffuselarge B cell lymphoma, Follicular lymphoma, marginal zone lymphoma,Mucosa-Associated Lymphatic Tissue lymphoma, small lymphocytic lymphoma,chronic lymphocytic leukemia, mantle cell lymphoma, Burkitt lymphoma,primary mediastinal (thymic) large B cell lymphoma, Lymphoplasmacyticlymphoma, Waldenstrom macroglobulinermia, Nodal marginal zone B celllymphoa, splenic marginal zone lymphoma, intravascular large B celllymphoma, Intravascular large B-cell lymphoma, Primary effusionlymphoma, Lymphomatoid granulomatosis, T cell/histiocyte-rich largeB-cell lymphoma, Primary central nervous system lymphoma, Primarycutaneous diffuse large B-cell lymphoma (leg type), EBV positive diffuselarge B-cell lymphoma of the elderly, Diffuse large B-cell lymphomaassociated with inflammation, Intravascular large B-cell lymphoma,ALK-positive large B-cell lymphoma, ALK-positive large B-cell lymphoma,Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associatedmulticentric Castleman's disease, B-cell lymphoma, unclassifiable withfeatures intermediate between diffuse large B-cell lymphoma and Burkittlymphoma, B-cell lymphoma, unclassifiable with features intermediatebetween diffuse large B-cell lymphoma and classical Hodgkin lymphoma, ornodular lymphocyte predominant Hodgkin's lymphoma. In some alternatives,the disease is a cancer. In some alternatives, the disease is aninfection, wherein the infection is a bacterial or viral infection. Insome alternatives, the cancer is a solid tumor. In some alternatives,the solid tumor is selected from the group consisting of a breastcancer, brain cancer, lung cancer, liver cancer, stomach cancer, spleencancer, colon cancer, renal cancer, pancreatic cancer, prostate cancer,uterine cancer, skin cancer, head cancer, neck cancer, sarcomas,neuroblastomas and ovarian cancer. In some alternatives, the subject hasrefractory and relapsed neuroblastoma. In some alternatives, the subjectis identified or selected to receive a non-B cell related diseasetherapy, anti-cancer therapy, anti-infection therapy, antibacterialtherapy, anti-viral therapy, or anti-tumoral therapy. In somealternatives, the method further comprises measuring or evaluating aninhibition of said non-B cell related disease, cancer, infection,bacterial infection, viral infection, or tumor. In some alternatives,the method further comprises introducing, providing, or administering tosaid subject an additional therapeutic agent, such as a chemotherapeuticagent, an antiviral agent, or an antibacterial agent or an adjuncttherapy such as radiation therapy and/or surgery before, during, orafter introducing, providing, or administering any one or more of thecells of the alternatives described herein or the cells made by any oneor more of the alternative methods described herein or the compositionof any one of the alternatives described herein into the subject fortherapy. In some alternatives, the composition comprises any one or moreof the cells of any of the alternatives described herein or the cellsmade by any one or more of the methods of the alternatives describedherein. In some alternatives, the composition comprises CD8+ T cytotoxiclymphocyte cells and/or CD4+ T helper lymphocyte cells, wherein the CD8+T cytotoxic lymphocyte cells are selected from the group consisting ofnaïve CD8+ T-cells, CD8+ memory T-cells, central memory CD8+ T-cells,regulatory CD8+ T-cells, IPS derived CD8+ T-cells, effector memory CD8+T-cells and bulk CD8+ T-cells and, wherein the CD4+T helper lymphocytecells are selected from the group consisting of naïve CD4+ T-cells, CD4+memory T-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells,IPS derived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the composition has a ratio of CD4+ Thelper lymphocyte cells to CD8+ T lymphocytes of 1:10 to 10:1. In somealternatives, the ratio of CD4+ T helper lymphocyte cells to CD8+ Tlymphocytes is 1:1. In some alternatives, the cells or compositions areintroduced, provided, or administered to said subject by adoptive celltransfer. In some alternatives, the method further comprisesintroducing, providing, or administering a drug that induces expressionof a chimeric antigen receptor or TcR. In some alternatives, the drug isa steroid. In some alternatives, the drug is tamoxifen and/or itsmetabolites. In some alternatives, the subject is a mammalian species.In some alternatives, the subject is a cow, sheep, pig, horse, dog, cat,primate or a human. In some alternatives, the subject is human. In somealternatives, the subject is of pediatric age. In some alternatives, themethod further comprises evaluating the subject for symptoms of cytokinestorm or B-cell aplasia. In some alternatives, the method furthercomprises administering to the subject a prodrug. In some alternatives,the prodrug is Erbitux, Herceptin, Ganciclovir, FK506 or a chemicalinducer of dimerization. In some alternatives, the subject is sufferingfrom refractory and relapsed neuroblastoma and wherein the methodcomprises administering the cell of any one of the alternativesdescribed herein.

BRIEF DESCRIPTION OF THE DRAWINGS

In addition to the features described above, additional features andvariations will be readily apparent from the following descriptions ofthe drawings and exemplary alternatives. It is to be understood thatthese drawings depict typical alternatives, and are not intended to belimiting in scope.

FIG. 1 shows a T-cell expressing a “driver” B cell targeting chimericantigen receptor (CAR) that is co-expressed with a “passenger” CAR thatis directed to a tumor cell.

FIG. 2 shows a schematic of the primary sequence of a CAR described inthe alternatives herein. As shown, the sequence encoding the CARcomprises a leader sequence (such as a sequence for targeting theprotein to the cell surface), an antigen binding domain (variable lightchain and variable heavy chain sequence of an immunoglobulin and alinker, a spacer domain (IgG4 hinge CH3 region, a signaling domain (CD28transmembrane region, 4-1BB domain, CD3 zeta), a T2A ribosome skipsequence, and a transduction marker (EGFRt or Her2tg marker).

FIGS. 3A-3D show the marker Her2t and its variants that demonstratevariable binding affinity to Herceptin based on their respective linker.The CARs used were dual CD19CAR-T2A-Her2tG/CD20CAR-T2A-EGFRt in theT-lymphocytes. FIG. 3A depicts H9 T cells were transduced with 3 ul oflentivirus containing the Her2t variant Her2t(CD28hinge),Her2t(IgG4hinge) or Her2tG (gly-ser linker). The transduced H9 cellswere then cultured for 5 days and stained with biotinylated Herceptin(Herceptin-bio) and a streptavidin conjugated secondary fluorophore(SA-PE). Results demonstrate that the Her2t variant Her2tG displays thegreatest ability to bind Herceptin, Her2t(IgG4hinge) with modestHerceptin binding and Her2t(CD28hinge) with the weakest Herceptinbinding. FIG. 3B depicts A timeline for the isolation (D0), growth(D0-21), selection (D14 and D21) and expansion (REP—D21) of CD4+ andCD8+ primary T cells isolated from PBMCs as per FIG. 4. FIG. 3C depictsCD8+ T cells were transduced with two separate lentiviruses containingCD19CAR-T2A-Her2tG or CD20CAR-T2A-EGFRt at an MOI=1 for each lentivirus.Pre-selection CD8+ T cells were stained with Erbitux-APC,biotinylated-Herceptin and a streptavidin conjugated secondaryfluorophore (SA-PE) seven days post transduction (D10 of culture), whilePost-selection cells were stained on S1Sp1D12 (See FIG. 4) FIG. 3Ddepicts a western blot that indicates the proteins in the cells. Celllysis for western blot analysis was carried out in RIPA buffercontaining protease inhibitor cocktail. Cell lysates were analyzed byBCA assay (Pierce), equally loaded onto gels and western blots wereprobed with the primary antibody anti CD247 (CD3ζ) and the secondaryIRDye 800CW conjugated goat anti-mouse antibody (LI-COR). Blots wereimaged on the Odyssey Infrared Imaging System (LI-COR).

FIG. 4 shows a Western Blot of the cells of interest S1Sp1D12. The cellswere purified for their respective marker/s. Dual CAR bearing CD8+ Tcells carry CD19CAR-T2A-Her2tG and CD20CAR-T2A-EGFRt. This western blotis specific to the zeta portion of the CAR. The western demonstrates CARexpression in the CD8+ T cells. Most importantly, expression of bothCARs (CD19CAR and CD20CAR) is demonstrated in the dual transduced CD8+ Tcells.

FIG. 5A depicts 4-hour chromium release assay showing CD19- and CD20-CART cell specificity against K562 target panel cells. CD8 Tcm wereco-cultured with K562 target cells at a 30:1, 10:1, 3.3:1 or 1.1:1ratio. Only the dual transduced T cells were able to target all antigenexpressing K562 cells. The CD19CAR-T2A-Her2t and CD19CAR-T2A-EGFRt CD8Tcm demonstrate similar lytic capacity. As shown representations areMock (X), CD19CAR-Her2tG (square), CD19CAR-EGFTt (triangle),CD20CAR-EGFRt (diamond) and CD19CAR-Her2tG/CD20CAR-EGFRt (upside-downtriangle) FIG. 5B depicts 24-hour cytokine release assay. CD8 Tcm wereco-cultured with K562 target cells at a 2:1 T cell-to-target ratio for24 hours and then the supernatant was analyzed for the presence ofeffector cytokines. CD19CAR-T2A-Her2t transduced CD8 Tcm produced a morediverse repertoire and higher levels of effector cytokines relative toCD19CAR-T2A-EGFRt transduced CD8 Tcm. The panels are the same as FIG. 5Aand FIG. 5B (Left to right in the bar graphs: K562 CD19, K562 CD20 andK562 CD19/CD20). FIG. 5C depicts similar results were seen for CD4 Tcm.As shown representations are Mock (X), CD19CAR-Her2tG (square),CD19CAR-EGFTt (triangle), CD20CAR-EGFRt (diamond) andCD19CAR-Her2tG/CD20CAR-EGFRt (upside-down triangle).

FIGS. 6A-6D show experimental results of Raji cells electroporated withplasmids containing CD19-targeted CRISPR guide sequences. FIG. 6Adepicts even days post electroporation the Raji cells were subjected tonegative selection using CD19 microbeads. Post-depletion of CD19+ cellsthe CD19− cells were clonally selected and expanded for downstreamexperiments. FIG. 6B and FIG. 6C depict 4 hour chromium release assaysand bioplex assay using the same cells from FIG. 5. As shownrepresentations are Mock (X), CD19CAR-Her2tG (square), CD19CAR-EGFTt(triangle), CD20CAR-EGFRt (diamond) and CD19CAR-Her2tG/CD20CAR-EGFRt(upside-down triangle). Against Raji parental and three Raji CRISPRclones. Shown in 6C clockwise, the top left graph are the Raji parental,Raji CRISPR (3), Raji CRISPR (15) and Raji CRISPR (27). The results onthe bottom graph are results from left to right, mock, CD19CAR-Her2tG,CD19CAR-EGFRt, CD20CAR-EGFRt and CD19CAR-Her2tG/CD20CAR-EGFRt (For IL-2,IFN-γ and TNF-α). FIG. 6D depicts CD4+ chromium release assay.

FIG. 7 shows experimental results of NSG mice injected with 5e⁶ NSO-IL15cells and then 10e⁶ Mock or CAR expressing T cells i.v. As shown in thetop row, on Day 14 post T cell injection, mouse bone marrow washarvested and subjected to flow analysis. The top row gates live,singlets. The middle row gates CD8+×CD45+ cells. The bottom row looks atthe CD45+ cell population and stains for the markers Her2tG and EGFRt.Results demonstrate that EGFRt and Her2tG can be used to efficientlytrack T cells in vivo. The panels in the middle row show cells gated forviable (93.6% lymphocytes), single (98.8%), and alive cells (99.9%). Asshown are CD8 and CD45 staining from left to right: Mock,CD19CAR-T2A-Her2t, CD19CAR-T2A-EGFRt Tcm andCD19CAR-Her2tg/CD20CAR-EGFRt). At least 1×10⁷ cells were recorded insideof the viable, single cell and alive gates. So although the CD45+ cellsrepresent around 1% of the population, it is equivalent to 1×10⁵ cells.The remaining cells are mouse bone marrow cells. Third row: Multisortpurification of Her2t and EGFRt positive T cells. H9 cells (5×10⁶parental, Her2t⁺, EGFRt⁺, or Her2t⁺/EGFRt⁺) were mixed together and thensubjected to purification. The cells were initially purified based onbiotinylated Herceptin and anti-biotin multisort beads. The multisortbeads were then removed and the positive fraction subsequently subjectedto purification based on Erbitux-APC and anti-APC microbeads. The finalpositive fraction was dual positive for Her2t and EGFRt. D)

Chromium Release Assays

FIG. 8 shows the experimental results of NSG mice injected with 0.5e⁶Raji eGFP:ffluc cells i.v. and then 10e⁶ Mock or CAR expressing T cellsat a 1:1 ratio of CD4:CD8. Serial tumor imaging was performed and totalflux graphed to demonstrate tumor growth or the inhibition of tumorgrowth. Results demonstrate that the single CAR or dual CAR expressing Tcells were able to inhibit tumor growth relative to Mock T cells. Asshown representations are Mock (

), CD19CAR-Her2tG (square), CD19CAR-EGFTt (triangle), CD20CAR-EGFRt(diamond) and CD19CAR-Her2tG/CD20CAR-EGFRt (upside-down triangle).

FIG. 9A shows that CD4 and CD8 T-cells can be transduced with twoseparate CAR-encoding lentiviral vectors. CD4 and CD8 purified T-cellswere stimulated with CD3/CD28 beads and then co-transduced with clinicalgrade virus encoding the 2^(nd) generation 41BB-ζ short spacerFMC63CD19CAR or the 2^(nd) generation 41BB-ζ short spacer CE7CAR. EachCAR was followed by an in-frame T2A-EGFRt. Transduced T-cells werepurified by EGFRt and frozen on S1D14 (CD4) or S1D15 (CD8). The processdevelopment project was PD0170. Flow analysis demonstrated thattransduced cells were purified to homogeneity based on EGFRt expression.Results do not demonstrate what percentage of the CD19- or CE7CAR isrepresented in the EGFRt⁺ population or whether the T-cells are indeeddual transduced with virus.

FIG. 9B shows that CD19 and CE7CAR dual transduced T-cells demonstratespecific lysis against CD19 or L1CAM positive target cell lines. Mock(CAR⁻) T-cells and dual transduced T-cells were co-cultured with targetcell lines at different effector to target ratios for 4-hours. K562 arenegative for both targets CD19 and L1CAM. TM-LCL, TM-LCL-OKT3,K562+CD19, and Raji are CD19-positive alone. SK-N-DZ is L1 CAM-positivealone. SK-N-DZ+CD19 are positive for both targets. Results demonstratethat the transduced CD8 or mixed CD4:CD8 T-cells elicit high levels ofCD19CAR activity. There was a lower level of CE7CAR activity asdemonstrated against the SK-N-DZ cell line. These results indicate thatT-cells can be successfully transduced with two separate CAR-encodingviruses and the resultant T-cell population is able to recognizemultiple antigens.

FIG. 9C shows that CD19- and CE7CAR dual transduced T-cell populationsproduce cytokines against CD19 or L1CAM positive target cell lines. Dualtransduced CD4 and CD8 T-cell populations were co-cultured for 24 hourswith target cell lines at a 2:1 effector-to-target ratio. Following the24 hour incubation period, supernatant from the co-cultures was analyzedfor the presence of IL-2, IFN-g, or TNF-a by Bioplex assay. The dualtransduced T-cells produced cytokine in response to all suspension cell(LCL and K562) targets expressing CD19. There was little to no cytokineproduced in response to SK-N-DZ which is not uncommon with the 2^(nd)Gen S-spacer CE7CAR even when expressed in 100% of the T-cellpopulation. Since it was not known what percentage of the T-cellpopulations contain the CE7CAR this was not surprising when combinedwith the chromium data in FIG. 9B.

FIG. 9D shows that dual-transduced T-cells elicit antitumor activity inan intracranial xenograft tumor model. Cohorts of mice were inoculatedwith 0.2e6 SK-N-DZ that express GFP:ffluc, CD19t, and IL-2 (Day 0) and2e6 dual transduced CD4:CD8 T-cells (1:1 ratio) (Day 7) intracranially(i.c.). Serial bioluminescence imaging of tumor in cohorts of micetreated with Mock (PBS only—left) or dual transduced CD4:CD8 CE7CART-cells (middle). Kaplan-Meier analysis (right) of survival in treatmentand control groups. The dual-transduced cells were able to regress andcontrol tumor growth as evidenced by a prolonged decrease inbioluminescence imaging.

FIG. 10A shows that CD4 and CD8 T-cells can be transduced with twoseparate CAR-encoding lentiviral vectors and dual positive populationscan be identified by associated markers. CD4 and CD8 purified T-cellswere stimulated with CD3/CD28 beads and then individually orco-transduced with lentivirus encoding the 2^(nd) generation 41BB-tshort spacer FMC63CD19CAR or/and the 2^(nd) generation 41BB-ζ longmutant (L235D, N297Q) spacer CE7CAR. The CD19CAR was followed by anin-frame T2A-Her2tG and the CE7CAR by a T2A-EGFRt. Transduced T-cellswere purified by EGFRt (CE7CAR) and frozen. Flow analysis was performedon day 9 and demonstrates that transduced cells were purified tohomogeneity based on EGFRt expression. For the CD4 T-cells there was˜56% Her2tG (CD19CAR) positivity and ˜44% dual-positivity for the CD8T-cells.

FIG. 10B shows that CD19 and CE7CAR dual transduced CD8⁺ T-cellsdemonstrate specific lysis against CD19 or L1CAM positive target celllines. Mock (CAR⁻), single transduced (CD19CAR or CE7CAR) and dualtransduced CD8⁺ T-cells were co-cultured with target cell lines atdifferent effector to target ratios for 4-hours. K562 are negative forboth targets CD19 and L1CAM. K562-OKT3 was used as a positive control.Be2 are L1CAM-positive alone. Be2+CD19t are positive for both targets.Results demonstrate that the single transduced CD8⁺ T-cells elicitspecific lysis against their cognate antigen. However, the dualtransduced T-cells efficiently recognized and lysed cells expressingCD19, L1CAM or both antigens. All CD8⁺ T-cells were able to elicitsimilar levels of cell lysis against the K562-OKT3. These resultsindicate that T-cells can be successfully transduced with two separateCAR-encoding viruses, purified by a selectable marker, and the resultantT-cell population is able to recognize multiple antigens.

FIG. 10C shows that CD19- and CE7CAR dual transduced T-cell populationsproduce cytokines against CD19 or L1CAM positive target cell lines. Mock(CAR⁻), single transduced (CD19CAR or CE7CAR) and dual transduced CD4⁺and CD8⁺ T-cells were co-cultured for 24 hours with target cell lines ata 2:1 effector-to-target ratio. Following the 24 hour incubation period,supernatant from the co-cultures was analyzed for the presence of IL-2,IFN-g, or TNF-a by Bioplex assay. Dual-transduced cells were able torelease cytokine against all target expressing cell lines. While therewas no difference in cytokine production between individualCE7CAR-expressing and dual CAR expressing T-cells against Be2-CD19t,there was a difference in cytokine production between CD19CAR-expressingand dual transduced T-cells against K562-CD19t. This data coincides withthe CD19CAR positivity of the dual transduced T-cell populations.

FIG. 10D shows that dual-transduced T-cells elicit antitumor activity inan intracranial xenograft tumor model. Cohorts of mice were inoculatedwith 0.2e6 SK-N-DZ that express GFP:ffluc and IL-2 (Day 0) and 2e6 dualtransduced CD4:CD8 T-cells (1:1 ratio) (Day 7) intracranially (i.c.).Serial bioluminescence imaging of tumor in cohorts of mice treated withMock (untransduced—left), CE7CAR-expressing (top row, middle) ordual-transduced CD4:CD8 CE7CAR T-cells (top row, right). Kaplan-Meieranalysis (bottom) of survival in treatment and control groups. Both thesingle CE7CAR-expressing and dual-transduced cells were able to regressand control tumor growth as evidenced by a prolonged decrease inbioluminescence imaging. A subset of mice treated with singleCE7CAR-expressing T-cells was euthanized prior to the arbitrary endpoint of the study due to outgrowth of tumor. These results show thatdual-transduced T-cells are able to eradicate tumor in vivo at levelssimilar to single CE7CAR-expressing T-cells. There was therefore noinhibition in CE7CAR activity for the dual-transduced T-cell population.

FIG. 11A shows that CD4 and CD8 T-cells can be transduced with twoseparate CAR-encoding lentiviral vectors and dual positive populationscan be identified by associated markers. CD4 and CD8 purified T-cellswere stimulated with CD3/CD28 beads and then individually orco-transduced with lentivirus encoding the 2^(nd) generation 41BB-tshort spacer FMC63CD19CAR or/and the 2^(nd) generation 41BB-ζ shortspacer ROR1CAR. The CD19CAR was followed by an in-frame T2A-Her2tG andthe ROR1CAR by a T2A-EGFRt. Transduced T-cells were purified by EGFRt(ROR1CAR) and frozen. Flow analysis was performed on day 9 anddemonstrates that transduced cells were purified to homogeneity based onEGFRt expression. For the CD4 T-cells there was ˜86.7% Her2tG (CD19CAR)positivity and ˜88.1% dual-positivity for the CD8 T-cells.

FIG. 11B shows that CD19 and ROR1CAR dual transduced CD8⁺ T-cellsdemonstrate specific lysis against CD19 or ROR1 positive target celllines. Mock (CAR), single transduced (CD19CAR or ROR1CAR) and dualtransduced CD8⁺ T-cells were co-cultured with target cell lines atdifferent effector to target ratios for 4-hours. Single ROR1CAR T-cellscontain either the 2^(nd) generation 41BB-ζ or CD28-ζ short spacer. K562are negative for both targets CD19 and ROR1. K562-OKT3 was used as apositive control. Raji (CD19⁺) were transduced to express ROR1. Be2,SK-N-AS and SK-N-DZ are ROR1 positive. Results demonstrate that thesingle transduced CD8⁺ T-cells elicit specific lysis against theircognate antigen. However, the dual transduced T-cells efficientlyrecognized and lysed cells expressing CD19, ROR1 or both antigens (RajiROR1). All CD8⁺ T-cells were able to elicit similar levels of cell lysisagainst the K562-OKT3. These results indicate that T-cells can besuccessfully transduced with two separate CAR-encoding viruses, purifiedby a selection marker, and the resultant T-cell population is able torecognize multiple antigens.

FIG. 11C shows that CD19− and ROR1CAR dual transduced T-cell populationsproduce cytokines against CD19 or ROR1 positive target cell lines. Mock(CAR), single transduced (CD19CAR or ROR1CAR) and dual transduced CD4⁺T-cells were co-cultured for 24 hours with target cell lines at a 2:1effector-to-target ratio. Following the 24 hour incubation period,supernatant from the co-cultures was analyzed for the presence of IL-2,IFN-g, or TNF-a by Bioplex assay. Dual-transduced cells were able torelease cytokine against all target expressing cell lines at similarlevels to single CAR-expressing T-cells.

FIG. 11D shows that CD19- and ROR1CAR dual transduced T-cell populationsproduce cytokines against CD19 or ROR1 positive target cell lines. Mock(CAR), single transduced (CD19CAR or ROR1CAR) and dual transduced CD8⁺T-cells were co-cultured for 24 hours with target cell lines at a 2:1effector-to-target ratio. Following the 24 hour incubation period,supernatant from the co-cultures was analyzed for the presence of IL-2,IFN-g, or TNF-a by Bioplex assay. Dual-transduced cells were able torelease cytokine against all target expressing cell lines at similarlevels to single CAR-expressing T-cells.

FIG. 11E shows that dual-transduced T-cells elicit antitumor activity inan intracranial xenograft tumor model. Cohorts of mice were inoculatedwith 0.2e6 Be2 that express GFP:ffluc (Day 0) and 2e6 dual transducedCD4:CD8 T-cells (1:1 ratio) (Day 7) intracranially (i.c.). Serialbioluminescence imaging of tumor in cohorts of mice treated with Mock(untransduced—left), ROR1CAR-expressing (middle-left) or dual-transducedCD4:CD8 CE7CAR T-cells (middle right). Kaplan-Meier analysis (right) ofsurvival in treatment and control groups. Both the singleROR1CAR-expressing and dual-transduced cells were able to transientlyregress tumor growth as evidenced by a short decrease in bioluminescenceimaging. Both the single and dual transduced T-cells were able tosignificantly prolong survival. These results show that dual-transducedT-cells are able to treat tumor in vivo at levels similar to singleROR1CAR-expressing T-cells. There was therefore no inhibition in ROR1CARactivity for the dual-transduced T-cell population.

DEFINITIONS

The following definitions are provided to facilitate understanding ofthe alternatives or alternatives of the invention.

As used herein, “a” or “an” can mean one or more than one.

As used herein, the term “about” indicates that a value includes theinherent variation of error for the method being employed to determine avalue, or the variation that exists among experiments.

“Chimeric antigen receptors” (CARs), as described herein, refers togenetically engineered protein receptors, which can confer specificityonto an immune effector cell, such as for example, a T-cell. Withoutbeing limiting, the use of CAR bearing T-cells can promote in vivoexpansion and activation. The CARs can also be designed to redirectT-cells to target cells that express specific cell-surface antigens,where they can activate lymphocytes, such as T-cells, upon targetrecognition. The CARs graft the specificity of a monoclonal antibody orbinding fragment thereof or scFv onto a T-cell, with the transfer oftheir coding sequence facilitated by vectors. In order to use CARs as atherapy for a subject in need, a technique called adoptive cell transferis used in which T-cells are removed from a subject and modified so thatthey can express the CARs that are specific for an antigen. The T-cells,which can then recognize and target an antigen, are reintroduced intothe patient. In some alternatives, CAR expressing lymphocytes aredescribed, wherein the CAR expressing lymphocyte can be delivered to asubject to target specific cells. In some alternatives, the lymphocytecan express two CARs for bi-specificity. In some alternatives, thelymphocyte can express a CAR and a specific T-cell receptor (TcR) forbi-specificity. A TcR is a molecule on the surface of T lymphocytes orT-cells that can recognize antigens. In some alternatives, thelymphocyte can express a bi-specific CAR for bi-specificity, wherein thebi-specific CAR comprises a first domain for binding a B-cell specificligand, and a second domain for binding a tumor specific ligand on atumor that is a non-B cell specific cancer. In some alternatives, thecancer is not a B-cell malignancy. As described herein, the B-cellspecific CAR promotes in vivo expansion and activation of effectorcells.

The structure of the CAR can comprise fusions of single-chain variablefragments (scFv) that are derived from monoclonal antibodies that areattached to transmembrane and cytoplasmic signaling domains. Most CARscan include an extracellular scFv that is linked to an intracellularCD3ζ domain (first generation CAR). Additionally, the scFv can be linkedto a co-stimulatory domain, which can increase their efficacy in thetherapy of a subject in need (second generation CAR). When T-cellsexpress this molecule they can recognize and kill target cells thatexpress a specific antigen targeted by the CAR.

In some alternatives, a CAR directed against CD19 comprises an aminoacid sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12

In some alternatives, a CAR directed against CD20 comprises an aminoacid sequence set forth in SEQ ID NO: 13 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 14.

In some alternatives, a CAR directed against CE7 comprises an amino acidsequence set forth in SEQ ID NO: 15 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 16.

In some alternatives, a CAR directed against ROR1 comprises an aminoacid sequence set forth in SEQ ID NO: 17 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 18.

In some alternatives, a CAR directed against EGFR 806 comprises an aminoacid sequence set forth in SEQ ID NO: 19 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 20.

In some alternatives, a CAR directed against Her2 comprises an aminoacid sequence set forth in SEQ ID NO: 21 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 22.

In some alternatives, a CAR directed against GD2 comprises an amino acidsequence set forth in SEQ ID NO: 23 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 24.

In some alternatives, a CAR directed against EphA2 comprises an aminoacid sequence set forth in SEQ ID NO: 25 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 26.

In some alternatives, a CAR directed against EphA2 comprises an aminoacid sequence set forth in SEQ ID NO: 27 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 28.

In some alternatives, the polynucleotide encoding the chimeric antigenreceptor comprises a sequence encoding a GMCSF signal sequence. In somealternatives, the GMCSF signal sequence signal sequence comprises anamino acid sequence set forth in SEQ ID NO: 29 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 30.

In some alternatives, the polynucleotide encoding the chimeric antigenreceptor comprises a sequence encoding a signal sequence. In somealternatives, the signal sequence signal sequence comprises an aminoacid sequence set forth in SEQ ID NO: 31 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 32. In some alternatives, thepolynucleotide encodes a scFv specific for CD20.

“EGFR 806,” as described herein, is a conformational epitope of wildtype EGFR.

The chimeric antigen receptor can comprise a binding portion that isspecific for a ligand. Without being limiting, the binding portion cancomprise an antibody or binding fragment thereof or scFv, a receptorligand or mutants thereof, peptide, and/or polypeptide affinity moleculeor binding partner. In some alternatives of the first chimeric antigenreceptor, the first chimeric antigen receptor comprises a bindingportion, wherein the binding portion comprises an antibody or bindingfragment thereof or scFv, a receptor ligand or mutants thereof, peptide,and/or polypeptide affinity molecule or binding partner. In somealternatives, the binding portion is specific for a ligand on a B-cell.In some alternatives of the second chimeric antigen receptor, the secondchimeric antigen receptor comprises a binding portion, wherein thebinding portion comprises an antibody or binding fragment thereof orscFv, a receptor ligand or mutants thereof, peptide, and/or polypeptideaffinity molecule or binding partner. In some alternatives, the bindingportion is specific for a ligand on a tumor cell. In some alternatives,the tumor is not a tumor of a B-cell related cancer. As shown in FIG. 1,vectors for the B-cell targeting CAR (Driver) and the tumor targetingCAR (Passenger) are delivered by two separate lentiviral vectors. Cellsthat contain the specific markers co-expressed with the two CARs arethen purified and used for therapy.

As shown in FIG. 2 is the schematic of the primary sequence of a CARdescribed in the alternatives herein. The CAR comprises a leadersequence, an antigen binding domain (variable light chain and variableheavy chain sequence of an immunoglobulin and a linker, a spacer domain(IgG4 hinge CH3 region, a signaling domain (CD28 transmembrane region,4-1BB domain, CD3 zeta), a T2A ribosome skip sequence, and atransduction marker (EGFRt or Her2tg marker). CAR bearing T-cellsdescribed herein, in several alternatives are CD19CAR-T2A-Her2tG,CD19CAR-T2A-EGFRt, CD20CAR-T2A-EGFRt, orCD19CAR-T2A-Her2tG/CD20CAR-T2A-EGFRt.

“Co-stimulation” as described herein, refers to the activation oflymphocytes. In some alternatives of the chimeric antigen receptor, thechimeric antigen receptor comprises an endodomain, wherein theendodomain comprises co-stimulatory domains for co-stimulatorysignaling. In some alternatives, the co-stimulatory domains comprise atransmembrane CD28 domain, 4-1BB domain and/or a CD3zeta domain. In somealternatives, the transmembrane CD28 domain comprises the amino acidsequence set forth in SEQ ID NO: 5; M F W V L V V V G G V L A C Y S L LV T V A F I I F W V). In some alternatives, the transmembrane CD28domain is encoded by the acid sequence set forth in SEQ ID NO: 6 (SEQ IDNO: 6; ATGTTCTGGGTGCTGGTGGTGGTCGGAGGCGTGCTGGCCTGCTACAGCCTGCTGGTCACCGTGGCCTTCATCATCTTTTGGGTG). In some alternatives, the 4-1BB domaincomprises the amino acid sequence set forth in SEQ ID NO: 7 (SEQ ID NO:7; K R G R K K L L Y I F K Q P F M R P V Q T T Q E E D G C S C R F P E EE E G G C E L R V K). In some alternatives, the 4-1BB domain is encodedby the nucleic acid sequence set forth in SEQ ID NO: 8 (SEQ ID NO: 8;AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAG). In some alternatives, the CD3-zeta domaincomprises the amino acid sequence set forth in SEQ ID NO: 9 (SEQ ID NO:9; F S R S A D A P A Y Q Q G Q N Q L Y N E L N L G R R E E Y D V L D K RR G R D P E M G G K P R R K N P Q E G L Y N E L Q K D K M A E A Y S E IG M K G E R R R G K G H D G L Y Q G L S T A T K D T Y D A L H M Q A L PP R). In some alternatives, the CD3-zeta domain is encoded by thenucleic acid sequence set forth in SEQ ID NO: 10 (SEQ ID NO: 10;TTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCCTG CCCCCAAGG).

“Ligand” as described herein, refers to a substance that can form acomplex with a biomolecule. By way of example and not of limitation,ligands can include substrates, proteins, small molecules, inhibitors,activators, nucleic acids and neurotransmitters. Binding can occurthrough intermolecular forces, for example ionic bonds, hydrogen bonds,and van der walls interactions. Ligand binding to a receptor protein canalter the three dimensional structure and determine its functionalstate. The strength of binding of a ligand is referred to as the bindingaffinity and can be determined by direct interactions and solventeffects. A ligand can be bound by a “ligand binding domain.” A ligandbinding domain, for example, can refer to a conserved sequence in astructure that can bind a specific ligand or a specific epitope on aprotein. The ligand binding domain or ligand binding portion cancomprise an antibody or binding fragment thereof or scFv, a receptorligand or mutants thereof, peptide, and/or polypeptide affinity moleculeor binding partner. Without being limiting, a ligand binding domain canbe a specific protein domain or an epitope on a protein that is specificfor a ligand or ligands.

A “B-cell ligand” or a “B-cell antigen” as described herein, refers to atarget antigen that is expressed in a B-cell or B-cell surface of asubject, in which the subject or patient does not have a B-cell relateddisease. In some alternatives, the subject does not have a B cellrelated disease. In some alternatives, the subject does not have aB-cell related disease and/or is being treated for a solid tumor.Without being limiting, examples of B-cell related diseases can includeB-cell lymphoma, Hodgkin's lymphomas, non-Hodgkins lymphomas, Diffuselarge B cell lymphoma, Follicular lymphoma, marginal zone lymphoma,Mucosa-Associated Lymphatic Tissue lymphoma, small lymphocytic lymphoma,chronic lymphocytic leukemia, mantle cell lymphoma, Burkitt lymphoma,primary mediastinal (thymic) large B cell lymphoma, Lymphoplasmacyticlymphoma, Waldenstrom macroglobulinermia, Nodal marginal zone B celllymphoa, splenic marginal zone lymphoma, intravascular large B celllymphoma, Intravascular large B-cell lymphoma, Primary effusionlymphoma, Lymphomatoid granulomatosis, T cell/histiocyte-rich largeB-cell lymphoma, Primary central nervous system lymphoma, Primarycutaneous diffuse large B-cell lymphoma (leg type), EBV positive diffuselarge B-cell lymphoma of the elderly, Diffuse large B-cell lymphomaassociated with inflammation, Intravascular large B-cell lymphoma,ALK-positive large B-cell lymphoma, ALK-positive large B-cell lymphoma,Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associatedmulticentric Castleman's disease, B-cell lymphoma, unclassifiable withfeatures intermediate between diffuse large B-cell lymphoma and Burkittlymphoma, B-cell lymphoma, unclassifiable with features intermediatebetween diffuse large B-cell lymphoma and classical Hodgkin lymphoma,and nodular lymphocyte predominant Hodgkin's lymphoma. In somealternatives, the patient does not have a B-cell related disease. Insome alternatives, the patient does not have B-cell lymphoma, Hodgkin'slymphomas, non-Hodgkins lymphomas, Diffuse large B cell lymphoma,Follicular lymphoma, marginal zone lymphoma, Mucosa-Associated LymphaticTissue lymphoma, small lymphocytic lymphoma, chronic lymphocyticleukemia, mantle cell lymphoma, Burkitt lymphoma, primary mediastinal(thymic) large B cell lymphoma, Lymphoplasmacytic lymphoma, Waldenstrommacroglobulinermia, Nodal marginal zone B cell lymphoa, splenic marginalzone lymphoma, intravascular large B cell lymphoma, Intravascular largeB-cell lymphoma, Primary effusion lymphoma, Lymphomatoid granulomatosis,T cell/histiocyte-rich large B-cell lymphoma, Primary central nervoussystem lymphoma, Primary cutaneous diffuse large B-cell lymphoma (legtype), EBV positive diffuse large B-cell lymphoma of the elderly,Diffuse large B-cell lymphoma associated with inflammation,Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma,ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-celllymphoma arising in HHV8-associated multicentric Castleman's disease,B-cell lymphoma, unclassifiable with features intermediate betweendiffuse large B-cell lymphoma and Burkitt lymphoma, B-cell lymphoma,unclassifiable with features intermediate between diffuse large B-celllymphoma and classical Hodgkin lymphoma, or nodular lymphocytepredominant Hodgkin's lymphoma.

Although rare, lymphomas can also transform into a malignant tumor ormass and metastasize or spread to other organs that are not in thelymphatic system. In this case, a patient has B-cell lymphoma and asolid tumor. Furthermore, patients with B-cell diseases, such assystemic lupus erythematosus and rheumatoid arthritis, are alsosusceptible to cancers such as solid tumors, for example. In somealternatives, the subject does not have a B-cell disease and/or is beingtreated for a cancer. In some alternatives, the cancer is a solid tumor.

In some alternatives, the ligand binding domain is an antibody, or aportion thereof. In some alternatives, the ligand binding domain is anantibody or binding fragment thereof or scFv, a receptor ligand ormutants thereof, peptide, and/or polypeptide affinity molecule orbinding partner. In some alternatives, the ligand binding domain is anscFv. In some alternatives described herein, a ligand on a B cell isCD1d, CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2R alphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148 or EMMPRIN/CD147. In some alternatives described herein, aligand on a B-cell is B-cell specific.

“B-cells” as described herein refers to a type of lymphocyte in thehumoral immunity of the adaptive immune system. B cells can bedistinguished from other lymphocytes, such as T-cells and natural killercells (NK cells), by the presence of a protein on the B cell's outersurface known as a B cell receptor (BCR). This specialized receptorprotein allows a B cell to bind to a specific antigen. In mammals,immature B cells are formed in the bone marrow. The principal functionsof B cells are to make antibodies in response to antigens, to performthe role of antigen-presenting cells (APCs), and to develop into memoryB cells after activation by antigen interaction. B cells also releasecytokines used for signaling immune regulatory functions. B cells have ashort-life span and undergo apoptosis when the inciting agent thatinduced immune response is eliminated. This occurs because of cessationof continuous exposure to various colony-stimulating factors, which isrequired for survival. In some alternatives described herein, a chimericantigen receptor is provided, wherein the chimeric antigen receptor isspecific for a ligand on a B cell, which promotes the in vivo expansionand activation of an effector cell. In some alternatives, binding of theB-cell ligand leads to the release of cytokines. In some alternativesdescribed herein, a bi-specific chimeric antigen receptor is provided,wherein the bi-specific chimeric antigen receptor comprises two bindingdomains, wherein a first binding domain is specific for a ligand on a Bcell, which promotes the in vivo expansion and activation of the B celland a second binding domain is specific for a ligand on a tumor. In somealternatives, the chimeric antigen receptor is specific for a B-cellligand, wherein the chimeric antigen receptor is specific for CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148 or EMMPRIN/CD147. In some alternatives, the first bindingdomain on the bi-specific chimeric antigen receptor is specific for CD1d, CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, EMMPRIN/CD147 and/or tumor targets that are non-B celltumors. In some alternatives, the first and second binding domaincomprises an antibody or portion thereof, a receptor ligand or mutantversion thereof, peptide, and/or polypeptide affinity molecule orbinding partner.

In some alternatives, binding of a chimeric antigen receptor to a B-cellligand elicits a cytokine response and supports T-cell expansion.

In some alternatives, a chimeric antigen receptor is provided, whereinthe ligand or target molecule is a cell surface molecule that is foundon tumor cells and is not substantially found on normal tissues, orrestricted in its expression to non-vital normal tissues. In somealternatives, the tumor does not originate from a B-cell related cancer.In some alternatives, the ligand or target molecule is found on a tumorcell as well as on normal tissues. In some alternatives the cellsexpressing a CAR that is specific for a ligand on tumor cells and normaltissue further comprises a suicide gene to limit the time of therapy andincrease their safety profile. Conditional suicide genes may also beapplied to the donor T-cells to limit the attack on normal tissue thatmay express a tumor associated antigen or ligand.

“Effector cells” as described herein, refers to a lymphocyte that hasbeen induced to differentiate into another cell type that can be capableof mounting a specific immune response, such as a terminallydifferentiated leukocyte that performs one or more specific functions.The main effector cells of the immune system, for example, are activatedlymphocytes and phagocytes that are involved in destroying pathogens andremoving them from the body. The effector cells can include largegranular lymphocytes, such as, for example, natural killer cells andcytotoxic T lymphocytes. In some alternatives of the cells providedherein, the cell comprises a first and second chimeric antigen receptor,wherein the first chimeric antigen receptor is specific for a ligand ona B cell, which promotes the in vivo expansion and activation of aneffector cell and, wherein the second chimeric antigen receptor isspecific for a ligand on a tumor. In some alternatives, the cells thatundergo expansion and activation are lymphocytes, phagocytes, largegranular lymphocytes, natural killer cells and/or cytotoxic Tlymphocytes.

“Cancer antigen,” “tumor antigen” or “tumor marker” refers to anantigenic substance that is produced in a tumor cell, which cantherefore trigger an immune response in the host. These cancer antigenscan be useful as markers for identifying a tumor cell, which will be apotential candidate during treatment or therapy. There are several typesof cancer or tumor antigens. There are tumor specific antigens (TSA)which are present only on tumor cells and not on healthy cells, as wellas tumor associated antigens (TAA) which are present in tumor cells andalso on some normal cells. In some alternatives of the methods andchimeric antigens provided herein, the chimeric antigen receptors arespecific for tumor specific antigens. In some alternatives, the chimericantigen receptors are specific for tumor associated antigens. In somealternatives described herein, the tumor does not originate from aB-cell related cancer. In some alternatives, cells expressing a CAR thatis specific for a TAA is further modified by the introduction of asuicide gene to limit the time of the CAR T-cell therapy and to reducethe attack of normal tissues expressing the TAA.

In some alternatives of the methods provided herein, the cancer antigenis EGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylatedGD2, GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cell surface tumor specific molecule is ROR1. In somealternatives, the cancer antigen is expressed by a tumor, wherein thetumor is not a B-cell related cancer.

“Specific” or “Specificity” can refer to the characteristic of a ligandfor the binding partner or alternatively, the binding partner for theligand, and can include complementary shape, charge and hydrophobicspecificity for binding. Specificity for binding can includestereospecificity, regioselectivity and chemoselectivity. In somealternatives, a chimeric antigen receptor is provided, wherein thechimeric antigen receptor is specific for a B-cell ligand. In somealternatives, a chimeric antigen receptor is provided, wherein thechimeric antigen receptor is specific for a tumor cell ligand.

“CE7” as described herein is an epitope on L1CAM.

In some alternatives, the lymphocyte can express a CAR and a specificT-cell receptor (TcR) for bi-specificity. In some alternatives, thespecific T-cell receptor is specific for EGFR, HER2, Mesothelin, cancertestis antigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2,glypican-2 (GPC2), HPV antigens, alphafetoprotein, carcinoembryonicantigen, CA-125, MUC-1, epithelial tumor antigen, abnormal products ofras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin,AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM,EphA3, EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, ROR1 or NY-ESO-1.

“Inducibly expressed” or “inducible expression” refers to the initiationor increase in the production of a protein at the level of genetictranscription. Induction of a protein can occur if a gene encoding aprotein of interest is under the control of a promoter. As used herein,a promoter can be constitutively active, repressible or inducible. If apromoter is an inducible promoter, then the rate of transcriptionincreases in response to an inducing agent. In contrast, the rate oftranscription is not regulated by an inducing agent if the promoter is aconstitutive promoter. Repressible promoters are also known. In somealternatives described herein, the first chimeric antigen receptorand/or the second chimeric antigen receptor or TcR are induciblyexpressed in said cell. In some alternatives, expression of the firstchimeric antigen receptor and/or the second chimeric antigen receptor orTcR is under the control of a regulatory element. In some alternativesthe repressible systems are controlled by a Tet-On/Off system usingdoxycycline. In some alternatives, the repressible systems arecontrolled by tamoxifen. In some alternatives, the expressible systemsare controlled by riboswitch/small molecule mRNA regulation. In somealternatives, the expressible system is controlled by a riboswitch,shRNA or microRNA.

A “regulatory element” as described herein, can refer to a regulatorysequence, which is any DNA sequence that is responsible for theregulation of gene expression, such as promoters and operators. Theregulatory element can be a segment of a nucleic acid molecule which iscapable of increasing or decreasing the expression of specific geneswithin an organism. In some alternatives described herein, a cell isprovided, wherein the cell comprises a first and second chimeric antigenreceptor or TcR, wherein the first chimeric antigen receptor is specificfor a ligand on a B cell, which promotes the in vivo expansion andactivation of an effector cell and, wherein the second chimeric antigenreceptor or TcR is specific for a ligand on a tumor. In somealternatives, the first chimeric antigen receptor and/or the secondchimeric antigen receptor or TcR are inducibly expressed in said cell.In some alternatives, expression of the first chimeric antigen receptorand/or the second chimeric antigen receptor or TcR is under the controlof a regulatory element.

“Transmembrane domain” as described herein is an integral protein thatcan span a cellular membrane.

A “promoter” is a nucleotide sequence that directs the transcription ofa structural gene. In some alternatives, a promoter is located in the 5′non-coding region of a gene, proximal to the transcriptional start siteof a structural gene. Sequence elements within promoters that functionin the initiation of transcription are often characterized by consensusnucleotide sequences. Without being limiting, these promoter elementscan include RNA polymerase binding sites, TATA sequences, CAATsequences, differentiation-specific elements (DSEs; McGehee et al., Mol.Endocrinol. 7:551 (1993); incorporated by reference in its entirety),cyclic AMP response elements (CREs), serum response elements (SREs;Treisman, Seminars in Cancer Biol. 1:47 (1990); incorporated byreference in its entirety), glucocorticoid response elements (GREs), andbinding sites for other transcription factors, such as CRE/ATF (O'Reillyet al., J. Biol. Chem. 267:19938 (1992); incorporated by reference inits entirety), AP2 (Ye et al., J. Biol. Chem. 269:25728 (1994);incorporated by reference in its entirety), SP1, cAMP response elementbinding protein (CREB; Loeken, Gene Expr. 3:253 (1993); incorporated byreference in its entirety) and octamer factors (see, in general, Watsonet al., eds., Molecular Biology of the Gene, 4th ed. (TheBenjamin/Cummings Publishing Company, Inc. 1987; incorporated byreference in its entirety)), and Lemaigre and Rousseau, Biochem. J.303:1 (1994); incorporated by reference in its entirety). As usedherein, a promoter can be constitutively active, repressible orinducible. If a promoter is an inducible promoter, then the rate oftranscription increases in response to an inducing agent. In contrast,the rate of transcription is not regulated by an inducing agent if thepromoter is a constitutive promoter. Repressible promoters are alsoknown. In some alternatives of the nucleic acid is provided, the nucleicacid comprises a promoter sequence. In some alternatives of the chimericantigen, the chimeric antigen is inducibly expressed in response to aninducing agent. In some alternatives, the TcR is inducibly expressed inresponse to an inducing agent.

In some alternatives, promoters used herein can be inducible orconstitutive promoters. Without being limiting, inducible promoters caninclude, for example, a tamoxifen inducible promoter, tetracyclineinducible promoter, and doxocycline inducible promoter (e.g. tre)promoter. Constitutive promoters can include, for example, SV40, CMV,UBC, EFlalpha, PGK, and CAGG. In some alternatives, the regulatory is apromoter. In some alternatives, the promoter is a tamoxifen induciblepromoter, a tetracycline inducible promoter, or a doxocycline induciblepromoter (e.g. tre) promoter. In some alternatives provided herein,expression of a chimeric antigen receptor or a TcR on a cell is inducedby tamoxifen and/or its metabolites. Metabolites for tamoxifen areactive metabolites such as 4-hyroxytamoxifen (afimoxifene) andN-desmethyl-4-hydroxytamoxifen (endoxifen), which can have 30-100 timesmore affinity with an estrogen receptor than tamoxifen itself. In somealternatives, the tamoxifen metabolites are 4-hyroxytamoxifen(afimoxifene) and/or N-desmethyl-4-hydroxytamoxifen (endoxifen). In somealternatives, vectors are provided wherein the vector has a firstpromoter for the CAR/TcR and a second promoter for the marker protein.

An “antibody” as described herein, refers to a large Y-shape proteinproduced by plasma cells that is used by the immune system to identifyand neutralize foreign objects such as bacteria and viruses. Theantibody protein can comprise four polypeptide chains; two identicalheavy chains and two identical light chains connected by disulfidebonds. Each chain is composed of structural domains calledimmunoglobulin domains. These domains can contain about 70, 80, 90, 100,110, 120, 130, 140, 150 amino acids or any number of amino acids inbetween in a range defined by any two of these values, and areclassified into different categories according to their size andfunction. In some alternatives, the ligand binding domain comprises anantibody or binding fragment thereof or scFv, a receptor ligand ormutants thereof, peptide, and/or polypeptide affinity molecule orbinding partner. In some alternatives, the ligand binding domain is anantibody fragment, desirably, a binding portion thereof. In somealternatives, the antibody fragment or binding portion thereof presenton a CAR is specific for a ligand on a B-cell. In some alternatives, theantibody fragment or binding portion thereof present on a CAR or TcR isspecific for a ligand on a tumor cell. In some alternatives, the tumoris not derived from a B-cell related cancer. In some alternatives, theantibody fragment or binding portion thereof present on a CAR isspecific for a ligand present on a tumor cell. In some alternatives, theligand binding domain is an antibody fragment or a binding portionthereof, such as a single chain variable fragment (scFv). In somealternatives, the ligand comprises a tumor specific mutation. In somealternatives, the antibody fragment or binding portion thereof presenton a CAR comprises one or more domains from a humanized antibody, orbinding portion thereof.

“ScFv” as described herein, is a fusion protein of the variable regionsof the heavy (VH) and light chains (VL) of immunoglobulins, connectedwith a short linker peptide of ten to about 25 amino acids. In somealternatives, a CAR is provided, wherein the CAR comprises a ScFvspecific for a cell surface tumor molecule. In some alternatives, thechimeric antigen receptor comprises a scFV specific for CD19. In somealternatives, the scFV specific for CD19 comprises an amino acidsequence set forth in SEQ ID NO: 11 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 12. In some alternatives, the chimericantigen receptor comprises a scFV specific for CD20. In somealternatives, the scFV specific for CD20 comprises an amino acidsequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. In some alternatives, the chimericantigen receptor comprises a scFV specific for CE7. In somealternatives, the scFV specific for CE7 comprises an amino acid sequenceset forth in SEQ ID NO: 15 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 16. In some alternatives, the chimeric antigenreceptor comprises a scFV specific for ROR1. In some alternatives, thescFV specific for ROR1 comprises an amino acid sequence set forth in SEQID NO: 17 and is encoded by a nucleic acid sequence set forth in SEQ IDNO: 18. In some alternatives, the chimeric antigen receptor comprises ascFV specific for EGFR 806. In some alternatives, the scFV specific forEGFR 806 comprises an amino acid sequence set forth in SEQ ID NO: 19 andis encoded by a nucleic acid sequence set forth in SEQ ID NO: 20. Insome alternatives, the chimeric antigen receptor comprises a scFVspecific for Her2. In some alternatives, the scFV specific for Her2comprises an amino acid sequence set forth in SEQ ID NO: 21 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 22. In somealternatives, the chimeric antigen receptor comprises a scFV specificfor GD2. In some alternatives, the scFV specific for GD2 comprises anamino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the chimeric antigen receptor comprises a scFV specific for EphA2 (2H4).In some alternatives, the scFV specific for EphA2 (2H4) comprises anamino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the chimeric antigen receptor comprises a scFV specific for EphA2 (4H5).In some alternatives, the scFV specific for EphA2 (4H5) comprises anamino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28.

“Marker domains” as described herein, refers to a protein that serves asa label for a cell. In some alternatives of the cells described herein,the cells co-express a marker protein for a specific chimeric antigenprotein that is expressed. In some alternatives of the cells providedherein, the chimeric antigen receptor is co-expressed with a specificmarker protein. In some alternatives of the cells provided herein, thecells comprise a nucleic acid encoding a chimeric antigen receptor. Insome alternatives, the nucleic acid comprises a first nucleic acidcomprising a sequence encoding a leader sequence, a second nucleic acidcomprising a sequence encoding an antibody or binding fragment thereofor scFv, wherein the antibody or binding fragment thereof or scFv isspecific for a B-cell specific cell surface molecule, and wherein thefirst nucleic acid is covalently attached to a 5′ end of the secondnucleic acid, a third nucleic acid comprising a sequence encoding ade-immunized extracellular spacer, wherein the third nucleic acid iscovalently attached to a 3′ end of the second nucleic acid, a fourthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the fourth nucleic acid is covalently attached to a 3′ end ofthe third nucleic acid, a fifth nucleic acid comprising a sequenceencoding a signaling domain, wherein the signaling domain comprises a4-1BB domain and/or CD3-zeta domain, and wherein the fifth nucleic acidis covalently attached to a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a linker, wherein the sixthnucleic acid is covalently attached to a 3′ end of the fifth nucleicacid and a seventh nucleic acid comprising a sequence encoding a markerdomain, wherein the seventh nucleic acid is covalently attached to a 3′end of the sixth nucleic acid, thereby having said nucleic acid encodinga chimeric antigen receptor. In some alternatives, the linker is aribosome skip sequence or an IRES sequence.

A “ribosome skip sequence” as described herein refers to a sequence thatduring translation, forces the ribosome to “skip” the ribosome skipsequence and translate the region after the ribosome skip sequencewithout formation of a peptide bond. Several viruses, for example, haveribosome skip sequences that allow sequential translation of severalproteins on a single nucleic acid without having the proteins linked viaa peptide bond. As described herein, this is the “linker” sequence. Insome alternatives of the nucleic acids provided herein, the nucleicacids comprise a ribosome skip sequence between the sequence for thechimeric antigen receptor and the sequence of the marker protein, suchthat the proteins are co-expressed and not linked by a peptide bond. Insome alternatives, the ribosome skip sequence is a P2A, T2A, E2A or F2Asequence. In some alternatives, the ribosome skip sequence is a T2Asequence. In some alternatives, the T2A sequence comprises the aminoacid sequence set forth in SEQ ID NO: 33 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 34. In some alternatives themarker protein is a EGFRt protein. In some alternatives, the markerprotein is a Her2tg protein. By placing the marker gene after theribosome skip motif, the expressed marker protein will not be bound tothe CAR but can be used in determining or purifying cells that expressthe CAR of interest. In some alternatives, the T-cell is identified forbeing a bi-specific T-cell by the determination of two marker proteinswherein the first marker protein is indicative of the presence of theB-cell specific CAR, and the second marker is indicative of the presenceof the tumor specific CAR. Determination of the marker proteins can beperformed by immunoselection, antibody binding to the marker protein andother methods of selection known to those skilled in the art.

In some alternatives the T2A sequence comprises an amino acid sequenceset forth in SEQ ID NO: 33 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 34.

“Internal ribosome entry site (IRES),” as described herein, is anucleotide sequence that allows for translation initiation in the middleof a messenger RNA (mRNA) sequence as part of the greater process ofprotein synthesis.

“Bi-specific chimeric antigen receptor” refers to a CAR that comprisestwo domains, wherein the first domain is specific for a first ligand,and wherein the second domain is specific for a second ligand. In somealternatives, the first ligand is a B-cell specific protein. In somealternatives, the second ligand is a tumor-specific ligand.

As used herein, “nucleic acid” or “nucleic acid molecule” refers topolynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid(RNA), oligonucleotides, fragments generated by the polymerase chainreaction (PCR), and fragments generated by any of ligation, scission,endonuclease action, and exonuclease action. Nucleic acid molecules canbe composed of monomers that are naturally-occurring nucleotides (suchas DNA and RNA), or analogs of naturally-occurring nucleotides (e.g.,enantiomeric forms of naturally-occurring nucleotides), or a combinationof both. Modified nucleotides can have alterations in sugar moietiesand/or in pyrimidine or purine base moieties. Sugar modificationsinclude, for example, replacement of one or more hydroxyl groups withhalogens, alkyl groups, amines, and azido groups, or sugars can befunctionalized as ethers or esters. Moreover, the entire sugar moietycan be replaced with sterically and electronically similar structures,such as aza-sugars and carbocyclic sugar analogs. Examples ofmodifications in a base moiety include alkylated purines andpyrimidines, acylated purines or pyrimidines, or other well-knownheterocyclic substitutes. Nucleic acid monomers can be linked byphosphodiester bonds or analogs of such linkages. Analogs ofphosphodiester linkages include phosphorothioate, phosphorodithioate,phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate,phosphoranilidate, phosphoramidate, and the like. The term “nucleic acidmolecule” also includes so-called “peptide nucleic acids,” whichcomprise naturally-occurring or modified nucleic acid bases attached toa polyamide backbone. Nucleic acids can be either single stranded ordouble stranded. In some alternatives, a nucleic acid encoding achimeric antigen receptor is provided. In some alternatives, a method ofmaking a nucleic acid encoding a chimeric antigen receptor is provided.In some alternatives, a nucleic acid encoding a chimeric antigenreceptor specific for a ligand on a B cell is provided. In somealternatives, a nucleic acid encoding a chimeric antigen receptorspecific for a ligand on a tumor cell is provided. In some alternativesthe nucleic acid is a DNA encoding a chimeric antigen receptor. In somealternatives, the nucleic acid is an mRNA encoding a chimeric antigenreceptor. In some alternatives, the chimeric antigen receptor isbi-specific.

“Vector” as described herein, is a nucleic acid vehicle that carries ageneric material encoding a protein or mRNA of interest into anothercell, such that it is replicated and/or expressed in the cell. There areseveral types of vectors. Without being limiting, a vector can be aplasmid, viral vector, cosmid, artificial chromosome, or an mRNA. Thevector can be linear or circular. In some alternatives provided herein,a viral vector is used to carry the nucleic acid encoding a chimericantigen receptor. In some alternatives, the viral vector is a lentiviralvector. In some alternatives, the viral vector is a retroviral vector.In some embodiments, the viral vector is a gammaretroviral vector. Insome alternatives, the vector is a foamy viral vector. In somealternatives, the vector is a plasmid. In some alternatives, the vectoris an mRNA. In some alternatives, the vector is linear and comprisestelomeres.

“Plasmid” as described herein, is a genetic structure in a cell that canreplicate independently of the chromosomes. Without being limiting, theplasmid can be a small circular DNA strand in the cytoplasm of abacterium or protozoan, or a linear nucleic acid.

“Minicircles,” as described herein, are small circular plasmidderivatives that have been freed from all prokaryotic vector parts.Minicircles can serve as an expression vector, where they have beenapplied as transgene carriers for the genetic modification of mammaliancells, with the advantage that, since they contain no bacterial DNAsequences, they are less likely to be perceived as foreign anddestroyed. As such, typical transgene delivery methods involve plasmids,which contain foreign DNA. The smaller size of minicircles also extendstheir cloning capacity and facilitates their delivery into cells.Without being limiting, the preparation of minicircles can follow atwo-step procedure, which can involve production of a parental plasmid(bacterial plasmid with eukaryotic inserts) in E. coli and induction ofa site-specific recombinase at the end of this process but still inbacteria. These steps can be followed by the excision of prokaryoticvector parts via two recombinase-target sequences at both ends of theinsert and recovery of the resulting minicircle (vehicle for the highlyefficient modification of the recipient cell) and the miniplasmid bycapillary gel electrophoresis (CGE).

An “inverted terminal repeat,” as described herein, is a sequence ofnucleotides followed downstream by its reverse complement and occur atopposite ends of a transposon.

As described herein, “transposable element” (TE), transposon orretrotransposon, can be referred to as a DNA sequence that can changeits position within the genome. The transposon can create or reversemutations and alter the cell's genome size. Transposition often resultsin duplication of the TE. TEs can make up a large fraction of theC-value of eukaryotic cells. “C-values,” as described herein, refers toamount, in picograms, of DNA contained within a haploid nucleus of onehalf the amount in a diploid somatic cells of a eukaryotic organism. Insome alternatives, the nucleic acid encoding a chimeric antigen receptorresides within a vector, wherein the vector is a minicircle transposon.In some alternatives, the vector comprises a transposon.

The “Sleeping Beauty transposon system” as described herein, is composedof a Sleeping Beauty (SB) transposase and a transposon that was designedin 1997 to insert specific sequences of DNA into genomes of vertebrateanimals. DNA transposons can translocate from one DNA site to another ina simple, cut-and-paste manner. Transposition is a precise process inwhich a defined DNA segment is excised from one DNA molecule and movedto another site in the same or different DNA molecule or genome. In somealternatives of the vectors provided herein, the vector comprises aSleeping Beauty transposon.

An SB transposase can insert a transposon into a TA dinucleotide basepair in a recipient DNA sequence. The insertion site can be elsewhere inthe same DNA molecule, or in another DNA molecule (or chromosome). Inmammalian genomes, including humans, there are approximately 200 millionTA sites. The TA insertion site is duplicated in the process oftransposon integration. This duplication of the TA sequence is ahallmark of transposition and used to ascertain the mechanism in someexperiments. The transposase can be encoded either within the transposonor the transposase can be supplied by another source, in which case thetransposon becomes a non-autonomous element.

“PiggyBac (PB) transposon,” as described herein refers to a mobilegenetic element that efficiently transposes between vectors andchromosomes via a “cut and paste” mechanism. During transposition, thePB transposase recognizes transposon-specific inverted terminal repeatsequences (ITRs) located on both ends of the transposon vector andefficiently moves the contents from the original sites and efficientlyintegrates them into TTAA chromosomal sites. The powerful activity ofthe PiggyBac transposon system enables genes of interest between the twoITRs in the PB vector to be easily mobilized into target genomes.

In some alternatives, the vector is a PiggyBac transposon. The PiggyBac(PB) transposon is a mobile genetic element that efficiently transposesbetween vectors and chromosomes via a “cut and paste” mechanism. Duringtransposition, the PB transposase recognizes transposon-specificinverted terminal repeat sequences (ITRs) located on both ends of thetransposon vector and efficiently moves the contents from the originalsites and efficiently integrates them into TTAA chromosomal sites. Thepowerful activity of the PiggyBac transposon system enables genes ofinterest between the two ITRs in the PB vector to be easily mobilizedinto target genomes.

In some alternatives, a PB contains a promoter linked to apolynucleotide coding for a chimeric antigen receptor operably linked toa genetic tag. One or more PB transposons can be employed. In somealternatives, a PB comprises a promoter linked to a polynucleotidecoding for a chimeric antigen receptor and a first genetic tag, anotherPB comprises a promoter linked to a polynucleotide coding for a chimericantigen receptor, and a second and different genetic tag. Each elementof the constructs is separated by a nucleic acid, such as that codingfor a self-cleaving T2A sequence. In some alternatives, each PB differsfrom one another in the chimeric antigen receptor including but notlimited to the spacer length and sequence, the intracellular signalingdomain, and/or the genetic tag sequence.

“Adoptive cell transfer” as described herein, refers to the transfer ofcells into a patient. In some alternatives, a method of treating,ameliorating, or inhibiting a non-B cell related disease in a subject isprovided, wherein the method comprises introducing, providing, oradministering any one or more of the cells or compositions of any of thealternatives described herein into a subject for therapy. In somealternatives, the cells are administered by adoptive cell transfer.

A “leader sequence” as described herein is also known as a signalsequence that can direct a protein to the cell surface. The leadersequence under the context of a CAR, refers to the first sequence ofamino acids in a CAR that directs surface expression. This leadersequence, or signal sequence can be required for surface expression of aprotein. In some alternatives, the leader sequence comprises aGranulocyte-macrophage colony-stimulating factor signal sequence. Insome alternatives, the signal sequence comprises an amino acid sequenceset forth in SEQ ID NO: 29 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 30. In some alternatives, the signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 31 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 32.

A “de-immunized spacer” as described herein, refers to a spacer thatinduces little to no immune response from a patient. In somealternatives, the chimeric antigen receptor comprises a spacer, whereinthe spacer does not induce an immune response in a subject in need.

The de-immunized spacer can comprise a polypeptide chain that can rangein length from a length of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56,57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108,109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122,123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136,137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150,151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164,165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178,179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192,193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206,207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220,221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234,235, 236, 237, 238, 239 or 240 amino acids or a length within a rangedefined by any two of the aforementioned lengths. A de-immunized spacercan comprise any of the 20 amino acids in any order to create adesirable length of polypeptide chain in a chimeric antigen receptor,which includes the amino acids arginine, histidine, lysine, asparticacid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine,glycine, proline, alanine, valine, isoleucine, methionine,phenylalanine, tyrosine and/or tryptophan. A de-immunized spacersequence can be a linker between the scFv and the transmembrane domainof the chimeric antigen receptor. In some alternatives, a method ofmaking a nucleic acid encoding a chimeric antigen receptor is provided.In some alternatives, a nucleic acid encoding a chimeric antigenreceptor is provided. In some alternatives, the nucleic acid comprises asequence for a de-immunized spacer. In some alternatives, thede-immunized spacer comprises a sequence with a length of 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66,67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101,102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115,116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129,130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143,144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157,158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171,172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185,186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199,200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213,214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227,228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239 or 240 aminoacids or a length within a range defined by any two of theaforementioned lengths. In some alternatives, the de-immunized spacerresides between the scFv and the transmembrane region of the chimericantigen receptor.

In some alternatives, a spacer region has at least 10 to 229 aminoacids, 10 to 200 amino acids, 10 to 175 amino acids, 10 to 150 aminoacids, 10 to 125 amino acids, 10 to 100 amino acids, 10 to 75 aminoacids, 10 to 50 amino acids, 10 to 40 amino acids, 10 to 30 amino acids,10 to 20 amino acids, or 10 to 15 amino acids, or a length that iswithin a range defined by any two of the aforementioned amino acidlengths. In some alternatives, a spacer region has 12 amino acids orless but greater than 1 amino acid, 119 amino acids or less but greaterthan 1 amino acid, or 229 amino acids or less but greater than 1 aminoacid.

In some alternatives, the spacer comprises an IgG4 hinge spacer. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 1 (SEQ ID NO: 1; E S K Y G P P C P P C P). In somealternatives, the spacer is encoded by a sequence set forth in SEQ IDNO: 2 (SEQ ID NO: 2; GAGAGCAAGTACGGACCGCCCTGCCCCCCTTGCCCT).

In some alternatives, the spacer comprises an IgG4-CH3 hinge spacer. Insome alternatives, the spacer comprises an amino acid sequence set forthin SEQ ID NO: 3 (SEQ ID NO:3; E S K Y G P P C P P C P G Q P R E P Q V YT L P P S Q E E M T K N Q V S L T C L V K G F Y P S D I A V E W E S N GQ P E N N Y K T T P P V L D S D G S F F L Y S R L T V D K S R W Q E G NV F S C S V M H E A L H N H Y T Q K S L S L S L G K). In somealternatives, the spacer is encoded by a sequence set forth in SEQ IDNO: 4 (SEQ ID NO: 4; GAGAGCAAGTACGGACCGCCCTGCCCCCCTTGCCCTGGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCACCCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG).

In some alternatives, the de-immunized spacer comprises a IgG4-CH2spacer (L235D, N297Q mutant). In some alternatives, the IgG4-CH2 spacer(L235D, N297Q mutant) comprises an amino acid sequence set forth in SEQID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQ IDNO: 40.

In some alternatives, the de-immunized spacer comprises a IgG4 hinge. Insome alternatives, the de-immunized spacer comprises a CD8αhinge. Insome alternatives, the de-immunized spacer comprises a CD28hinge andtheir fusion to the CH2 and/or CH3 domains of IgG molecules.

“Signaling domain” as described herein is a domain on a chimeric antigenreceptor that can promote cytokine release, in vivo T cell survival andtumor elimination. In some alternatives herein, a signaling domaincomprises CD28, 4-1BB and/or CD3-zeta cytoplasmic domains.

“Steroid” as described herein refers to a small cyclic organic compoundwith a common characteristic comprising an arrangement of seventeencarbon atoms within a four ring structure. In some alternatives providedherein, the expression of a CAR is induced by a steroid, such asestrogen, testosterone, or a glucocorticoid or retinoic acid. In somealternatives described here, the steroid tamoxifen is used to induceexpression of a CAR or TcR. In some alternatives, estrogen orglucocorticoid are used to induce expression of a CAR or TcR.

“Non-B cell related disease” refers to any cancer or disease that is notrelated to B-cell cancers or diseases. Therefore expression of specificproteins on the cell surface that are markers for a cancer are markersfor diseases that are not caused by any B-cell related abnormalities inthe alternatives described herein. Without being limiting, non-B cellrelated diseases can include B-cell lymphoma, Hodgkin's lymphomas,non-Hodgkins lymphomas, Diffuse large B cell lymphoma, Follicularlymphoma, marginal zone lymphoma, Mucosa-Associated Lymphatic Tissuelymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia,mantle cell lymphoma, Burkitt lymphoma, primary mediastinal (thymic)large B cell lymphoma, Lymphoplasmacytic lymphoma, Waldenstrommacroglobulinermia, Nodal marginal zone B cell lymphoa, splenic marginalzone lymphoma, intravascular large B cell lymphoma, Intravascular largeB-cell lymphoma, Primary effusion lymphoma, Lymphomatoid granulomatosis,T cell/histiocyte-rich large B-cell lymphoma, Primary central nervoussystem lymphoma, Primary cutaneous diffuse large B-cell lymphoma (legtype), EBV positive diffuse large B-cell lymphoma of the elderly,Diffuse large B-cell lymphoma associated with inflammation,Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma,ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-celllymphoma arising in HHV8-associated multicentric Castleman's disease,B-cell lymphoma, unclassifiable with features intermediate betweendiffuse large B-cell lymphoma and Burkitt lymphoma, B-cell lymphoma,unclassifiable with features intermediate between diffuse large B-celllymphoma and classical Hodgkin lymphoma, or nodular lymphocytepredominant Hodgkin's lymphoma.

“Solid Tumors” as described herein, refers to a malignant cancerous massof tissue. In some alternatives of the methods of treating,ameliorating, or inhibiting a non-B cell related disease in a subjectprovided herein, the method comprises introducing, providing, oradministering any one or more of the cells or compositions of any of thealternatives herein or the cells made by any one or more of the methodsof the alternatives herein into a subject for therapy. In somealternatives, the subject has a cancer. In some alternatives, the canceris a solid tumor. In some alternatives, the solid tumor is selected fromthe group consisting of a breast cancer, brain cancer, lung cancer,liver cancer, stomach cancer, spleen cancer, colon cancer, renal cancer,pancreatic cancer, prostate cancer, uterine cancer, skin cancer, headcancer, neck cancer, sarcomas, neuroblastomas and ovarian cancer.

“Neuroblastoma” as described herein, refers to an extracranial solidcancer in childhood and infancy that is a neuroendocrine tumor that canarise from a neural crest element of the sympathetic nervous system.Without being limiting, a tumor can originate, for example, in theadrenal glands, and nerve tissues of the neck, check, abdomen, and/orpelvis. In some alternatives of the methods described herein, T-cellscomprising a bi-specific chimeric antigen receptor or two chimericantigen receptors for bi-specificity are administered to a subject inneed by adoptive cell transfer. In some alternatives, the subject inneed suffers from neuroblastoma. In some alternatives, the subject inneed is a person of pediatric age. Pediatric age as described hereinrefers to a person of age 24 or under. A person of pediatric age is atage 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, 20, 21, 22, 23, 24 years old or any other age within a range inbetween any two of the aforementioned values described.

“Refractory and relapsed neuroblastoma” as described herein, refers tothe children who are considered “high risk” that do not respondcompletely to treatment and are labeled refractory. The children thatare considered high-risk are removed from frontline therapy and areconsidered to be eligible for clinical trials that can use newtherapies. Children who have had a good response to frontline therapyand achieved a disease reoccurrence (relapse) are considered high-riskand are also eligible for new therapies tested in clinical trials. Insome alternatives of the methods described herein, the patients sufferfrom refractory and/or relapsed neuroblastoma. In some alternatives, thesubject in need is a person of pediatric age. Pediatric age as describedherein refers to a person of age 24 or under. A person of pediatric ageis at age 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24 years old or any other age within a range inbetween any two of the aforementioned values described. In somealternatives, the patient is receiving cancer therapy. In somealternatives, the cancer therapy comprises administration of 131I-MIBGto the patient.

“Suicide gene therapy,” “suicide genes” and “suicide gene systems” asdescribed herein, can refer to methods to destroy a cell throughapoptosis, which requires a suicide gene that will cause a cell to killitself by apoptosis. Due to safety concerns for the patients in need ofCAR therapy, strategies are being developed in order to prevent or abateadverse events. Adverse effects of CAR T-cell therapy can include“cytokine storms” which is a cytokine release syndrome in which theinfused T-cells release cytokines into the bloodstream, which can leadto dangerously high fevers as well as a precipitous drop in bloodpressure. To date, cytokine-release syndrome is a common problem inpatients treated with CAR T-cells and patients with the most extensivedisease, prior to receiving the CAR T-cells were shown to be more likelyto experience severe cases of cytokine-release syndrome. Off targetadverse effects can also occur, if a tumor specific antigen is alsoexpressed in healthy tissue.

Suicide gene therapy can be used to increase the safety of chimericantigen receptor redirected T-cells and manage the adverse events thatcan occur following infusion of CAR bearing T-cells. Pharmacologictherapies, suicide genes or novel strategies are needed to limit thecytotoxic effect only to malignant cells. There are several methods forsuicide gene therapy. Without being limiting, methods can includegene-directed enzyme producing therapy or virus directed enzyme prodrugtherapy. For gene-directed enzyme producing therapy (GDEPT), a gene istaken from the cancer cell and then modified with other genes to formenzymes that are harmless to healthy cells. This foreign enzyme isinserted into the tumor cells where it releases a prodrug, which is asmall molecule harmless to healthy cells, but destructive to cancerouscells. The modified suicide gene converts the non-toxic prodrug into acytotoxic substance. For virus directed enzyme prodrug therapy, a virus,such as herpes simplex or cold virus, as the carrier, or vector, is usedto deliver the modified genes to the cancer cells. Suicide gene therapyis not necessarily expected to completely eliminate the need forchemotherapy and radiation treatment for all cancerous tumors. Thedamage inflicted upon the tumor cells, however, makes them moresusceptible to the chemo or radiation. This approach has already proveneffective against prostate and bladder cancers. The application ofsuicide gene therapy is being expanded to several other forms of canceras well. Cancer patients often experience depressed immune systems, sothey can suffer some side effects of the use of a virus as a deliveryagent. Management of adverse effects of CAR T-cell therapy can beperformed by expressing the CARs under the control of a promoter. Aspreviously described in several reviews, T-lymphocytes that express aCAR can further be genetically modified ex vivo with a suicide gene.Without being limiting, the suicide gene can be a gene encoding for afactor that is able to convert at a cellular level a non-toxic prodruginto a toxic compound. During adverse effect that may follow infusion ofCAR T-cells by adoptive cell transfer, the prodrug can be administratedto the subject suffering from adverse effects, and the prodrug canselectively eliminate suicide gene modified T-cells without interferingwith the process of immune reconstitution operated by the non-modifiedT-cells. Suicide systems using the herpes simplex thymidine kinase(Hsv-tk)/ganciclovir (GCV) suicide system have been described. (Casucciet al. 2011, Journal of Cancer 2011, 2; incorporated in its entiretyherein). In some alternatives, a cell comprising a first and secondchimeric antigen receptor is provided, wherein the first chimericantigen receptor is specific for a ligand on a B cell, which promotesthe in vivo expansion and activation of an effector cell and, whereinthe second chimeric antigen receptor is specific for a ligand on atumor. In some alternative, a cell comprising a bi-specific chimericantigen receptor is provided, wherein the bi-specific chimeric antigenreceptor comprises two binding domains, wherein a first binding domainis specific for a ligand on a B cell, which promotes the in vivoexpansion and activation of the B cell and a second binding domain isspecific for a ligand on a tumor. In some alternatives, the cell furthercomprises a suicide gene system.

In some alternatives, the suicide gene system is an EGFRt suicide genesystem, wherein the patient is administered Erbitux as the prodrug. Insome alternatives, the subject is administered 0.04 mg/cm² Erbitux aday. In some alternatives, wherein Erbitux is the prodrug, 0.04 mg/cm²can be considered the initial dose and in some alternatives includes aweekly 0.025 mg/cm² dose of Erbitux after the initial dose. In somealternatives, wherein a rash develops on the patient, the weekly dosecan go down to 0.03 mg/cm², 0.02 mg/cm² or 0.01 mg/cm², or any otherdosage between any two of the aforementioned values described. In somealternatives, the suicide gene system is a Her2tG suicide gene system,wherein the patient is administered Herceptin as the prodrug. In somealternatives, the subject is administered 2 mg/kg, 3 mg/kg or 4 mg/kgHerceptin or any dosage between any two of the aforementioned valuesdescribed. In some alternatives of the methods of making a cellcomprising a first and second chimeric antigen receptor or TcR, themethod further comprises introducing into a cell a nucleic acid encodinga suicide gene. In some alternatives, the nucleic acid encoding asuicide gene is resides on a vector. In some alternatives, the vector isa viral vector. In some alternatives, the viral vector is a lentiviralvector or a retroviral vector. In some alternatives, the Her2tGcomprises an amino acid sequence set forth in SEQ ID NO: 35 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 36.

“Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir (GCV) suicidegene system,” as described herein, is a suicide gene system using thethymidine kinase gene from the herpes simplex virus in combination withthe prodrug ganciclovir.

In some alternatives of the methods of making a cell comprising a firstand second chimeric antigen receptor or TcR, the method furthercomprises introducing into a cell a nucleic acid encoding a suicide genesystem. In some alternatives, the suicide gene system is a HerpesSimplex Virus Thymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide genesystem. In some alternatives, the nucleic acid encoding the suicide geneis resides on a vector. In some alternatives, the vector is a viralvector. In some alternatives, the viral vector is a lentiviral vector ora retroviral vector. In some alternatives, the suicide gene resides onthe vector carrying the nucleic acid encoding the chimeric antigenreceptor, wherein the suicide gene system is located upstream ordownstream from the nucleic acid encoding the chimeric antigen receptor,and wherein the suicide gene system is separated from the nucleic acidencoding the chimeric antigen receptor by a gene encoding a cleavablelinker. In some alternatives, 1000 mg of Ganciclovir is administered toa subject in need three times a day with food.

In some alternatives, wherein Ganciclovir is the prodrug, the patientcan be administered Ganciclovir as induction therapy at a 5 mg/kgintravenously (IV) at a constant rate for 1, 2, or 3 hours or any amountof time in between any two of the aforementioned values, every 12 hoursfor 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days or 21days or any number of days within a range in between any twoaforementioned values. In some alternatives, wherein Ganciclovir is theprodrug, the amount of Ganciclovir in the patient is maintained, whereinthe patient is administered Ganciclovir intravenously (IV) at 5 mg/kg ata constant rate over 1, 2 or 3 hours or any amount of time within arange in between any two of the aforementioned values. In somealternatives, the Ganciclovir is administered once a day, for seven daysa week. In some alternatives, wherein Ganciclovir is the prodrug, theamount of Ganciclovir in the patient is maintained, wherein the patientis administered Ganciclovir intravenously (IV) at 6 mg/kg at a constantrate over 1, 2 or 3 hours or any amount of time in between any two ofthe aforementioned values, once a day, for five days a week.

In some alternatives of the methods of making a cell comprising a firstand second chimeric antigen receptor or TcR, the method furthercomprises introducing into a cell a nucleic acid encoding a suicide genesystem. In some alternatives, the suicide gene system is a Caspase basedsuicide gene system. Without being limiting, examples of induciblecaspase suicide gene systems can include the inducible caspase-9 suicidegene system and the casepace-8 suicide gene system. The use of induciblecaspase 9 (iCasp9) mediated suicide is based on the conditionaldimerization of pro-apoptotic molecules that are constructed from humanproteins and are less likely to be immunogenic. In some alternatives,wherein the iCasp9 suicide system is used, the iCasp9 protein comprisesa human FK506 binding protein.

In some alternatives of the suicide gene system is a Caspase system,such as the Caspase 9 suicide gene system. In some alternatives, theprodrug is FK506 or another chemical inducer of dimerization. In somealternatives of the methods of making a cell comprising a first andsecond chimeric antigen receptor or TcR, the cell comprises introducinginto a cell a nucleic acid encoding a suicide gene. In somealternatives, the nucleic acid encoding a suicide gene is resides on avector. In some alternatives, the vector is a viral vector. In somealternatives, the viral vector is a lentiviral vector or a retroviralvector. In some alternatives, the subject is administered a prodrug toinduce apoptosis. In some alternatives, the prodrug is FK506. In somealternatives, the subject is administered a dosage of 0.075 mg/kg/day,0.1 mg/kg/day, 0.125 mg/kg/day, 0.150 mg/kg/day, 0.175 mg/kg/day or 0.2mg/kg/day or any dosage within a range in between any two of theaforementioned values described.

In some alternatives, the suicide gene system comprises a suicide vectorfor tamoxifen inducible apoptosis. In particular, an inducible apoptosissystem with a Fas-estrogen receptor fusion protein can be used in orderto rapidly eliminate transduced cells. In some alternatives, the systemcan induce apoptosis independently from endogenously expressed estrogen.

“Prodrug” as described herein, is a medication that is administered in apharmacologically inactive form which is then converted to an activeform through a normal metabolic process. In some alternatives, a methodof treating, ameliorating, or inhibiting a non-B cell related disease ina subject is provided wherein the method comprise introducing,providing, or administering any one or more of the cells or compositionsof any of the alternatives described herein or the cells made by any oneor more of the methods of any of the alternatives described herein intoa subject for therapy. In some alternatives, the method furthercomprises evaluating the subject for symptoms of cytokine storm orB-cell aplasia. In some alternatives, the subject is suffering from highfevers, increase or decrease of blood pressure, hypotension, hypoxia,seizures, or aphasia. In some alternatives, the subject has an elevationin ferritin and/or C-reactive protein. In some alternatives of themethods provided herein, wherein the cells comprise a suicide genesystem, the methods further comprise administering to the subject aprodrug.

In some alternatives, wherein the transduced T-cell comprises a suicidegene system, wherein the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system orinducible Caspase 9 suicide gene system, the prodrug is FK506. In somealternatives, the subject is administered 0.075-0.2 mg/kg/day of FK506.In some alternatives, the subject is administered a dosage of 0.075mg/kg/day, 0.1 mg/kg/day, 0.125 mg/kg/day, 0.150 mg/kg/day, 0.175mg/kg/day or 0.2 mg/kg/day or any dosage within a range in between anytwo of the aforementioned values described.

In some alternatives, wherein the transduced T-cell comprises a suicidegene system, wherein the suicide gene system is the suicide gene systemcomprises a suicide vector for tamoxifen inducible apoptosis, theprodrug is tamoxifen. In some alternatives, the subject is administered20 mg/day tamoxifen.

In some alternatives, wherein the transduced T-cell comprises a suicidegene system, wherein the suicide gene system is the Herpes Simplex VirusThymidine Kinase (HSVTK) suicide gene system comprises a suicide vectorfor tamoxifen inducible apoptosis, the prodrug is GCV. In somealternatives, the subject is administered 1000 mg orally 3×/day GCV withfood.

“Engraftment” as described herein, refers to the incorporation ofgrafted tissue into the body of the host. Several characteristics ofeffective CAR T-cells include showing signs of adequate engraftment,which is required for responses. For example, detection of the CARtransgene by polymerase chain reaction is not informative about thesurface expression of the CAR, which is the only form that matters forefficacy. Thus, the availability of reagents to specifically detect CARsat the cell surface by flow cytometry or other methods known to thoseskilled in the art is crucial to understand the activity and engraftmentof CAR T-cells. In the alternatives described herein, the therapeuticpotency of the adoptively transferred CARs are improved by allowing aB-cell targeting CAR to drive the activation, proliferation anddispersion of infused CAR T-cells that have a second CAR that providesfor redirected killing of the solid tumor. In some alternativesdescribed herein, the methods and cells comprising a CAR with B-cellspecificity led to the surprising effect of having an improved level ofengraftment compared to T-cells that only comprised CARs specific for atumor ligand. As described in the alternatives herein, the obstacle offailure to exhibit engraftment is overcome by allowing a B celltargeting CAR to drive the activation, proliferation and dispersion ofinfused CAR T-cells that have a CAR that provides for redirected killingof the solid tumor.

“Subject” or “patient,” as described herein, refers to any organism uponwhich the alternatives described herein may be used or administered,e.g., for experimental, diagnostic, prophylactic, and/or therapeuticpurposes. Subjects or patients include, for example, animals. In somealternatives, the subject is mice, rats, rabbits, non-human primates,and humans. In some alternatives, the subject is a cow, sheep, pig,horse, dog, cat, primate or a human.

DETAILED DESCRIPTION

Although the invention is described in various exemplary alternativesand implementations as provided herein, it should be understood that thevarious features, aspects, and functionality described in one or more ofthe individual alternatives are not limited in their applicability tothe particular alternative with which they are described. Instead, theycan be applied alone or in various combinations to one or more of theother alternatives of the invention, whether the alternatives aredescribed or whether the features are presented as being a part of thedescribed alternative. The breadth and scope of the present inventionshould not be limited by any exemplary alternatives described or shownherein.

Aspects of the present invention relate to methods, cells andcompositions for augmenting the therapeutic potency of adoptivelytransferred chimeric antigen receptor (CAR) bearing T-cells againstsolid tumors. In particular, methods, cells and compositions for CART-cell products that co-express two CARs in individual T-cells, a B celltargeting “driver” CAR for promoting in vivo expansion and activation ofan effector cell, and a CAR or T-cell receptor (TcR) of a desiredspecificity for targeting a solid tumor (passenger CAR/TcR), areprovided herein.

Cells Expressing a First and Second Chimeric Antigen Receptor

In accordance with some preferred alternatives, there are cells providedwherein the cells comprise a first and second chimeric antigen receptoror TcR, wherein the first chimeric antigen receptor is specific for aligand on a B cell, which promotes the in vivo expansion and activationof an effector cell and, wherein the second chimeric antigen receptor orTcR is specific for a ligand on a tumor. In some alternatives of thecells, the ligand on a B cell is CD1d, CD5, CD19, CD20, CD21, CD22,CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32, CD34,CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54 (ICAM-1),CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA, B-cell receptor(BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5, BAFFR/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1,HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, EMMPRIN/CD147 and/ortumor targets on tumors that are non-B cell tumors. In somealternatives, the ligand on the tumor is a cancer antigen. In somealternatives, the cancer antigen is EGFR, HER2, Mesothelin, cancertestis antigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2,glypican-2 (GPC2), HPV antigens, alphafetoprotein, carcinoembryonicantigen, CA-125, MUC-1, epithelial tumor antigen, abnormal products ofras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin,AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM,EphA3, EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In some alternatives, the cancerantigen is L1CAM. In some alternatives, the cancer antigen is ROR1. Insome alternatives, the first chimeric antigen receptor and/or the secondchimeric antigen receptor or TcR are inducibly expressed in said cell.In some alternatives, expression of the first chimeric antigen receptorand/or the second chimeric antigen receptor or TcR is under the controlof a regulatory element. In some alternatives, the first chimericantigen receptor comprises an antibody or binding fragment thereof orscFv, a receptor ligand or mutant thereof, peptide, and/or polypeptideaffinity molecule or binding partner. In some alternatives, the secondchimeric antigen receptor or TcR comprises an antibody or bindingfragment thereof or scFv, a receptor ligand or mutant thereof, peptide,and/or polypeptide affinity molecule or binding partner. In somealternatives, a first marker protein is co-expressed with the firstchimeric antigen receptor and a second marker protein is co-expressedwith the second chimeric antigen receptor or TcR. In some alternatives,the first marker protein co-expressed with the first chimeric antigenreceptor is EGFRt and the second marker protein co-expressed with thesecond chimeric antigen receptor or TcR is Her2tg or first markerprotein co-expressed with the first chimeric antigen receptor is Her2tgand the second marker protein co-expressed with the second chimericantigen receptor or TcR is EGFRt.

In some alternatives, the lymphocyte can express a CAR and a specificT-cell receptor (TcR) for bi-specificity. In some alternatives, thespecific T-cell receptor is specific for EGFR, HER2, Mesothelin, cancertestis antigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2,glypican-2 (GPC2), HPV antigens, alphafetoprotein, carcinoembryonicantigen, CA-125, MUC-1, epithelial tumor antigen, abnormal products ofras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin,AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM,EphA3, EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, NY-ESO-1 or ROR1.

In some alternatives, the ligand on the tumor is a cancer antigen. Insome alternatives, the cancer antigen is EGFR, HER2, Mesothelin, cancertestis antigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2,glypican-2 (GPC2), HPV antigens, alphafetoprotein, carcinoembryonicantigen, CA-125, MUC-1, epithelial tumor antigen, abnormal products ofras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin,AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM,EphA3, EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In some alternatives, the cellsurface tumor specific molecule is ROR1. In some alternatives, the firstchimeric antigen receptor and/or the second chimeric antigen receptorare inducibly expressed in said cell. In some alternatives, expressionof the first chimeric antigen receptor and/or the second chimericantigen receptor is under the control of a regulatory element. In somealternatives, the first chimeric receptor comprises a first ligandbinding domain and the second chimeric receptor comprises a secondligand binding domain. In some alternatives, the ligand binding domaincomprises an antibody or binding fragment thereof or scFv, a receptorligand or mutants thereof, peptide, and/or polypeptide affinity moleculeor binding partner. In some alternatives, the first chimeric antigenreceptor comprises an antibody or binding fragment thereof or scFv, areceptor ligand, peptide, and/or polypeptide affinity molecule. In somealternatives, the second chimeric antigen receptor comprises an antibodyor binding fragment thereof or scFv, a receptor ligand, peptide, and/orpolypeptide affinity molecule. In some alternatives, a first markerprotein is co-expressed with the first chimeric antigen receptor and asecond marker protein is co-expressed with the second chimeric antigenreceptor. In some alternatives, the first marker protein co-expressedwith the first chimeric antigen receptor is EGFRt and the second markerprotein co-expressed with the second chimeric antigen receptor is Her2tgor first marker protein co-expressed with the first chimeric antigenreceptor is Her2tg and the second marker protein co-expressed with thesecond chimeric antigen receptor is EGFRt. In some alternatives, thecell is a CD8+ T cytotoxic lymphocyte cell selected from the groupconsisting of naïve CD8+ T-cells, CD8+ memory T-cells, central memoryCD8+ T-cells, regulatory CD8+ T-cells, IPS derived CD8+ T-cells,effector memory CD8+ T-cells and bulk CD8+ T-cells. In somealternatives, the cell is a CD4+ T helper lymphocyte cell that isselected from the group consisting of naïve CD4+ T-cells, CD4+ memoryT-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells, IPSderived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the EGFRt comprises an amino acidsequence set forth in SEQ ID NO: 37 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 38.

Some alternatives described herein, incorporate a novel strategy toaugment the therapeutic potency of adoptively transferred CAR redirectedT cells against solid tumors. The alternatives also include CAR T cellproducts that co-express two CARs in individual T-cells (CD4+ and CD8+T-cells subsets) incorporating a B cell targeting “driver” CAR (specificfor CD19, CD22, CD20, CD10, CD79c, ROR1 or another cell surface moleculeexpressed by B cells) for promoting in vivo expansion and activation anda CAR or TcR of a desired specificity for targeting a solid tumor(passenger CAR/TcR). Dual CAR (or CAR/TcR) T-cells can be identified andselected by using two cell surface tags developed in the alternativesdescribed herein, that consist of modified human EGFR and HER2polypeptides, EGFRt and HER2tg, respectively. Additionally, single CARsthat house a B cell targeting domain and solid tumor targeting domainare also envisioned to achieve bi-specificity for B cells and solidtumors. A variety of gene transfer methods are envisioned to generatebispecific CAR T-cells inclusive of viral vectors, non-viral transposonvectors, and mRNA. Additionally, a genetic system is envisioned in whichthe B cell targeting CAR is housed in a drug regulated expression formatsuch as TamR. A preferred alternative of this system is theco-expression of a CD19 specific CAR, ideally housing a human scFvbinding domain, deimmunized extracellular spacer and 4-1 BB:zeta secondgeneration cytoplasmic tail, in conjunction with either EGFRt or HER2tg(or another appropriate cell surface tag) coexpressed via a geneticelement that links the cDNA's, such as a ribosome skip sequence or IRES,along with a CAR or TcR developed for solid tumor therapy co-expressedwith the second cell surface tag. One iteration of this system allowsfor separate lentiviral vectors to house each CAR/tag (or TcR/tag) andthe use of a mixture of the two lentiviruses to co-transduce human Tcells. These alternatives anticipates cell selections (immunomagnetic,cell sorting, other) that allows for purification of transduced T cellsthat express both cell surface tags and their corresponding CARs.

The dual CAR (or CAR/TcR) T-cells can be identified and selected byusing two cell surface tags developed and described herein, and canconsist of marker proteins (e.g., modified human EGFR and HER2polypeptides, EGFRt and HER2tg, respectively). Additionally, single CARsthat house a B cell targeting domain and solid tumor targeting domainare also envisioned to achieve bi-specificity for B cells and solidtumors, and are provided herein. A variety of gene transfer methods areenvisioned to generate bispecific CAR T-cells inclusive of viralvectors, non-viral transposon vectors, and mRNA. Additionally, a geneticsystem is envisioned in which the B cell targeting CAR is housed in adrug regulated expression format such as TamR. A preferred alternativeof this system is the co-expression of a CD19 specific CAR, which canalso house a human scFv binding domain, deimmunized extracellular spacerand 4-1 BB:zeta second generation cytoplasmic tail, in conjunction withan cell surface tag (e.g. EGFRt or HER2tg) or the CAR can beco-expressed via a genetic element that links the cDNA's, such as aribosome skip sequence or IRES, along with a CAR or TcR developed forsolid tumor therapy co-expressed with the second cell surface tag. Onealternative of this system allows for separate lentiviral vectors tohouse each CAR/tag (or TcR/tag) and the use of a mixture of the twolentiviruses to co-transduce human T-cells. The alternatives describedherein, anticipates cell selections (immunomagnetic, cell sorting,other) that allows for purification of transduced T-cells that expressboth cell surface tags and their corresponding CARs.

The novel feature of bispecific CAR T-cells housing a driver CAR thattargets normal B cells and a second solid tumor targeting passenger CAR,arises from the observations made from the several alternativesdescribed herein, that CD19 CAR T-cells infused into leukemia patientsundergo multi-log expansion and are activated to mediate the regressionof systemic leukemia inclusive of the central nervous system (CNS). Thisphenomenon has been observed in patients in remission who have CD19 CART-cell expansion in response to activation by non-malignant B cells. Theexpansion mediated by B cells reflects their unique immune-stimulatoryproperties for CD19 CAR T-cells and their distribution in the blood,lymph nodes, and bone marrow where infused CAR T-cells migrate followingintravenous infusion.

In contrast, CAR T-cells targeting solid tumors such as CE7 CAR T-cellsused in clinical trials involving patients with metastatic neuroblastomafail to exhibit engraftment, presumably due to limited migration ofinfused T-cells to sites of tumor metastasis, and the limitedimmune-stimulatory activity of solid tumors and their immunosuppressiveenvironment. The cells described herein overcomes this obstacle byallowing a B cell targeting CAR to drive the activation, proliferationand dispersion of infused CAR T-cells that have a second passenger CARthat provides for redirected killing of the solid tumor.

In several of the alternatives described herein, data has been generatedthat can demonstrate the following: 1) Human T-cells can beco-transduced with two lentiviruses that house a CD19CAR-T2AEGFRt and asecond CAR (antiCD20)-T2A-HER2t; 2) Co-transduced human T-cells have aportion of cells that co-express both EGFRt and HER2t. 3) Doublepositive T-cells can be purified to homogeneity using immunomagneticselection reagents specific for EGFRt (Erbitux) and HER2 (Herceptin); 4)Dual CAR T-cells retain CD19 redirected specificity and an acquiredsecond specificity (example CD20); 5) The TamR regulated transgeneexpression genetic system allows for tamoxifen dependent expression ofthe CD19CAR; 6) Ongoing experiments are testing CD19 driver×L1CAMpassenger dual CAR expressing T-cells to be activated by B cells andsubsequently exhibit enhanced anti-solid tumor activity.

The anticipated use of the alternatives described herein, is to augmentthe curative potential of CAR T-cell therapy for human cancer,specifically solid tumors. This driver/passenger CAR product could beused in the treatment any patient harboring a solid tumor for whichthere is a passenger CAR and overcome suboptimal activation andexpansion following administration to patient by the driver CAR thatrecognizes a B cell lineage cell surface antigen, such as CD19. In onealternative, the driver CAR is placed into a drug regulated expressionsystem, such as TamR-tf, allowing for cycles of driver CAR expansionfollowed by periods of “rest” and B cell reconstitution. Further,boosting of this effect to achieve augmented tumor targeting isanticipated by the infusion of patient derived B cells, T-APCs thatexpress the cell surface B cell antigen. This strategy could be employedin the setting by which the tumor specificity is achieved by isolatingtumor reactive T-cells through their endogenous TcR or an introduced TcRand the driver is the B cell antigen specific CAR.

In some alternatives, it is demonstrated that the dual CAR constructscan be introduced using co-transduction with lentivirus. It iscontemplated to condense the vectorization into a single vector, e.g.,using a nonviral transposon systems such as Sleeping Beauty TransposonTransposase.

CAR bearing T-cells exhibit the potential for prolonged B cell aplasiain treated patients. Accordingly, the TamR regulated expression systemis contemplated for use to turn ON and OFF CD19 driver CAR reactivity,allowing for episodic B cell reconstitution. Alternately, CAR T-cellsare equipped with a suicide gene to allow for periods of B cellrecovery, and or the re-infusion of patient B cells after CAR T-cellablation. In some alternatives, the B-cell targeting CAR is under thecontrol of a drug.

However, other adverse effects of the CAR bearing T-cells of the presentinvention can also include cytokine storms. Therefore management of theadverse effects of CAR T-cell therapy can be performed by expressing theCARs under the control of a promoter or by the incorporation of asuicide gene system by ex vivo methods known to those skilled in theart. In some alternatives of the cells provided herein, the cellsfurther comprise a suicide gene system.

Cells Expressing a Bi-Specific Chimeric Antigen Receptor

As described herein, cells comprising a bi-specific CAR are alsoprovided. In some alternatives, a cell is provided wherein the cellcomprises a bi-specific chimeric antigen receptor, wherein thebi-specific chimeric antigen receptor comprises two binding domains,wherein a first binding domain is specific for a ligand on a B cell,which promotes the in vivo expansion and activation of the B cell and asecond binding domain is specific for a ligand on a tumor. In somealternatives, the ligand on a B cell is CD1d, CD5, CD19, CD20, CD21,CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32,CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54(ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA,B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5,BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5,ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, EMMPRIN/CD147and/or tumor targets that are non-B cell tumors. In some alternatives,the ligand on the tumor is a cancer antigen. In some alternatives, thecancer antigen is EGFR, HER2, Mesothelin, cancer testis antigens, L1CAM,o-acetylated GD2, GD2, neoantigens, Var2, glypican-2 (GPC2), HPVantigens, alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1,epithelial tumor antigen, abnormal products of ras or p53, EphA2,MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1,BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2,FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2,Intestinal carboxylesterase, alpha-foetoprotein, kallikrein4, KIF20A,Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC,p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS,secernin 1, SOX10, STEAP1, survivin, telomerase, TPBG, VEGF, WT1,NY-ESO-1 or ROR1. In some alternatives, the cell surface tumor specificmolecule is ROR1. In some alternatives, the epitope for binding L1CAM isa CE7 epitope. In some alternatives, the target for binding L1CAM is theCE7 epitope. In some alternatives, the first and second binding domaincomprises an antibody or portion thereof, a receptor ligand or mutantversion thereof, peptide, and/or polypeptide affinity molecule orbinding partner.

T-cells expressing a bi-specific CAR, wherein the bi-specific CARcomprises two binding domains is provided, wherein a first bindingdomain is specific for a ligand on a B cell, which promotes the in vivoexpansion and activation of the B cell and a second binding domain isspecific for a ligand on a tumor, are also anticipated to augment thetherapeutic potency of adoptively transferred CAR redirected T cellsagainst solid tumors, as the B-cell binding domain promotes in vivoexpansion and activation of effector cells. In some alternatives, thefirst and second binding domain comprises an antibody or portionthereof, a receptor ligand or mutant version thereof, peptide, and/orpolypeptide affinity molecule or binding partner.

Bi-specific CAR bearing T-cells have the potential for prolonged B cellaplasia in treated patients. This is mitigated by use of the TamRregulated expression system to turn ON and OFF the bi-specific CARreactivity, allowing for episodic B cell reconstitution. Alternately,bi-specific CAR T-cells could be equipped with a suicide gene to allowfor periods of B cell recovery, and or the re-infusion of patient Bcells after bi-specific CAR T-cell ablation. In some alternatives, thebi-specific CAR is under the control of a drug.

In some instances, bi-specific CAR bearing T-cells can cause cytokinestorms. Management of these adverse effects of bi-specific CAR T-celltherapy can be performed by expressing the bi-specific CARs under thecontrol of a promoter or by the incorporation of a suicide gene systemby ex vivo methods known to those skilled in the art. In somealternatives of the cells provided herein, the cells further comprise asuicide gene system.

Compositions

In some alternatives of the methods and compositions, the methods andcomposition are used to treat, ameliorate or eliminate cancer in a humansuffering from cancer. In some alternatives of the methods andcompositions provided herein, the patients in need are people ofpediatric age with relapsed refractory neuroblastoma. In somealternatives, the cancer is a solid tumor. In some alternatives, thesolid tumor is selected from the group consisting of a breast cancer,brain cancer, lung cancer, liver cancer, stomach cancer, spleen cancer,colon cancer, renal cancer, pancreatic cancer, prostate cancer, uterinecancer, skin cancer, head cancer, neck cancer, sarcomas, neuroblastomasand ovarian cancer.

The cell product will be a defined composition CD4+ and CD8+ subsetproduct. The product will be co-transduced with the SCR lentivirus thatdirects the expression of the CD19CAR(4-1BB:zeta) and EGFRt along withthe CE7R CAR(4-1 BB:zeta) and EGFRt. In some alternatives describedherein trials have used a CAR/lentivirus pair that used EGFRt andHER2tg.

As described herein, are developed CD19 specific CARs and solid tumortargeting CARs. The alternatives described herein are dual specific CARproducts through expressing multiple CARs in T-cells or engineering ofbispecific CARs. The concept of using a driver CAR specific for B cellsco-expressed with a passenger CAR or TcR having solid tumor specificityas a strategy for driving high levels of engraftment for augmented tumorresponses is original.

In some alternatives, a composition is provided, wherein the compositioncomprises any one or more of the cells described herein. In somealternatives, the cell comprises a bi-specific chimeric antigenreceptor, wherein the bi-specific chimeric antigen receptor comprisestwo binding domains, wherein a first binding domain is specific for aligand on a B cell, which promotes the in vivo expansion and activationof the B cell and a second binding domain is specific for a ligand on atumor. In some alternatives, the ligand on a B cell is CD1d, CD5, CD19,CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, EMMPRIN/CD147 and/or tumor targets that are non-B celltumors. In some alternatives, the ligand on the tumor is a cancerantigen. In some alternatives, the ligand on the tumor is a cancerantigen. In some alternatives, the cancer antigen is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cell surface tumor specific molecule is ROR1. In somealternatives, the first and second binding domain comprises an antibodyor portion thereof, a receptor ligand or mutant version thereof,peptide, and/or polypeptide affinity molecule or binding partner.

In some alternatives, the cell comprises a bi-specific chimeric antigenreceptor. In some alternatives, the bi-specific chimeric antigenreceptor comprises two binding domains, wherein a first binding domainis specific for a ligand on a B cell, which promotes the in vivoexpansion and activation of the B cell and a second binding domain isspecific for a ligand on a tumor. In some alternatives, the ligand on aB cell is CD1d, CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24,CD25/IL-2 R alphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5),CD44, CD45, CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80,CD84/SLAMF5, LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD,B220/CD45R, C1q R1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R,B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14,BLIMP1/PRDM1, CXCR4, DEP-1/CD148, EMMPRIN/CD147 and/or tumor targetsthat are non-B cell tumors. In some alternatives, the ligand on thetumor is a cancer antigen. In some alternatives, the ligand on the tumoris a cancer antigen. In some alternatives, the cancer antigen is EGFR,HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cell surface tumor specific molecule is ROR1. In somealternatives, the first and second binding domain comprises an antibodyor portion thereof, a receptor ligand or mutant version thereof,peptide, and/or polypeptide affinity molecule or binding partner.

Pharmaceutical excipient,” or pharmaceutical vehicle as described hereincan refer to a carrier or inert medium used as a solvent in which themedicinally active agent or T-cells for treatment is formulated and oradministered. Vehicles can include polymeric micelles, liposomes,lipoprotein-based carriers, nano-particle carriers, dendrimers, and/orother vehicles for T-cells that are known to one skilled in the art. Anideal vehicle or excipient can be non-toxic, biocompatible,non-immunogenic, biodegradable, and can avoid recognition by the host'sdefense mechanisms.

In some alternatives, a composition or product combination for humantherapy is provided, wherein the composition or product combinationcomprises a pharmaceutical excipient and at least one population ofgenetically modified T-cells of any of the alternatives describedherein. In some alternatives, the excipients are pharmaceuticalvehicles. In some alternatives, the pharmaceutical vehicles includepharmaceutical compositions.

The composition can further comprise a vehicle, or pharmaceuticalvehicle. Vehicles as described herein can refer to a substance of notherapeutic value that is used to convey an active medicine or cells foradministration. Pharmaceutical vehicle as described herein can refer toa carrier or inert medium used as a solvent in which the medicinallyactive agent is formulated and or administered. An ideal vehicle can benon-toxic, biocompatible, non-immunogenic, biodegradable, and can avoidrecognition by the host's defense mechanisms. In several alternativesdescribed herein, compositions are described which comprise vehicles orexcipients that help maintain the integrity of the T-cells. In somealternatives, the vehicles are pharmaceutical vehicles. In somealternatives, the pharmaceutical vehicles include pharmaceuticalcompositions.

In some alternatives, the composition comprises CD8+ T cytotoxiclymphocyte cells and/or CD4+ T helper lymphocyte cells, wherein the CD8+T cytotoxic lymphocyte cells are selected from the group consisting ofnaïve CD8+ T-cells, CD8+ memory T-cells, central memory CD8+ T-cells,regulatory CD8+ T-cells, IPS derived CD8+ T-cells, effector memory CD8+T-cells and bulk CD8+ T-cells, and wherein the CD4+ T helper lymphocytecells are selected from the group consisting of naïve CD4+ T-cells, CD4+memory T-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells,IPS derived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the composition has a ratio of CD4+ Thelper lymphocyte cells to CD8+ T lymphocytes of 1:10 to 10:1. In somealternatives, the ratio of CD4+ T helper lymphocyte cells to CD8+ Tlymphocytes is 1:1.

Methods of Making a Cell Comprising Two Chimeric Antigen Receptors forBi-Specificity

In some alternatives, a method of making a cell comprising a chimericantigen receptor is provided. In some alternatives, the method comprisesintroducing into a cell a first nucleic acid comprising a polynucleotidesequence encoding a first chimeric antigen receptor that comprises abinding domain specific for a ligand on a B cell, which promotes the invivo expansion and activation of the B cell, introducing into the cell asecond nucleic acid comprising a polynucleotide sequence encoding asecond chimeric antigen receptor or TcR that comprises a binding domainspecific for a ligand on a solid tumor, expanding the cell and isolatingthe cell. In some alternatives, the first nucleic acid and the secondnucleic acid reside on two separate vectors. In some alternatives, thefirst nucleic acid and the second nucleic acid reside on the samevector. In some alternatives, the first nucleic acid and the secondnucleic acid reside on two separate viral vectors. In some alternatives,the first nucleic acid and the second nucleic acid reside on the samevectors. In some alternatives, the viral vectors are retroviral vectors,gammaretroviral vectors, foamy viral vectors and/or lentiviral vectors.In some alternatives of the method, the vectors are introduced to thecell in a composition comprising a mixture of the two vectors. In somealternatives, the first and/or the second nucleic acid are introduced bya plasmid or a minicircle transposon. In some alternatives, theintroducing the first and second nucleic acid is performed concurrently,wherein the first and second nucleic acid are prepared as a compositionfor delivery to the cell. In some alternatives, expression of the firstchimeric antigen receptor is linked to co-expression of EGFRt andexpression of the second chimeric antigen receptor is linked toco-expression of Her2tg, or wherein expression of the first chimericantigen receptor is linked to co-expression of Her2tg, and expression ofthe second chimeric antigen receptor is linked to co-expression ofEGFRt. In some alternatives, the method further comprises furthercomprising introducing a vector comprising a sequence encoding a solubleprotein into said cell. In some alternatives, the soluble proteins aredominant negative versions of inhibitory proteins or constitutivelyactive versions of pro-proliferative, T cell signal regulating or tumormicroenvironment responsive proteins. In some alternatives, the solubleprotein is a bi-specific T-cell engager (BiTE). BiTEs, as describedherein are artificial bispecific monoclonal antibodies that can be usedas anti-cancer drugs. In some alternatives, the BiTE is a Blinatomomabor Solitomab. BiTEs are fusion proteins comprising single chain variablefragments of different antibodies or amino acid sequences from fourdifferent genes. In some alternatives, the soluble proteins arehomeostatic cytokines, fusion proteins or peptides. In somealternatives, the homeostatic cytokines are IL2, IL7, IL12 and/or IL15.In some alternatives of the method, the method further comprisesstimulating the cells. In some alternatives, cells are stimulated (S1)with 50 U/ml interleukin-2 (IL-2) for CD8 cells. In some alternatives,cells are stimulated with interleukin-7 (IL-7) for CD4 cells. In somealternatives cells are stimulated with anti-CD3/CD28 beads.

In some aspects, utilization of Her2tg or EGFRt tag as a genetictag/marker allows for the ex vivo selection and purification ofhomogenous populations of cellular therapeutics that express thetransgene of interest. In addition, Her2tg can be used to track cellulartherapeutics in vivo; for instance, Her2tg can be used as a target forHerceptin staining of blood, bone marrow and cerebrospinal fluidaspirates to check for the persistence of transgene-expressing cellulartherapeutics to follow cancer remission to therapeutic persistence in apatient. Her2tg extends the therapeutic reach of CAR therapy by allowingfor the concerted purification of cells expressing multiple transgeneswhen used with another genetic tag such as EGFRt. In some alternatives,the method further comprises selecting the cells by immunomagneticselection or cell sorting. In some alternatives, the method furthercomprises selecting the cells by immunobinding the marker protein on thecell surface. In some alternatives, the marker protein is Her2tg and/orEGFRt.

Method of Making a Cell Comprising Two Chimeric Antigen Receptors with aTransposase System

In some alternatives, a method of making a cell comprising a chimericantigen receptor is provided. In some alternatives, the method comprisesco-delivering into a cell two vectors, wherein a first vector comprisesa first nucleic acid encoding a first chimeric antigen receptor, whereinthe chimeric antigen receptor comprises a binding domain specific for aligand on a B cell, which promotes the in vivo expansion and activationof the B cell, and a second vector comprising a second nucleic acidsequence encoding a second chimeric antigen receptor or TcR thatcomprises a binding domain specific for a ligand on a solid tumor,expanding the cell and isolating the cell. In some alternatives, thefirst nucleic acid and the second nucleic acid reside between a twoinverted terminal repeat gene sequences. In some alternatives, theinverted terminal repeat gene sequences are Sleeping Beauty invertedterminal repeat gene sequences or PiggyBaC inverted terminal repeat genesequences. In some alternatives, the vector is a plasmid or a minicircletransposon. In some alternatives, the method further comprisesintroducing into the cell a polynucleotide, wherein the polynucleotidesequence encodes an mRNA, wherein the mRNA encodes a transposase. Insome alternatives, the transposase is a Sleeping Beauty transposase or aPiggyback transposase. In some alternatives, expression of the firstchimeric antigen receptor is linked to co-expression of EGFRt andexpression of the second chimeric antigen receptor is linked toco-expression of Her2tg, or wherein expression of the first chimericantigen receptor is linked to co-expression of Her2tg, and expression ofthe second chimeric antigen receptor is linked to co-expression ofEGFRt. In some alternatives, the method further comprises furthercomprising introducing a vector comprising a sequence encoding a solubleprotein into said cell.

In some alternatives, the vector contains a promoter linked to apolynucleotide coding for a chimeric antigen receptor operably linked toa genetic tag. One or more PiggyBac transposons can be employed. In somealternatives, a PB comprises a promoter linked to a polynucleotidecoding for a chimeric antigen receptor and a first genetic tag, anotherPiggyBac comprises a promoter linked to a polynucleotide coding for achimeric antigen receptor, and a second and different genetic tag. Eachelement of the constructs is separated by a nucleic acid, such as thatcoding for a self-cleaving T2A sequence. In some alternatives, eachPiggyBac differs from one another in the chimeric antigen receptorincluding but not limited to the spacer length and sequence, theintracellular signaling domain, and/or the genetic tag sequence.

In some aspects, utilization of Her2tg or EGFRt tag as a genetictag/marker allows for the ex vivo selection and purification ofhomogenous populations of cellular therapeutics that express thetransgene of interest. In addition, Her2tg can be used to track cellulartherapeutics in vivo; for instance, Her2tg can be used as a target forHerceptin staining of blood, bone marrow and cerebrospinal fluidaspirates to check for the persistence of transgene-expressing cellulartherapeutics to follow cancer remission to therapeutic persistence in apatient. Her2tg extends the therapeutic reach of CAR therapy by allowingfor the concerted purification of cells expressing multiple transgeneswhen used with another genetic tag such as EGFRt. In some alternatives,the method further comprises selecting the cells by immunomagneticselection or cell sorting. In some alternatives, the method furthercomprises selecting the cells by immunobinding the marker protein on thecell surface. In some alternatives, the marker protein is Her2tg and/orEGFRt.

Methods of Making a Cell Comprising a Bi-Specific Chimeric AntigenReceptor for Bi-Specificity

In some alternatives, a method of making a cell having a bi-specificchimeric antigen receptor is provided, wherein the method comprisesintroducing into a cell a nucleic acid comprising a polynucleotidesequence encoding a bi-specific chimeric antigen receptor that comprisesa first binding domain specific for a ligand on a B cell, which promotesthe in vivo expansion and activation of the B cell, and a second bindingdomain specific for a ligand on a solid tumor, expanding the cells andisolating the cells. In some alternatives, the polynucleotide resides ona viral vector. In some alternatives, the viral vector is a lentiviralvector or a retroviral vector. In some embodiments, the viral vector isa gammaretroviral vector. In some alternatives, the bi-specific chimericantigen receptor is co-expressed with a marker protein. In somealternatives, the marker protein is EGFRt or Her2tg. In somealternatives, the method further comprises introducing a vector encodinga soluble protein into said cell.

In some alternatives, the method further comprises selecting the cellsby immunomagnetic selection or cell sorting. In some alternatives, themethod further comprises selecting the cells by immunobinding the markerprotein on the cell surface.

In some aspects, utilization of Her2tg or EGFRt tag as a genetictag/marker allows for the ex vivo selection and purification ofhomogenous populations of cellular therapeutics that express thetransgene of interest. In addition, Her2t can be used to track cellulartherapeutics in vivo; for instance, Her2t can be used as a target forHerceptin staining of blood, bone marrow and cerebrospinal fluidaspirates to check for the persistence of transgene-expressing cellulartherapeutics to follow cancer remission to therapeutic persistence in apatient. Her2t extends the therapeutic reach of CAR therapy by allowingfor the concerted purification of cells expressing multiple transgeneswhen used with another genetic tag such as EGFRt. In some alternatives,the method further comprises selecting the cells that express thebi-specific CAR by immunomagnetic selection or cell sorting. In somealternatives, the method further comprises selecting the cellsexpressing the bi-specific marker by immunobinding the marker protein onthe cell surface. In some alternatives, the marker protein is Her2tgand/or EGFRt.

Methods of Making a Cell Comprising a Bi-Specific Chimeric AntigenReceptor for Bi-Specificity Using a Transposase System

In some alternatives, a method of making a cell comprising a bi-specificchimeric antigen receptor is provided. In some alternatives, the methodcomprises introducing into a cell a vector, wherein the vector comprisesa first nucleic acid encoding a bi-specific chimeric antigen receptorcomprising a first binding domain and a second binding domain, whereinthe first binding domain is specific for a ligand on a B cell, whichpromotes the in vivo expansion and activation of the B cell, and thesecond binding domain is specific for a ligand on a solid tumor,expanding the cell and isolating the cell. In some alternatives, thefirst nucleic acid and the second nucleic acid reside between a firstinverted terminal repeat gene sequence and a second inverted terminalrepeat gene sequence. In some alternatives, the first inverted terminalrepeat gene sequence and the second inverted terminal repeat genesequence are Sleeping Beauty inverted terminal repeat gene sequences orPiggyBaC inverted terminal repeat gene sequences. In some alternatives,the vector is a plasmid or a minicircle transposon. In somealternatives, the method further comprises introducing into the cell apolynucleotide, wherein the polynucleotide sequence encodes an mRNA,wherein the mRNA encodes a transposase. In some alternatives, thetransposase is a Sleeping Beauty transposase or a Piggyback transposase.In some alternatives, expression of the bi-specific chimeric antigenreceptor is linked to co-expression of EGFRt or Her2tg. In somealternatives, the method further comprises further comprisingintroducing a vector comprising a sequence encoding a soluble proteininto said cell.

In some alternatives, the vector contains a promoter linked to apolynucleotide coding for a chimeric antigen receptor operably linked toa genetic tag. One or more PiggyBac transposons can be employed. In somealternatives, a PB comprises a promoter linked to a polynucleotidecoding for a chimeric antigen receptor and a first genetic tag, anotherPiggyBac comprises a promoter linked to a polynucleotide coding for achimeric antigen receptor, and a second and different genetic tag. Eachelement of the constructs is separated by a nucleic acid, such as thatcoding for a self-cleaving T2A sequence. In some alternatives, eachPiggyBac differs from one another in the chimeric antigen receptorincluding but not limited to the spacer length and sequence, theintracellular signaling domain, and/or the genetic tag sequence.

In some aspects, utilization of Her2tg or EGFRt tag as a genetictag/marker allows for the ex vivo selection and purification ofhomogenous populations of cellular therapeutics that express thetransgene of interest. In addition, Her2tg can be used to track cellulartherapeutics in vivo; for instance, Her2tg can be used as a target forHerceptin staining of blood, bone marrow and cerebrospinal fluidaspirates to check for the persistence of transgene-expressing cellulartherapeutics to follow cancer remission to therapeutic persistence in apatient. Her2tg extends the therapeutic reach of CAR therapy by allowingfor the concerted purification of cells expressing multiple transgeneswhen used with another genetic tag such as EGFRt. In some alternatives,the method further comprises selecting the cells by immunomagneticselection or cell sorting. In some alternatives, the method furthercomprises selecting the cells by immunobinding the marker protein on thecell surface. In some alternatives, the marker protein is Her2tg and/orEGFRt.

Methods of Treating, Ameliorating, or Inhibiting a Non-B Cell RelatedDisease in a Subject

In some alternatives, a method of treating, ameliorating, or inhibitinga non-B cell related disease in a subject is provided, wherein themethod comprises introducing, providing, or administering any one ormore of the cells or compositions of any of the alternatives describedherein or the cells made by any one or more of the methods of any of thealternatives described herein into a subject for therapy. In somealternatives, the cells that are administered are provided by anallogeneic transfer. In some alternatives, the cells that areadministered are provided by an autologous transfer. In somealternatives the cells comprise a first and second chimeric antigenreceptor, wherein the first chimeric antigen receptor is specific for aligand on a B cell, which promotes the in vivo expansion and activationof an effector cell and, wherein the second chimeric antigen receptor isspecific for a ligand on a tumor. In some alternatives of the cells, theligand on a B cell is CD1d, CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilonRII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40(TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79,CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD,B220/CD45R, C1q R1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R,B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14,BLIMP1/PRDM1, CXCR4, DEP-1/CD148, EMMPRIN/CD147 and/or tumor targets ontumors that are non-B cell tumors.

In some alternatives, the ligand on the tumor is a cancer antigen. Insome alternatives, the cancer antigen is EGFR, HER2, Mesothelin, cancertestis antigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2,glypican-2 (GPC2), HPV antigens, alphafetoprotein, carcinoembryonicantigen, CA-125, MUC-1, epithelial tumor antigen, abnormal products ofras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin,AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM,EphA3, EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In some alternatives, the cellsurface tumor specific molecule is ROR1. In some alternatives, the firstchimeric antigen receptor and/or the second chimeric antigen receptorare inducibly expressed in said cell. In some alternatives, expressionof the first chimeric antigen receptor and/or the second chimericantigen receptor is under the control of a regulatory element. In somealternatives, the first chimeric antigen receptor comprises an antibodyor binding fragment thereof or scFv, a receptor ligand, peptide, and/orpolypeptide affinity molecule. In some alternatives, the second chimericantigen receptor comprises an antibody or binding fragment thereof orscFv, a receptor ligand, peptide, and/or polypeptide affinity molecule.In some alternatives, a first marker protein is co-expressed with thefirst chimeric antigen receptor and a second marker protein isco-expressed with the second chimeric antigen receptor. In somealternatives, the first marker protein co-expressed with the firstchimeric antigen receptor is EGFRt and the second marker proteinco-expressed with the second chimeric antigen receptor is Her2tg orfirst marker protein co-expressed with the first chimeric antigenreceptor is Her2tg and the second marker protein co-expressed with thesecond chimeric antigen receptor is EGFRt. In some alternatives, thecell is a CD8+ T cytotoxic lymphocyte cell selected from the groupconsisting of naïve CD8+ T-cells, CD8+ memory T-cells, central memoryCD8+ T-cells, regulatory CD8+ T-cells, IPS derived CD8+ T-cells,effector memory CD8+ T-cells and bulk CD8+ T-cells. In somealternatives, the cell is a CD4+ T helper lymphocyte cell that isselected from the group consisting of naïve CD4+ T-cells, CD4+ memoryT-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells, IPSderived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells.

In some alternatives, the cell comprises a bi-specific chimeric antigenreceptor, wherein the bi-specific chimeric antigen receptor comprisestwo binding domains, wherein a first binding domain is specific for aligand on a B cell, which promotes the in vivo expansion and activationof the B cell and a second binding domain is specific for a ligand on atumor. In some alternatives, the ligand on a B cell is CD1d, CD5, CD19,CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, EMMPRIN/CD147 and/or tumor targets that are non-B celltumors. In some alternatives, the ligand on the tumor is a cancerantigen. In some alternatives, the ligand on the tumor is a cancerantigen. In some alternatives, the cancer antigen is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAMS, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cell surface tumor specific molecule is ROR1. In somealternatives, the first and second binding domain comprises an antibodyor portion thereof, a receptor ligand or mutant thereof, peptide, and/orpolypeptide affinity molecule or binding partner.

In some alternatives, the subject is monitored for B-cell aplasia. Insome alternatives, the subject is administered a drug to induce theB-Cell specific CAR expression.

In some alternatives, expression of a CAR is under the control of afirst promoter inducible by a drug. The drug is selected based on safetyrecord, favorable pharmacokinetic profile, tissue distribution, a lowpartition coefficient between the extracellular space and cytosol, lowimmunogenicity, low toxicities, and/or high expression in lymphocytes.In a specific alternative, a drug is selected that is FDA approved,provides for transgene expression in lymphocytes, does not activateother undesirable gene expression, and induces a promoter that does notcontain any xenogeneic components. In some alternatives, the induciblepromoter is activated by a transcriptional activator that interacts witha drug. The transcriptional activator is activated or able to bind toand activate the inducible promoter in the presence of the drug.

A specific alternative of a drug is a drug that binds to an estrogenreceptor ligand binding domain of a transcriptional activator. In somealternatives, the drug includes tamoxifen, its metabolites, analogs, andpharmaceutically acceptable salts and/or hydrates or solvates thereof.In some alternatives, a specific alternative of a drug is a drug thatbinds to an estrogen receptor ligand binding domain of a transcriptionalactivator. In some alternatives, the drug is estrogen or glucocorticoid.

Tamoxifen, CAS RN: 10540-29-1, is also known as2-(4-((1Z)-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-ethanamine, or(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC),and has a molecular formula of C₂₆H₂₉NO, M.W. 371.52. Tamoxifen is aSelective Estrogen Receptor Modulator with tissue-specific activities.Tamoxifen acts as an anti-estrogen (inhibiting agent) agent in themammary tissue, but as an estrogen (stimulating agent) in cholesterolmetabolism, bone density, and cell proliferation in the endometrium.Tamoxifen is frequently administered orally as a pharmaceuticallyacceptable salt. For example, Tamoxifen citrate (RN 54965-24-1, M.W.563.643) is indicated for treatment of metastatic breast cancer, and asan adjuvant for the treatment of breast cancer in women followingmastectomy axillary dissection, and breast irradiation. Tamoxifencitrate is also indicated to reduce incidence of breast cancer in womenat high risk for breast cancer.

Metabolites of tamoxifen in rat, mouse and human breast cancer patients,including major metabolites N-desmethyltamoxifen (RN 31750-48-8, M.W.357.494) and 4-hydroxytamoxifen (4-OHT) (RN 68392-35-8, M.W. 387.52,Afimoxifene), are disclosed in Robinson et al., Metabolites,pharmacodynamics, and pharmacokinetics of tamoxifen in rats and micecompared to the breast cancer patient. Drug Metab Dispos January 199119:36-43, which is incorporated by reference herein in its entirety.Additional cytochrome P-450 metabolites are disclosed in Crewe et al.,2002, including cis-4-hydroxytamoxifen (RN 174592, M.W. 387.52;Afimoxifene, E-isomer), and 4′-hydroxytamoxifen((Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-1-phenylbut-1-en-2-yl)phenol).See Crewe et al., 2002, Metabolism of Tamoxifen by recombinant humancytochrome P-450 enzymes: Formation of the 4-hydroxy, 4′-hydroxy andN-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen,Drug Metab Dispos, 30(8): 869-874, FIG. 1, which is incorporated hereinin its entirety by reference.

Compounds with structural similarity to tamoxifen include, but are notlimited to, cis-tamoxifen (RN 13002-65-8, M.W. 371.521),4-methyltamoxifen (RN 73717-95-5, M.W. 385.548), N-desmethyltamoxifen(RN 31750-48-8, M.W. 357.494), (Z)-desethyl methyl tamoxifen (RN15917-50-7, M.W. 357.494), (E)-desethyl methyl tamoxifen (RN 31750-45-5,M.W. 357.494), trans-4-hydoxytamoxifen (RN 68047-06-3, M.W. 387.52),Afimoxifene (RN 68392-35-8, M.W. 387.52, 4-hydroxytamoxifen),Afimoxifene, E-isomer (RN 174592-47-3, M.W. 387.52), 4-chlorotamoxifen(RN 77588-46-6, M.W. 405.966), 4-fluorotamoxifen (RN 73617-96-6, M.W.389.511), Toremifene (RN 89778-26-7, M.W. 405.966), desethyl tamoxifen(RN 19957-51-8, M.W. 343.47), (E)-desethyl tamoxifen (RN 97151-10-5,M.W. 343.47), (Z)-desethyl tamoxifen (RN 97151-11-6, M.W. 343.47),Miproxifene (RN 129612-87-9, M.W. 429.6),2-(p-(beta-ethyl-alpha-phenylstyryl)phenoxy)triethylamine (RN 749-86-0,M.W. 399.575), Droloxifene (RN 82413-20-5, M.W. 387.52),4-iodo-tamoxifen (RN 116057-68-2, M.W. 497.413), dihydrotamoxifen (RN109640-20-2, M.W. 373.537),(E)-N,N-dimethyl-2-(4-(1-(2-methylphenyl)-2-phenyl-1-butenyl)phenoxy)ethanamine(RN 97150-96-4, M.W. 385.548), or 4-hydroxytoremifene (RN 110503-62-3,M.W. 421.965); and/or pharmaceutically acceptable salts and/or hydratesor solvates thereof.

For example, citrate salts of tamoxifen, or citrate salts of compoundswith structural similarity to tamoxifen, include, but are not limited totamoxifen citrate (RN 54965-24-1, M.W. 563.64),2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine citrate (RN7244-97-5, 563.64), (E)-tamoxifen citrate (RN 76487-65-5, M.W. 563.64),Toremifene citrate (RN 89778-27-8, M.W. 598.088), Droloxifene citrate(RN 97752-20-0, M.W. 579.64),2-(p-(1,2-bis(p-methoxyphenyl)-1-butenyl)phenoxy)triethylamine citrate(RN 42920-39-8, M.W. 651.748),2-(4-(1,2-diphenylethenyl)phenoxy)-N,N-diethyl-ethanamine2-hydroxy-1,2,3-propanetricarboxylate (RN 40297-42-5, M.W. 563.643),2-(p-(alpha-phenylstyryl)phenoxy)triethylamine citrate (RN 102433-95-4,M.W. 563.64),2-(p-(2-(p-methoxyphenyl)-1-phenyl-1-butenyl)phenoxy)triethylaminecitrate (1:1) (RN 42824-34-0, M.W. 637.72),2-(p-(1-(p-methoxyphenyl)-2-phenylpropenyl)phenoxy)triethylamine citrate(RN 13554-24-0, M.W. 607.696),2-(p-(alpha-(p-methoxyphenyl)styryl)phenoxy)triethylamine citratemonohydrate (RN 13542-71-7, M.W. 593.669),2-(p-(p-methoxy-alpha-phenylphenethyl) phenoxy)triethylamine citrate (RN16421-72-0, M.W. 595.685),alpha-(p-(2-(diethylamino)ethoxy)phenyl)-beta-ethyl-p-methoxy-alpha-phenylphenethylalcohol citrate (1:1) (RN 35263-93-5, M.W. 639.737),1-(p-(2-(diethylamino)ethoxy)phenyl)-2-(p-methoxyphenyl)-1-phenylethanolcitrate (M.W. 611.68),alpha-p-(2-(diethylamino)ethoxy)phenyl)-beta-ethyl-alpha-(p-hydroxyphenyl)-p-methoxyphenethylalcohol citrate (RN 35263-96-8, M.W. 655.737), and/or2-(p-(p-methoxy-alpha-methylphenethyl)phenoxy)-triethylamine citrate (RN15624-34-7, M.W. 533.614).

In some alternatives, an affective amount of the drug for inducingexpression of a chimeric antigen receptor is an amount that provides foran increase in transgene expression over uninduced and/or basal level ofexpression. In some alternatives, this amount can be readily determinedusing known dosages and pharmacokinetic profile of the drug.

In some alternatives, the inducible promoter has a low level of basalactivity. When a lentiviral vector is used, the level of basal activityin uninduced cells is 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% or less, ascompared to when cells are induced to express the gene. The level ofbasal activity can be determined by measuring the amount of theexpression of the transgene (e.g. marker gene) in the absence of theinducer (e.g. drug) using flow cytometry.

In some alternatives, the inducible promoter provides for a high levelof induced activity, as compared to uninduced or basal activity. In somealternatives, the level of activity in the induced state is 2, 4, 6, 8,or 10 fold or greater than the activity level in the uninduced state. Insome alternatives, transgene expression under control of the induciblepromoter is turned off in the absence of a transactivator in less than10, 8, 6, 4, 2, or 1 days excluding 0 days.

In some alternatives, an inducible promoter can be designed and/ormodified to provide for a low level of basal activity, a high level ofinducibility, and/or a short time for reversibility. In somealternatives, the inducible promoter is the 7xHBD/mE1b promoter.

In some alternatives, the subject is administered a drug to induce a CARthat is specific for tumor targeting. In some alternatives, the subjectis administered tamoxifen, or its active metabolite, wherein thetamoxifen, or its active metabolite induce expression of the B-Cellspecific CAR. In some alternatives, wherein the subject is diagnosedwith B-cell aplasia, the administration of tamoxifen or its metaboliteis stopped. In some alternatives, the method further comprises cycles ofadministering tamoxifen or its metabolite and periods of rest. In somealternatives, the method further comprises administering to the subjectin need, subject derived B-cells. In some alternatives, the methodfurther comprises administering T-APCs that express the cell surface Bcell ligand or antigen. In some alternatives, the subject does not havea B-cell related disease. In some alternatives, the disease is a cancer.In some alternatives, the disease is an infection. In some alternatives,the infection is a bacterial or viral infection. In some alternatives,the cancer is a solid tumor. In some alternatives, the solid tumor isselected from the group consisting of a breast cancer, brain cancer,lung cancer, liver cancer, stomach cancer, spleen cancer, colon cancer,renal cancer, pancreatic cancer, prostate cancer, uterine cancer, skincancer, head cancer, neck cancer, sarcomas, neuroblastomas and ovariancancer. In some alternatives, the subject is identified or selected toreceive a non-B cell related disease therapy, anti-cancer therapy,anti-infection therapy, antibacterial therapy, anti-viral therapy, oranti-tumoral therapy. In some alternatives, the method further comprisesfurther comprising measuring or evaluating an inhibition of said non-Bcell related disease, cancer, infection, bacterial infection, viralinfection, or tumor. In some alternatives, the method further comprisesmeasuring or evaluating an inhibition of said non-B cell relateddisease, cancer, infection, bacterial infection, viral infection, ortumor. In some alternatives, the method further comprises introducing,providing, or administering to said subject an additional therapeuticagent, such as a chemotherapeutic agent, an antiviral agent, or anantibacterial agent or an adjunct therapy such as radiation therapyand/or surgery before, during, or after introducing, providing, oradministering any one or more of the cells or compositions providedherein or the cells made by any one or more of the methods providedherein into the subject. In some alternatives, the cells or compositionsare introduced, provided, or administered to said subject by adoptivecell transfer. In some alternatives, the method further comprisesintroducing, providing, or administering a drug that induces expressionof a chimeric antigen receptor. In some alternatives, the drug istamoxifen and/or its metabolites. In some alternatives, the drug is asteroid. In some alternatives, the subject is a mammalian species. Insome alternatives, the subject is a cow, sheep, pig, horse, dog, cat,primate or a human. In some alternatives, the subject is human.

In some alternatives, the method further comprises evaluating thesubject for symptoms of cytokine storm or B-cell aplasia. In somealternatives, the subject is suffering from high fevers, increase ordecrease of blood pressure, hypotension, hypoxia, seizures, or aphasia.In some alternatives, the subject has an elevation in ferritin and/orC-reactive protein. In some alternatives of the methods provided herein,wherein the cells comprise a suicide gene system, the methods furthercomprise administering to the subject a prodrug.

In some alternatives, the subject does not have B-cell lymphoma,Hodgkin's lymphomas, non-Hodgkins lymphomas, Diffuse large B celllymphoma, Follicular lymphoma, marginal zone lymphoma, Mucosa-AssociatedLymphatic Tissue lymphoma, small lymphocytic lymphoma, chroniclymphocytic leukemia, mantle cell lymphoma, Burkitt lymphoma, primarymediastinal (thymic) large B cell lymphoma, Lymphoplasmacytic lymphoma,Waldenstrom macroglobulinermia, Nodal marginal zone B cell lymphoa,splenic marginal zone lymphoma, intravascular large B cell lymphoma,Intravascular large B-cell lymphoma, Primary effusion lymphoma,Lymphomatoid granulomatosis, T cell/histiocyte-rich large B-celllymphoma, Primary central nervous system lymphoma, Primary cutaneousdiffuse large B-cell lymphoma (leg type), EBV positive diffuse largeB-cell lymphoma of the elderly, Diffuse large B-cell lymphoma associatedwith inflammation, Intravascular large B-cell lymphoma, ALK-positivelarge B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablasticlymphoma, Large B-cell lymphoma arising in HHV8-associated multicentricCastleman's disease, B-cell lymphoma, unclassifiable with featuresintermediate between diffuse large B-cell lymphoma and Burkitt lymphoma,B-cell lymphoma, unclassifiable with features intermediate betweendiffuse large B-cell lymphoma and classical Hodgkin lymphoma, or nodularlymphocyte predominant Hodgkin's lymphoma. In some alternatives, thesubject has breast cancer, brain cancer, lung cancer, liver cancer,stomach cancer, spleen cancer, colon cancer, renal cancer, pancreaticcancer, prostate cancer, uterine cancer, skin cancer, head cancer, neckcancer, sarcomas, neuroblastomas or ovarian cancer. In somealternatives, the subject has refractory and relapsed neuroblastoma.

Nucleic Acids Encoding a Chimeric Antigen Receptor or a Bi-SpecificChimeric Antigen Receptor and Method of Making the Nucleic AcidsEncoding a Chimeric Antigen Receptor or a Bi-Specific Chimeric AntigenReceptor

In some alternatives, a nucleic acid encoding a chimeric antigenreceptor is provided wherein the nucleic acid comprises a first nucleicacid comprising a sequence encoding a leader sequence, a second nucleicacid comprising a sequence encoding an antibody or binding fragmentthereof or scFv, wherein the antibody or binding fragment thereof orscFv is specific for a B-cell specific cell surface molecule, andwherein the first nucleic acid is covalently attached to a 5′ end of thesecond nucleic acid, a third nucleic acid comprising a sequence encodinga de-immunized extracellular spacer, wherein the third nucleic acid iscovalently attached to a 3′ end of the second nucleic acid, a fourthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the fourth nucleic acid is covalently attached to a 3′ end ofthe third nucleic acid, a fifth nucleic acid comprising a sequenceencoding a signaling domain, wherein the signaling domain comprises a4-1BB domain and/or CD3-zeta domain, and wherein the fifth nucleic acidis covalently attached to a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a linker, wherein the sixthnucleic acid is covalently attached to a 3′ end of the fifth nucleicacid and a seventh nucleic acid comprising a sequence encoding a markerdomain, wherein the seventh nucleic acid is covalently attached to a 3′end of the sixth nucleic acid, thereby having said nucleic acid encodinga chimeric antigen receptor. In some alternatives, the linker sequenceis a ribosome skip sequence or an IRES sequence. In some alternatives,the first promoter is inducible by tamoxifen and/or its metabolites. Insome alternatives, the first promoter is inducible by a steroid e.g., acompound capable of binding to the estrogen receptor, or an estrogenreceptor ligand. In some alternatives, the steroid is flustravant.

In some alternatives, a nucleic acid encoding a chimeric antigenreceptor is provided wherein the nucleic acid comprises a first nucleicacid comprising a sequence encoding a leader sequence, a second nucleicacid comprising a sequence encoding a first promoter inducible by adrug, wherein the first nucleic acid is covalently attached to a 5′ endof the second nucleic acid, a third nucleic acid comprising a sequenceencoding an antibody or binding fragment thereof or scFv, wherein theantibody or binding fragment thereof or scFv is specific for a cellsurface molecule expressed by B cells, and wherein the third nucleicacid is covalently attached to a 3′ end of the second nucleic acid, afourth nucleic acid comprising a sequence encoding a de-immunizedextracellular spacer, wherein the fourth nucleic acid is covalentlyattached to a 3′ end of the third nucleic acid, a fifth nucleic acidcomprising a sequence encoding a transmembrane domain, wherein the fifthnucleic acid is covalently attached to a 3′ end of the fourth nucleicacid, a sixth nucleic acid comprising a sequence encoding a signalingdomain, wherein the signaling domain comprises a 4-1BB domain and/orCD3-zeta domain, and wherein the sixth nucleic acid is covalentlyattached to a 3′ end of the fifth nucleic acid, a seventh nucleic acidcomprising a sequence encoding a linker, wherein the seventh nucleicacid is covalently attached to a 3′ end of the sixth nucleic acid and aneighth nucleic acid comprising a sequence encoding a marker domain,wherein the eighth nucleic acid is covalently attached to a 3′ end ofthe seventh nucleic acid, thereby having said nucleic acid encoding achimeric antigen receptor. In some alternatives, the linker sequence isa ribosome skip sequence or an IRES sequence. In some alternatives, thefirst promoter is inducible by tamoxifen and/or its metabolites. In somealternatives, the first promoter is inducible by flustravant. In somealternatives, the first promoter is inducible by a steroid (e.g.estrogen, glucocorticoid).

In some alternatives, a nucleic acid encoding a bi-specific chimericantigen receptor is provided, wherein the nucleic acid comprises a firstnucleic acid sequence comprising a sequence encoding a leader sequence,a second nucleic acid comprising a sequence encoding an antibody orbinding fragment thereof or scFv, wherein the antibody or bindingfragment thereof or scFv is specific for a B cell specific cell surfacemolecule or is specific for a cell surface tumor specific molecule, andwherein the first nucleic acid is covalently attached at a 5′ end of thesecond nucleic acid, a third nucleic acid comprising a sequence encodingan antibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B cell specific cellsurface molecule or is specific for a cell surface tumor specificmolecule, and wherein the third nucleic acid is covalently attached at a3′ end of the second nucleic acid, a fourth nucleic acid comprising asequence encoding a de-immunized extracellular spacer, wherein thefourth nucleic acid is covalently attached at a 3′ end of the thirdnucleic acid, a fifth nucleic acid comprising a sequence encoding atransmembrane domain, wherein the fifth nucleic acid is covalentlyattached at a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a signaling domain sequence, wherein thesignaling domain comprises a co-stimulatory domain, wherein theco-stimulatory domain comprises a 4-1BB domain, CD3-zeta domain and/orCD28-zeta domain and wherein the sixth nucleic acid is covalentlyattached at a 3′ end of the fifth nucleic acid, a seventh nucleic acidcomprising a sequence encoding a linker, wherein the seventh nucleicacid is covalently attached at a 3′ end of the sixth nucleic acid and aneighth nucleic acid comprising a sequence encoding a marker domain,wherein the eighth nucleic acid is covalently attached at a 3′ end ofthe seventh nucleic acid, thereby having said nucleic acid encoding abi-specific chimeric antigen receptor. In some alternatives, the linkersequence is a ribosome skip sequence or an IRES sequence. In somealternatives, the fifth nucleic acid sequence further comprises an IRESsequence at the 3′ end of the fifth nucleic acid sequence. In somealternatives, the second nucleic acid encodes an antibody or bindingfragment thereof or scFv, and wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface moleculeand the third nucleic acid comprises a sequence encoding an antibody orbinding fragment thereof or scFv, wherein the antibody or bindingfragment thereof or scFv is specific for a cell surface tumor specificmolecule or wherein the second nucleic acid encodes an antibody orbinding fragment thereof or scFv, wherein the antibody or bindingfragment thereof or scFv is specific for a cell surface tumor specificmolecule and the third nucleic acid comprises a sequence encoding anantibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific B cell specific cellsurface molecule.

In some alternatives, a nucleic acid encoding a suicide gene system isprovided.

Vectors

In some alternatives, a vector for expression of a chimeric antigenreceptor specific for promoting in vivo expansion and activation of Bcells is provided, wherein the vector comprises the nucleic acid of anyof the alternatives described herein. In some alternatives, the nucleicacid comprises a first nucleic acid comprising a sequence encoding aleader sequence, a second nucleic acid comprising a sequence encoding anantibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B-cell specific cellsurface molecule, and wherein the first nucleic acid is covalentlyattached to a 5′ end of the second nucleic acid, a third nucleic acidcomprising a sequence encoding a de-immunized extracellular spacer,wherein the third nucleic acid is covalently attached to a 3′ end of thesecond nucleic acid, a fourth nucleic acid comprising a sequenceencoding a transmembrane domain, wherein the fourth nucleic acid iscovalently attached to a 3′ end of the third nucleic acid, a fifthnucleic acid comprising a sequence encoding a signaling domain, whereinthe signaling domain comprises a 4-1BB domain and/or CD3-zeta domain,and wherein the fifth nucleic acid is covalently attached to a 3′ end ofthe fourth nucleic acid, a sixth nucleic acid comprising a sequenceencoding a linker, wherein the sixth nucleic acid is covalently attachedto a 3′ end of the fifth nucleic acid and a seventh nucleic acidcomprising a sequence encoding a marker domain, wherein the seventhnucleic acid is covalently attached to a 3′ end of the sixth nucleicacid, thereby having said nucleic acid encoding a chimeric antigenreceptor. In some alternatives, the linker sequence is a ribosome skipsequence or an IRES sequence. In some alternatives, the first promoteris inducible by tamoxifen and/or its metabolites. In some alternatives,the first promoter is inducible by a steroid.

In some alternatives, the nucleic acid comprises a first nucleic acidcomprising a sequence encoding a leader sequence, a second nucleic acidcomprising a sequence encoding a first promoter inducible by a drug,wherein the first nucleic acid is covalently attached to a 5′ end of thesecond nucleic acid, a third nucleic acid comprising a sequence encodingan antibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a cell surface moleculeexpressed by B cells, and wherein the third nucleic acid is covalentlyattached to a 3′ end of the second nucleic acid, a fourth nucleic acidcomprising a sequence encoding a de-immunized extracellular spacer,wherein the fourth nucleic acid is covalently attached to a 3′ end ofthe third nucleic acid, a fifth nucleic acid comprising a sequenceencoding a transmembrane domain, wherein the fifth nucleic acid iscovalently attached to a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a signaling domain, whereinthe signaling domain comprises a 4-1BB domain and/or CD3-zeta domain,and wherein the sixth nucleic acid is covalently attached to a 3′ end ofthe fifth nucleic acid, a seventh nucleic acid comprising a sequenceencoding a linker, wherein the seventh nucleic acid is covalentlyattached to a 3′ end of the sixth nucleic acid and an eighth nucleicacid comprising a sequence encoding a marker domain, wherein the eighthnucleic acid is covalently attached to a 3′ end of the seventh nucleicacid, thereby having said nucleic acid encoding a chimeric antigenreceptor. In some alternatives, the linker sequence is a ribosome skipsequence or an IRES sequence. In some alternatives, the first promoteris inducible by tamoxifen and/or its metabolites. In some alternatives,the first promoter is inducible by flustravant. In some alternatives,the first promoter is inducible by a steroid.

In some alternatives, the nucleic acid comprises a first nucleic acidsequence comprising a sequence encoding a leader sequence, a secondnucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface moleculeor is specific for a cell surface tumor specific molecule, and whereinthe first nucleic acid is covalently attached at a 5′ end of the secondnucleic acid, a third nucleic acid comprising a sequence encoding anantibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B cell specific cellsurface molecule or is specific for a cell surface tumor specificmolecule, and wherein the third nucleic acid is covalently attached at a3′ end of the second nucleic acid, a fourth nucleic acid comprising asequence encoding a de-immunized extracellular spacer, wherein thefourth nucleic acid is covalently attached at a 3′ end of the thirdnucleic acid, a fifth nucleic acid comprising a sequence encoding atransmembrane domain, wherein the fifth nucleic acid is covalentlyattached at a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a signaling domain sequence, wherein thesignaling domain comprises a co-stimulatory domain, wherein theco-stimulatory domain comprises a 4-1BB domain, CD3-zeta domain and/orCD28-zeta domain and wherein the sixth nucleic acid is covalentlyattached at a 3′ end of the fifth nucleic acid, a seventh nucleic acidcomprising a sequence encoding a linker, wherein the seventh nucleicacid is covalently attached at a 3′ end of the sixth nucleic acid and aneighth nucleic acid comprising a sequence encoding a marker domain,wherein the eighth nucleic acid is covalently attached at a 3′ end ofthe seventh nucleic acid, thereby having said nucleic acid encoding abi-specific chimeric antigen receptor. In some alternatives, the linkersequence is a ribosome skip sequence or an IRES sequence. In somealternatives, the fifth nucleic acid sequence further comprises an IRESsequence at the 3′ end of the fifth nucleic acid sequence. In somealternatives, the second nucleic acid encodes an antibody or bindingfragment thereof or scFv, and wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface moleculeand the third nucleic acid comprises a sequence encoding an antibody orbinding fragment thereof or scFv, wherein the antibody or bindingfragment thereof or scFv is specific for a cell surface tumor specificmolecule or wherein the second nucleic acid encodes an antibody orbinding fragment thereof or scFv, wherein the antibody or bindingfragment thereof or scFv is specific for a cell surface tumor specificmolecule and the third nucleic acid comprises a sequence encoding anantibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific B cell specific cellsurface molecule.

In some alternatives, the vector expresses a chimeric antigen receptorspecific for promoting in vivo expansion and activation of B cells. Insome alternatives, the vector expresses a chimeric antigen receptorspecific for targeting a solid tumor. In some alternatives, the vectorcomprises a first sequence encoding a first promoter sequence, whereinthe first promoter sequence promotes expression of the chimeric antigenreceptor, and wherein the vector comprises a second sequence encoding asecond promoter sequence, wherein the second promoter sequence promotesexpression of a marker protein.

In some alternatives, the vector further comprises a nucleic acidencoding a suicide gene system. In some alternatives, the vectorcomprises two inverted repeats, wherein the nucleic acid resides betweenthe two inverted repeats. In some alternatives, the vector is aminicircle. In some alternatives, the inverted repeats are SleepingBeauty or PiggyBac inverted repeats.

Additional Alternatives

Significant Expression of the Markers EGFRt and HertG Along with theirAppended CARs

As shown in FIG. 3, the marker Her2t and its variants demonstratevariable binding affinity to Herceptin based on their respective linker.The CARs used were dual CD19CAR-T2A-Her2tG/CD20CAR-T2A-EGFRt in theT-lymphocytes. As shown in FIG. 3A, H9 T cells were transduced with 3 ulof lentivirus containing the Her2t variant Her2t(CD28hinge),Her2t(IgG4hinge) or Her2tG (gly-ser linker). The transduced H9 cellswere then cultured for 5 days and stained with biotinylated Herceptin(Herceptin-bio) and a streptavidin conjugated secondary fluorophore(SA-PE). Results demonstrate that the Her2t variant Her2tG displays thegreatest ability to bind Herceptin, Her2t(IgG4hinge) with modestHerceptin binding and Her2t(CD28hinge) with the weakest Herceptinbinding. These cells were never stimulated with CD3/CD28 beads (FIG.3C). Shown in FIG. 3B, is a timeline for the isolation (D0), growth(D0-21), selection (D14 and D21) and expansion (REP—D21) of CD4+ andCD8+ primary T cells isolated from PBMCs as per FIG. 4 below. These areCD8+ T cells transduced with two separate lentiviruses containingCD19CAR-T2A-Her2tG or CD20CAR-T2A-EGFRt at an MOI=1 for each lentivirus.Pre-selection CD8+ T cells were stained with Erbitux-APC,biotinylated-Herceptin and a streptavidin conjugated secondaryfluorophore (SA-PE) seven days post transduction (D10 of culture), whilePost-selection cells were stained on S1Sp1D12 (See FIG. 4). As shown inFIG. 3D, cell lysis for western blot analysis was carried out in RIPAbuffer containing protease inhibitor cocktail. Cell lysates wereanalyzed by BCA assay (Pierce), equally loaded onto gels and westernblots were probed with the primary antibody anti CD247 (CD3ζ) and thesecondary IRDye 800CW conjugated goat anti-mouse antibody (LI-COR).Blots were imaged on the Odyssey Infrared Imaging System (LI-COR).

Selection of CD4 and CD8 T-Cells

CD4 and CD8 bulk T cells were isolated from human peripheral bloodmononuclear cells (PBMCs) derived from blood discard kits of healthydonors (Puget Sound Blood Center). PBMCs from each donor were split intotwo groups (CD4 or CD8 bulk isolation) and Automacs depleted using CD4or CD8 isolation kits (Miltenyi Biotec) as per the manufacturer'sprotocol. Isolated cells were then stimulated (S1) with 50 U/mlinterleukin-2 (IL-2) for CD8, 5 ng/ml interleukin-7 (IL-7) for CD4, 1ng/ml interleukin-15 (IL-15) and anti-CD3/CD28 beads (LifeTechnologies). CD4 and CD8 T cells were transduced on day 3 afteractivation using protamine sulfate (1:100 dilution) and a virus MOI of 1followed by centrifugation at 800×g for 30 minutes at 32° C. The Her2t⁺or EGFRt subset of each cell line was enriched by immunomagneticselection with biotin-conjugated Herceptin or Erbitux and anti-biotinmicrobeads (Miltenyi). Selected CD19CAR⁺ and/or CD20CAR⁺ T cells wereexpanded 12-18 days post transduction by stimulation with irradiated(8000 rad) TM-LCL (Sp1) at a T cell:TM-LCL ratio of 1:7 in the presenceof 50 U/ml IL-2 (CD8), 5 ng/ml IL-7 (CD4) and 1 ng/ml IL-15. Cells wereharvested on Day 12 (D12) post stimulation and subjected to flowanalysis.

The cells of interest in the western blot are S1Sp1D12 (see FIG. 3) andhave already been purified for their respective marker/s. The dualtransduced cells are the CD19CAR-T2A-Her2tG and CD20CAR-T2A-EGFRtcontaining CD8+ T cells. This western blot is specific to the zetaportion of the CAR. It does not speak to the expression of the twomarker proteins Her2tG or EGFRt (see FIG. 3C and FIG. 4). The westernblot demonstrates CAR expression in the CD8+ T cells. Most importantly,expression of both CARs (CD19CAR and CD20CAR) in the dual transducedCD8+ T cells is seen.

Specificity of CD19 and CD20 CAR T-Cells Against K562 Target Panel Cells

CD8 Tcm were co-cultured with K562 target cells at a 30:1, 10:1, 3.3:1or 1.1:1 ratio. Only the dual transduced T cells were able to target allantigen expressing K562 cells. As shown in FIG. 5A, a 4-hour chromiumrelease assay was performed showing CD19- and CD20-CAR T cellspecificity against K562 target panel cells. CD8 Tcm were co-culturedwith K562 target cells at a 30:1, 10:1, 3.3:1 or 1.1:1 ratio. Only thedual transduced T cells were able to target all antigen expressing K562cells. The CD19CAR-T2A-Her2t and CD19CAR-T2A-EGFRt CD8 Tcm demonstratesimilar lytic capacity. A 24-hour cytokine release assay was alsoperformed using CD19, CD20 and CD19/CD20 bearing cells against K562targets. CD8 Tcm were co-cultured with K562 target cells at a 2:1 Tcell-to-target ratio for 24 hours and then supernatant was analyzed forthe presence of effector cytokines. CD19CAR-T2A-Her2t transduced CD8 Tcmproduced a more diverse repertoire and higher levels of effectorcytokines relative to CD19CAR-T2A-EGFRt transduced CD8 Tcm. The panelsare the same as in FIGS. 5A and 5B (Left to right: K562 CD19, K562 CD20and K562 CD19/CD20). Similar results were seen for CD4 Tcm. TheCD19CAR-T2A-Her2t and CD19CAR-T2A-EGFRt CD8 Tcm demonstrate similarlytic capacity, showing the efficacy of the CAR bearing T-cells. Asshown in FIG. 5C, similar results were seen for CD4 Tcm.

Raji Cells Electroporated with Plasmids Containing CD19 Targeted CRISPRGuide Sequences

Shown in FIGS. 6A-D are the experimental results of Raji cellselectroporated with plasmids containing CD19-targeted CRISPR guidesequences. Raji cells were subjected to negative selection using CD19microbeads. Post-depletion of CD19+ cells the CD19-cells were clonallyselected and expanded for downstream experiments. Seven days postelectroporation the Raji cells were subjected to negative selectionusing CD19 microbeads. (FIG. 6A). 4 hour chromium release assays andbioplex assays were then performed using the same cells from FIGS. 5Band C. A chromium release assay was also performed using CD4+ cells.

NSG Mice Injected with CAR Expressing T-Cells

Shown in FIG. 7 are the experimental results of NSG mice injected with5e⁶ NSO-IL15 cells and then 10e⁶ Mock or CAR expressing T cells i.v. OnDay 14 post T cell injection, mouse bone marrow was harvested andsubjected to flow analysis. Shown in the top row are gates live andsinglets. The middle row gates show CD8+×CD45+ cells. The bottom rowlooks at the CD45+ cell population and stains for the markers Her2tG andEGFRt. Results demonstrate that EGFRt and Her2tG can be used toefficiently track T cells in vivo. (FIG. 7, top row). Shown in themiddle row of FIG. 7, are cells gated for viable (93.6% lymphocytes),single (98.8%), and alive cells (99.9%). CD8 and CD45 staining of thecells are shown from left to right as Mock, CD19CAR-T2A-Her2t,CD19CAR-T2A-EGFRt Tcm, and CD19CAR-Her2tg/CD20CAR-EGFRt. At least 1×10⁷cells were recorded inside of the viable, single cell and alive gates.So although the CD45+ cells represent around 1% of the population, it isequivalent to 1×10⁵ cells. The remaining cells are mouse bone marrowcells. Shown in the last row of FIG. 7, are the Multisort purificationof Her2t and EGFRt positive T cells. For the experiment, H9 cells (5×10⁶parental, Her2t⁺, EGFRt⁺, or Her2t⁺/EGFRt⁺ were mixed together and thensubjected to purification. The cells were initially purified based onbiotinylated Herceptin and anti-biotin multisort beads. The multisortbeads were then removed and the positive fraction subsequently subjectedto purification based on Erbitux-APC and anti-APC microbeads. The finalpositive fraction was dual positive for Her2t and EGFRt.

Mice Expressing CAR T-Cells to Inhibit Tumor Growth

eGFP:ffluc expressing Raji target cells (10⁶) were i.v. injected into6-10 week old mice. Seven days later a total of 10⁷ CAR-Her2t⁺,CAR-EGFRt⁺ or dual CAR expressing T cells (1:1 ratio CD4:CD8) wereinjected intravenously (IV). Bioluminescent imaging was performed weeklyby intraperitoneal (i.p.) injection of 4.29 mg/mouse D-luciferin(Xenogen), anesthetization by isoflurane and imaging 10 minutes postD-luciferin injection using the IVIS Spectrum Imaging System (PerkinElmer). Luciferase activity was analyzed using Living Image SoftwareVersion 4.3 (Perkin Elmer) and photon flux was analyzed within regionsof interest. Shown in FIG. 8, the single CAR or dual CAR expressing Tcells were able to inhibit tumor growth relative to Mock T cells.

CD4 and CD8 T-Cells can be Transduced with Two Separate CAR-EncodingLentiviral Vectors

CD4 and CD8 purified T-cells were stimulated with CD3/CD28 beads andthen co-transduced with clinical grade virus encoding the 2^(nd)generation 41BB-t short spacer FMC63CD19CAR or the 2nd generation 41BB-ζshort spacer CE7CAR. Each CAR was followed by an in-frame T2A-EGFRt.Transduced T-cells were purified by EGFRt and frozen on S1D14 (CD4) orS1D15 (CD8). The process development project was PD0170. Shown in FIG.9A, the flow analysis demonstrates that transduced cells were purifiedto homogeneity based on EGFRt expression. Results do not demonstratewhat percentage of the CD19- or CE7CAR is represented in the EGFRt⁺population or whether the T-cells are indeed dual transduced with virus.FMC63 CD19CAR comprises the amino acid sequence set forth in SEQ ID NO:11 and is encoded by the sequence set forth in SEQ ID NO: 12. In somealternatives, FMC63 CD19CAR comprises the amino acid sequence set forthin SEQ ID NO: 11 and is encoded by the sequence set forth in SEQ ID NO:12.

CD19 and CE7CAR Dual Transduced T-Cells Demonstrate Specific LysisAgainst CD19 or L1CAM Positive Target Cell Lines

Mock (CAW) T-cells and dual transduced T-cells were co-cultured withtarget cell lines at different effector to target ratios for 4-hours.K562 are negative for both targets CD19 and L1CAM. TM-LCL, TM-LCL-OKT3,K562+CD19, and Raji are CD19-positive alone. SK-N-DZ are L1CAM-positivealone. SK-N-DZ+CD19 are positive for both targets. Shown in FIG. 9B, thetransduced CD8 or mixed CD4:CD8 T-cells elicit high levels of CD19CARactivity. There was a lower level of CE7CAR activity as demonstratedagainst the SK-N-DZ cell line. These results indicate that T-cells canbe successfully transduced with two separate CAR-encoding viruses andthe resultant T-cell population is able to recognize multiple antigens.

CD19- and CE7CAR Dual Transduced T-Cell Populations Produce CytokinesAgainst CD19 or L1CAM Positive Target Cell Lines

Dual transduced CD4 and CD8 T-cell populations were co-cultured for 24hours with target cell lines at a 2:1 effector-to-target ratio.Following the 24 hour incubation period, supernatant from theco-cultures was analyzed for the presence of IL-2, IFN-g, or TNF-a byBioplex assay as shown in FIG. 9C. The dual transduced T-cells producedcytokine in response to all suspension cell (LCL and K562) targetsexpressing CD19. There was little to no cytokine produced in response toSK-N-DZ which is not uncommon with the 2^(nd) Gen S-spacer CE7CAR evenwhen expressed in 100% of the T-cell population. Since it is not knownwhat percentage of the T-cell populations contain the CE7CAR this is notsurprising when combined with the chromium data in FIG. 9B.

Dual-Transduced T-Cells Elicit Antitumor Activity in an IntracranialXenograft Tumor Model

Cohorts of mice were inoculated with 0.2e6 SK-N-DZ that expressGFP:ffluc, CD19t, and IL-2 (Day 0) and 2e6 dual transduced CD4:CD8T-cells (1:1 ratio) (Day 7) intracranially (i.c.). Shown in FIG. 9D arethe results from serial bioluminescence imaging of tumors in cohorts ofmice treated with Mock (PBS only—left) or dual transduced CD4:CD8 CE7CART-cells (middle). Kaplan-Meier analysis (right) of survival in treatmentand control groups. The dual-transduced cells were able to regress andcontrol tumor growth as evidenced by a prolonged decrease inbioluminescence imaging. However, the tumor did grow out over time andthe mice slowly succumbed to tumor growth and were euthanized.

CD4 and CD8 T-Cells can be Transduced with Two Separate CAR-EncodingLentiviral Vectors and Dual Positive Populations can be Identified byAssociated Markers

CD4 and CD8 purified T-cells were stimulated with CD3/CD28 beads andthen individually or co-transduced with lentivirus encoding the 2^(nd)generation 41BB-t short spacer FMC63CD19CAR or/and the 2nd generation41BB-ζ long mutant (L235D, N297Q) spacer CE7CAR. The CD19CAR wasfollowed by an in-frame T2A-Her2tG and the CE7CAR by a T2A-EGFRt.Transduced T-cells were purified by EGFRt (CE7CAR) and frozen. Flowanalysis was performed on day 9 and demonstrates that transduced cellswere purified to homogeneity based on EGFRt expression (See FIG. 10A).For the CD4 T-cells there was ˜56% Her2tG (CD19CAR) positivity and ˜44%dual-positivity for the CD8 T-cells.

CD19 and CE7CAR Dual Transduced CD8⁺ T-Cells Demonstrate Specific LysisAgainst CD19 or L1CAM Positive Target Cell Lines

Mock (CAR⁻), single transduced (CD19CAR or CE7CAR) and dual transducedCD8⁺ T-cells were co-cultured with target cell lines at differenteffector to target ratios for 4-hours. K562 are negative for bothtargets CD19 and L1CAM. K562-OKT3 was used as a positive control. Be2are L1CAM-positive alone. Be2+CD19t are positive for both targets.Results demonstrate that the single transduced CD8⁺ T-cells elicitspecific lysis against their cognate antigen. However, the dualtransduced T-cells efficiently recognized and lysed cells expressingCD19, L1CAM or both antigens. All CD8⁺ T-cells were able to elicitsimilar levels of cell lysis against the K562-OKT3. These resultsindicate that T-cells can be successfully transduced with two separateCAR-encoding viruses, purified by a selection marker, and the resultantT-cell population is able to recognize multiple antigens (See FIG. 10B).

CD19- and CE7CAR Dual Transduced T-Cell Populations Produce CytokinesAgainst CD19 or L1CAM Positive Target Cell Lines

Mock (CAR⁻), single transduced (CD19CAR or CE7CAR) and dual transducedCD4⁺ and CD8⁺ T-cells were co-cultured for 24 hours with target celllines at a 2:1 effector-to-target ratio. Following the 24 hourincubation period, supernatant from the co-cultures was analyzed for thepresence of IL-2, IFN-g, or TNF-a by Bioplex assay, as shown in FIG.10C. Dual-transduced cells were able to release cytokine against alltarget expressing cell lines. While there was no difference in cytokineproduction between individual CE7CAR-expressing and dual CAR expressingT-cells against Be2-CD19t, there was a difference in cytokine productionbetween CD19CAR-expressing and dual transduced T-cells againstK562-CD19t. This coincides with the CD19CAR positivity of the dualtransduced T-cell populations.

Dual-Transduced T-Cells Elicit Antitumor Activity in an IntracranialXenograft Tumor Model

Cohorts of mice were inoculated with 0.2e6 SK-N-DZ that expressGFP:ffluc and IL-2 (Day 0) and 2e6 dual transduced CD4:CD8 T-cells (1:1ratio) (Day 7) intracranially (i.c.). Serial bioluminescence imaging oftumor in cohorts of mice treated with Mock (untransduced—left),CE7CAR-expressing (middle) or dual-transduced CD4:CD8 CE7CAR T-cells(right). Kaplan-Meier analysis (bottom) of survival in treatment andcontrol groups. Both the single CE7CAR-expressing and dual-transducedcells were able to regress and control tumor growth as evidenced by aprolonged decrease in bioluminescence imaging. A subset of mice treatedwith single CE7CAR-expressing T-cells was euthanized prior to thearbitrary end point of the study due to outgrowth of tumor. Theseresults show that dual-transduced T-cells are able to eradicate tumor invivo at levels similar to single CE7CAR-expressing T-cells. There wastherefore no inhibition in CE7CAR activity for the dual-transducedT-cell population (See FIG. 10D).

CD4 and CD8 T-Cells can be Transduced with Two Separate CAR-EncodingLentiviral Vectors and Dual Positive Populations can be Identified byAssociated Markers

CD4 and CD8 purified T-cells were stimulated with CD3/CD28 beads andthen individually or co-transduced with lentivirus encoding the 2^(nd)generation 41BB-t short spacer FMC63CD19CAR or/and the 2^(nd) generation41BB-ζ short spacer ROR1CAR. The CD19CAR was followed by an in-frameT2A-Her2tG and the ROR1CAR by a T2A-EGFRt. Transduced T-cells werepurified by EGFRt (ROR1CAR) and frozen. Flow analysis was performed onday 9 and demonstrates that transduced cells were purified tohomogeneity based on EGFRt expression (See FIG. 11A). For the CD4T-cells there was ˜86.7% Her2tG (CD19CAR) positivity and ˜88.1%dual-positivity for the CD8 T-cells.

CD19 and ROR1CAR Dual Transduced CD8⁺ T-Cells Demonstrate Specific LysisAgainst CD19 or ROR1 Positive Target Cell Lines

Mock (CAR⁻), single transduced (CD19CAR or ROR1CAR) and dual transducedCD8⁺ T-cells were co-cultured with target cell lines at differenteffector to target ratios for 4-hours. Single ROR1CAR T-cells containeither the 2^(nd) generation 41BB-ζ or CD28-t short spacer. K562 arenegative for both targets CD19 and ROR1. K562-OKT3 was used as apositive control. Raji (CD19^(k)) were transduced to express ROR1. Be2,SK-N-AS and SK-N-DZ are ROR1 positive. Results demonstrate that thesingle transduced CD8⁺ T-cells elicit specific lysis against theircognate antigen. However, the dual transduced T-cells efficientlyrecognized and lysed cells expressing CD19, ROR1 or both antigens (RajiROR1). All CD8⁺ T-cells were able to elicit similar levels of cell lysisagainst the K562-OKT3. These results indicate that T-cells can besuccessfully transduced with two separate CAR-encoding viruses, purifiedby a selection marker, and the resultant T-cell population is able torecognize multiple antigens (See FIG. 11B).

CD19- and ROR1CAR Dual Transduced T-Cell Populations Produce CytokinesAgainst CD19 or ROR1 Positive Target Cell Lines

Mock (CAR⁻), single transduced (CD19CAR or ROR1CAR) and dual transducedCD4⁺ T-cells were co-cultured for 24 hours with target cell lines at a2:1 effector-to-target ratio. Following the 24 hour incubation period,supernatant from the co-cultures was analyzed for the presence of IL-2,IFN-gamma, or TNF-α by Bioplex assay. Dual-transduced cells were able torelease cytokine against all target expressing cell lines at similarlevels to single CAR-expressing T-cells (See FIG. 11C).

CD19- and ROR1CAR Dual Transduced T-Cell Populations Produce CytokinesAgainst CD19 or ROR1 Positive Target Cell Lines

Mock (CAR⁻), single transduced (CD19CAR or ROR1CAR) and dual transducedCD4⁺ T-cells were co-cultured for 24 hours with target cell lines at a2:1 effector-to-target ratio. Following the 24 hour incubation period,supernatant from the co-cultures was analyzed for the presence of IL-2,IFN-gamma, or TNF-α by Bioplex assay. Dual-transduced cells were able torelease cytokine against all target expressing cell lines at similarlevels to single CAR-expressing T-cells (See FIG. 11D).

Dual-Transduced T-Cells Elicit Antitumor Activity in an IntracranialXenograft Tumor Model

Cohorts of mice were inoculated with 0.2e6 Be2 that express GFP:ffluc(Day 0) and 2e6 dual transduced CD4:CD8 T-cells (1:1 ratio) (Day 7)intracranially (i.c.). Serial bioluminescence imaging of tumor incohorts of mice treated with Mock (untransduced—left),ROR1CAR-expressing (middle-left) or dual-transduced CD4:CD8 CE7CART-cells (middle right). Kaplan-Meier analysis (right) of survival intreatment and control groups. Both the single ROR1CAR-expressing anddual-transduced cells were able to transiently regress tumor growth asevidenced by a short decrease in bioluminescence imaging. However, micesuccumbed to Be2 tumor outgrowth quickly thereafter. Both the single anddual transduced T-cells were able to significantly prolong survival.These results show that dual-transduced T-cells are able to treat tumorin vivo at levels similar to single ROR1CAR-expressing T-cells (See FIG.11D). There was therefore no inhibition in ROR1CAR activity for thedual-transduced T-cell population.

More Alternatives

A Nucleic Acid Encoding a Chimeric Antigen Receptor Specific for a BCell Specific Cell Surface Molecule

In some alternatives, a nucleic acid encoding a chimeric antigenreceptor is provided, wherein the nucleic acid comprises a first nucleicacid comprising a sequence encoding a leader sequence, a second nucleicacid comprising a sequence encoding an antibody or binding fragmentthereof or scFv, wherein the antibody or binding fragment thereof orscFv is specific for a B cell specific cell surface molecule, andwherein the first nucleic acid is covalently attached to a 5′ end of thesecond nucleic acid, a third nucleic acid comprising a sequence encodinga de-immunized extracellular spacer, wherein the third nucleic acid iscovalently attached to a 3′ end of the second nucleic acid, a fourthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the fourth nucleic acid is covalently attached to a 3′ end ofthe third nucleic acid, a fifth nucleic acid comprising a sequenceencoding a signaling domain, wherein the signaling domain comprises a4-1BB domain and/or CD3-zeta domain, and wherein the fifth nucleic acidis covalently attached to a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a linker, wherein the sixthnucleic acid is covalently attached to a 3′ end of the fifth nucleicacid; and a seventh nucleic acid comprising a sequence encoding a markerdomain, wherein the seventh nucleic acid is covalently attached to a 3′end of the sixth nucleic acid, thereby having said nucleic acid encodinga chimeric antigen receptor. In some alternatives, the linker is aribosome skip sequence or an IRES sequence. In some alternatives, theribosome skip sequence is a P2A, T2A, E2A or F2A sequence. In somealternatives, the ribosome skip sequence is T2A. In some alternatives,the T2A sequence comprises an amino acid sequence set forth in SEQ IDNO: 33 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:34. In some alternatives, the linker further comprises an IRES sequenceat the 5′ end of the linker. In some alternatives, the sequence encodingthe transmembrane domain further comprises an IRES sequence at the 3′end of the sequence encoding the transmembrane domain. In somealternatives, the B-cell specific cell surface molecule is CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the nucleic acidfurther comprises a polynucleotide encoding a suicide gene system. Insome alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the spacer is an IgG4 hinge spacer. In some alternatives,the spacer comprises an amino acid sequence set forth in SEQ ID NO: 1and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 2. Insome alternatives, the spacer comprises an amino acid sequence set forthin SEQ ID NO: 3 and is encoded by a nucleic acid sequence set forth inSEQ ID NO: 4. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 39 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 40. In some alternatives, the CD28-zetadomain comprises an amino acid sequence set forth in SEQ ID NO: 5 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 6. In somealternatives, the 4-1BB domain comprises an amino acid sequence setforth in SEQ ID NO: 7 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 8. In some alternatives, the CD3-zeta domaincomprises an amino acid sequence set forth in SEQ ID NO: 9 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 10. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule is specific for CD19. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12. In some alternatives, theantibody or binding fragment thereof or scFv specific for the B cellspecific cell surface molecule is specific for CD20. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule comprises an aminosequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. In some alternatives, the leadersequence comprises a Granulocyte-macrophage colony-stimulating factorsignal sequence. In some alternatives, the Granulocyte-macrophagecolony-stimulating factor signal sequence comprises an amino acidsequence set forth in SEQ ID NO: 29 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 30. In some alternatives, the leadersequence comprises an amino acid sequence set forth in SEQ ID NO: 31 andis encoded by a nucleic acid sequence set forth in SEQ ID NO: 32. Insome alternatives, the marker domain comprises Her2tG. In somealternatives, Her2tG comprises an amino acid sequence set forth in SEQID NO: 35 and is encoded by a nucleic acid sequence set forth in SEQ IDNO: 36. In some alternatives, the marker domain comprises EGFRt. In somealternatives, EGFRt comprises an amino acid sequence set forth in SEQ IDNO: 37 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:38.

A Nucleic Acid Encoding an Inducible Chimeric Antigen Receptor Specificfor a B Cell Specific Cell Surface Molecule

In some alternatives, a nucleic acid encoding a chimeric antigenreceptor is provided wherein the nucleic acid comprises a first nucleicacid comprising a sequence encoding a leader sequence, a second nucleicacid comprising a sequence encoding a first promoter inducible by adrug, wherein the first nucleic acid is covalently attached to a 5′ endof the second nucleic acid, a third nucleic acid comprising a sequenceencoding an antibody or binding fragment thereof or scFv, wherein theantibody or binding fragment thereof or scFv is specific for a B cellspecific cell surface molecule, and wherein the third nucleic acid iscovalently attached to a 3′ end of the second nucleic acid, a fourthnucleic acid comprising a sequence encoding a de-immunized extracellularspacer, wherein the fourth nucleic acid is covalently attached to a 3′end of the third nucleic acid, a fifth nucleic acid comprising asequence encoding a transmembrane domain, wherein the fifth nucleic acidis covalently attached to a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a signaling domain, whereinthe signaling domain comprises a 4-1BB domain and/or CD3-zeta domain,and wherein the sixth nucleic acid is covalently attached to a 3′ end ofthe fifth nucleic acid, a seventh nucleic acid comprising a sequenceencoding a linker, wherein the seventh nucleic acid is covalentlyattached to a 3′ end of the sixth nucleic acid and an eighth nucleicacid comprising a sequence encoding a marker domain, wherein the eighthnucleic acid is covalently attached to a 3′ end of the seventh nucleicacid, thereby having said nucleic acid encoding a chimeric antigenreceptor. In some alternatives, the linker is a ribosome skip sequenceor an IRES sequence. In some alternatives, the ribosome skip sequence isa P2A, T2A, E2A or F2A sequence. In some alternatives, the ribosome skipsequence is T2A. In some alternatives, the T2A sequence comprises anamino acid sequence set forth in SEQ ID NO: 33 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 34. In some alternatives,the linker further comprises an IRES sequence at the 5′ end of thelinker. In some alternatives, the first promoter is inducible bytamoxifen and/or its metabolites. In some alternatives, the firstpromoter is inducible by a drug. In some alternatives, the sequenceencoding the transmembrane domain further comprises an IRES sequence atthe 3′ end of the sequence encoding the transmembrane domain. In somealternatives, the B-cell specific cell surface molecule is CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the nucleic acidfurther comprises a polynucleotide encoding a suicide gene system. Insome alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the spacer is an IgG4 hinge spacer. In some alternatives,the spacer comprises an amino acid sequence set forth in SEQ ID NO: 1and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 2. Insome alternatives, the spacer comprises an amino acid sequence set forthin SEQ ID NO: 3 and is encoded by a nucleic acid sequence set forth inSEQ ID NO: 4. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 39 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 40. In some alternatives, the CD28-zetadomain comprises an amino acid sequence set forth in SEQ ID NO: 5 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 6. In somealternatives, the 4-1BB domain comprises an amino acid sequence setforth in SEQ ID NO: 7 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 8. In some alternatives, the CD3-zeta domaincomprises an amino acid sequence set forth in SEQ ID NO: 9 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 10. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule is specific for CD19. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12. In some alternatives, theantibody or binding fragment thereof or scFv specific for the B cellspecific cell surface molecule is specific for CD20. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule comprises an aminosequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. In some alternatives, the leadersequence comprises a Granulocyte-macrophage colony-stimulating factorsignal sequence. In some alternatives, the Granulocyte-macrophagecolony-stimulating factor signal sequence comprises an amino acidsequence set forth in SEQ ID NO: 29 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 30. In some alternatives, the leadersequence comprises an amino acid sequence set forth in SEQ ID NO: 31 andis encoded by a nucleic acid sequence set forth in SEQ ID NO: 32. Insome alternatives, the marker domain comprises Her2tG. In somealternatives, Her2tG comprises an amino acid sequence set forth in SEQID NO: 35 and is encoded by a nucleic acid sequence set forth in SEQ IDNO: 36. In some alternatives, the marker domain comprises EGFRt. In somealternatives, EGFRt comprises an amino acid sequence set forth in SEQ IDNO: 37 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:38.

A Nucleic Acid Encoding a Chimeric Antigen Receptor Specific for a CellSurface Tumor Specific Molecule

In some alternatives, a nucleic acid encoding a chimeric antigenreceptor is provided wherein the nucleic acid comprises a first nucleicacid comprising a sequence encoding a leader sequence, a second nucleicacid comprising a sequence encoding an antibody or binding fragmentthereof or scFv, wherein the antibody or binding fragment thereof orscFv is specific for a cell surface tumor specific molecule, and whereinthe first nucleic acid is covalently attached at a 5′ end of the secondnucleic acid, a third nucleic acid comprising a sequence encoding ade-immunized extracellular spacer, wherein the third nucleic acidsequence is covalently attached at a 3′ end of the second nucleic acid,a fourth nucleic acid comprising a sequence encoding a transmembranedomain, wherein the fourth nucleic acid is covalently attached at a 3′end of the third nucleic acid, a fifth nucleic acid comprising asequence encoding a signaling domain sequence, wherein the signalingdomain comprises a 4-1BB domain, CD3-zeta domain and/or CD28-zetadomain, and wherein the fifth nucleic acid is covalently attached at a3′ end of the fourth nucleic acid, a sixth nucleic acid comprising asequence encoding a linker, wherein the sixth nucleic acid is covalentlyattached at a 3′ end of the fifth nucleic acid and a seventh nucleicacid comprising a sequence encoding a marker domain, wherein the seventhnucleic acid is covalently attached at a 3′ end of the sixth nucleicacid, thereby having said nucleic acid encoding a chimeric antigenreceptor. In some alternatives, the linker is a ribosome skip sequenceor an IRES sequence. In some alternatives, the ribosome skip sequence isa P2A, T2A, E2A or F2A sequence. In some alternatives, the ribosome skipsequence is T2A. In some alternatives, the T2A sequence comprises anamino acid sequence set forth in SEQ ID NO: 33 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 34. In some alternatives,the linker further comprises an IRES sequence at the 5′ end of thelinker. In some alternatives, the sequence encoding the transmembranedomain further comprises an IRES sequence at the 3′ end of the sequenceencoding the transmembrane domain. In some alternatives, the nucleicacid further comprises a polynucleotide encoding a suicide gene system.In some alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the cell surface tumor specific molecule is a cancerantigen. In some alternatives, the cell surface tumor specific moleculeis EGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylatedGD2, GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1 In some alternatives, the spacer is an IgG4 hingespacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for a cell surface tumor specificmolecule is specific for L1CAM. In some alternatives, the antibody orbinding fragment thereof or scFv specific for a cell surface tumorspecific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives,Granulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38.

A Nucleic Acid Encoding an Inducible Chimeric Antigen Receptor Specificfor a Cell Surface Tumor Specific Molecule

In some alternatives, a nucleic acid encoding a chimeric antigenreceptor is provided, wherein the nucleic acid comprises a first nucleicacid comprising a sequence encoding a leader sequence, a second nucleicacid comprising a sequence encoding a first promoter inducible by adrug, wherein the first nucleic acid is covalently attached to a 5′ endof the second nucleic acid, a third nucleic acid comprising a sequenceencoding an antibody or binding fragment thereof or scFv, wherein theantibody or binding fragment thereof or scFv is specific for a cellsurface tumor specific molecule, and wherein the third nucleic acid iscovalently attached at a 3′ end of the second nucleic acid, a fourthnucleic acid comprising a sequence encoding a de-immunized extracellularspacer, wherein the fourth nucleic acid sequence is covalently attachedat a 3′ end of the third nucleic acid, a fifth nucleic acid comprising asequence encoding a transmembrane domain, wherein the fifth nucleic acidis covalently attached at a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a signaling domain sequence,wherein the signaling domain comprises a 4-1BB domain, CD3-zeta domainand/or CD28-zeta domain, and wherein the sixth nucleic acid iscovalently attached at a 3′ end of the fifth nucleic acid, a seventhnucleic acid comprising a sequence encoding a linker, wherein theseventh nucleic acid is covalently attached at a 3′ end of the sixthnucleic acid, and an eighth nucleic acid comprising a sequence encodinga marker domain, wherein the eighth nucleic acid is covalently attachedat a 3′ end of the seventh nucleic acid, thereby having said nucleicacid encoding a chimeric antigen receptor. In some alternatives, thelinker is a ribosome skip sequence or an IRES sequence. In somealternatives, the ribosome skip sequence is a P2A, T2A, E2A or F2Asequence. In some alternatives, the ribosome skip sequence is T2A. Insome alternatives, the T2A sequence comprises an amino acid sequence setforth in SEQ ID NO: 33 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 34. In some alternatives, the linker furthercomprises an IRES sequence at the 5′ end of the linker. In somealternatives, the first promoter is inducible by tamoxifen and/or itsmetabolites. In some alternatives, the first promoter is inducible by adrug. In some alternatives, the sequence encoding the transmembranedomain further comprises an IRES sequence at the 3′ end of the sequenceencoding the transmembrane domain. In some alternatives, the nucleicacid further comprises a polynucleotide encoding a suicide gene system.In some alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the cell surface tumor specific molecule is a cancerantigen. In some alternatives, the cell surface tumor specific moleculeis EGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylatedGD2, GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1v the spacer is an IgG4 hinge spacer. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 1 and is encoded by a nucleic acid sequence set forth in SEQID NO: 2. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 3 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 4. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 39 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 40. In somealternatives, the CD28-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 5 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 6. In some alternatives, the 4-1BB domain comprisesan amino acid sequence set forth in SEQ ID NO: 7 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 8. In some alternatives,the CD3-zeta domain comprises an amino acid sequence set forth in SEQ IDNO: 9 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:10. In some alternatives, the antibody or binding fragment thereof orscFv specific for a cell surface tumor specific molecule is specific forL1CAM. In some alternatives, the antibody or binding fragment thereof orscFv specific for a cell surface tumor specific molecule is specific fora CE7 epitope on L1CAM. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 15 and is encoded by a nucleic acid sequence set forth in SEQID NO: 16. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for ROR1. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 17 and is encoded by a nucleic acid sequence set forth in SEQID NO: 18. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for EGFR 806. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 19 and is encoded by a nucleic acid sequence set forth in SEQID NO: 20. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for Her2. In some alternatives, the antibody or bindingfragment thereof or scFv comprises an amino acid sequence set forth inSEQ ID NO: 21 and is encoded by a nucleic acid sequence set forth in SEQID NO: 22. In some alternatives, the antibody or binding fragmentthereof or scFv specific for a cell surface tumor specific molecule isspecific for GD2. In some alternatives, the antibody or binding fragmentthereof or scFv comprises an amino acid sequence set forth in SEQ ID NO:23 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 24.In some alternatives, the antibody or binding fragment thereof or scFvspecific for a cell surface tumor specific molecule is specific forEphA2 (2H4). In some alternatives, the antibody or binding fragmentthereof or scFv comprises an amino acid sequence set forth in SEQ ID NO:25 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 26.In some alternatives, the antibody or binding fragment thereof or scFvspecific for a cell surface tumor specific molecule is specific forEphA2 (4H5). In some alternatives, the antibody or binding fragmentthereof or scFv comprises an amino acid sequence set forth in SEQ ID NO:27 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 28.In some alternatives, the leader sequence comprises aGranulocyte-macrophage colony-stimulating factor signal sequence. Insome alternatives, the Granulocyte-macrophage colony-stimulating factorsignal sequence comprises an amino acid sequence set forth in SEQ ID NO:29 and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 30.In some alternatives, the leader sequence comprises an amino acidsequence set forth in SEQ ID NO: 31 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 32. In some alternatives, the markerdomain comprises Her2tG. In some alternatives, Her2tG comprises an aminoacid sequence set forth in SEQ ID NO: 35 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 36. In some alternatives, themarker domain comprises EGFRt. In some alternatives, EGFRt comprises anamino acid sequence set forth in SEQ ID NO: 37 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 38.

A Nucleic Acid Encoding a Bi-Specific Chimeric Antigen Receptor

In some alternatives, a nucleic acid encoding a bi-specific chimericantigen receptor is provided, wherein the nucleic acid comprises a firstnucleic acid sequence comprising a sequence encoding a leader sequence,a second nucleic acid comprising a sequence encoding an antibody orbinding fragment thereof or scFv, wherein the antibody or bindingfragment thereof or scFv is specific for a B cell specific cell surfacemolecule or is specific for a cell surface tumor specific molecule, andwherein the first nucleic acid is covalently attached at a 5′ end of thesecond nucleic acid, a third nucleic acid comprising a sequence encodingan antibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B cell specific cellsurface molecule or is specific for a cell surface tumor specificmolecule, and wherein the third nucleic acid is covalently attached at a3′ end of the second nucleic acid, a fourth nucleic acid comprising asequence encoding a de-immunized extracellular spacer, wherein thefourth nucleic acid is covalently attached at a 3′ end of the thirdnucleic acid, a fifth nucleic acid comprising a sequence encoding atransmembrane domain, wherein the fifth nucleic acid is covalentlyattached at a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a signaling domain sequence, wherein thesignaling domain comprises a co-stimulatory domain, wherein theco-stimulatory domain comprises a 4-1BB domain, CD3-zeta domain and/orCD28-zeta domain and wherein the sixth nucleic acid is covalentlyattached at a 3′ end of the fifth nucleic acid, a seventh nucleic acidcomprising a sequence encoding a linker, wherein the seventh nucleicacid is covalently attached at a 3′ end of the sixth nucleic acid, andan eighth nucleic acid comprising a sequence encoding a marker domain,wherein the eighth nucleic acid is covalently attached at a 3′ end ofthe seventh nucleic acid, thereby having said nucleic acid encoding abi-specific chimeric antigen receptor. In some alternatives, the linkeris a ribosome skip sequence or an IRES sequence. In some alternatives,the ribosome skip sequence is a P2A, T2A, E2A or F2A sequence. In somealternatives, the ribosome skip sequence is T2A. In some alternatives,the T2A sequence comprises an amino acid sequence set forth in SEQ IDNO: 33 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:34. In some alternatives, the linker further comprises an IRES sequenceat the 5′ end of the linker. In some alternatives, the sequence encodingthe transmembrane domain further comprises an IRES sequence at the 3′end of the sequence encoding the transmembrane domain. In somealternatives, the B-cell specific cell surface molecule is CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the nucleic acidfurther comprises a polynucleotide encoding a suicide gene system. Insome alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the cell surface tumor specific molecule is a cancerantigen. In some alternatives, the cell surface tumor specific moleculeis EGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylatedGD2, GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the spacer is an IgG4hinge spacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for the B cell specific cell surfacemolecule is specific for CD19. In some alternatives, the antibody orbinding fragment thereof or scFv specific for the B cell specific cellsurface molecule comprises an amino sequence set forth in SEQ ID NO: 11and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 12. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule is specific forCD20. In some alternatives, the antibody or binding fragment thereof orscFv specific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 13 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 14. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for L1CAM. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38.

A Nucleic Acid Encoding an Inducible Bi-Specific Chimeric AntigenReceptor

In some alternatives, a nucleic acid encoding a bi-specific chimericantigen receptor is provided, wherein the nucleic acid comprises a firstnucleic acid comprising a sequence encoding a leader sequence, a secondnucleic acid comprising a sequence encoding a first promoter inducibleby a drug, wherein the first nucleic acid is covalently attached to a 5′end of the second nucleic acid, a third nucleic acid comprising asequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora B cell specific cell surface molecule or is specific for a cellsurface tumor specific molecule, and wherein the third nucleic acid iscovalently attached at a 3′ end of the second nucleic acid, a fourthnucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface moleculeor is specific for a cell surface tumor specific molecule, and whereinthe fourth nucleic acid is covalently attached at a 3′ end of the thirdnucleic acid, a fifth nucleic acid comprising a sequence encoding ade-immunized extracellular spacer, wherein the fifth nucleic acid iscovalently attached at a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the sixth nucleic acid is covalently attached at a 3′ end of thefifth nucleic acid, a seventh nucleic acid comprising a sequenceencoding a signaling domain sequence, wherein the signaling domaincomprises a co-stimulatory domain, wherein the co-stimulatory domaincomprises a 4-1BB domain, CD3-zeta domain and/or CD28-zeta domain andwherein the seventh nucleic acid is covalently attached at a 3′ end ofthe sixth nucleic acid, an eighth nucleic acid comprising a sequenceencoding a linker, wherein the eighth nucleic acid is covalentlyattached at a 3′ end of the seventh nucleic acid, and a ninth nucleicacid comprising a sequence encoding a marker domain, wherein the ninthnucleic acid is covalently attached at a 3′ end of the eighth nucleicacid, thereby having said nucleic acid encoding a bi-specific chimericantigen receptor. In some alternatives, the linker is a ribosome skipsequence or an IRES sequence. In some alternatives, the ribosome skipsequence is a P2A, T2A, E2A or F2A sequence. In some alternatives, theribosome skip sequence is T2A. In some alternatives, the T2A sequencecomprises an amino acid sequence set forth in SEQ ID NO: 33 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 34. In somealternatives, the linker further comprises an IRES sequence at the 5′end of the linker. In some alternatives, the first promoter is inducibleby tamoxifen and/or its metabolites. In some alternatives, the firstpromoter is inducible by a drug. In some alternatives, the sequenceencoding the transmembrane domain further comprises an IRES sequence atthe 3′ end of the sequence encoding the transmembrane domain. In somealternatives, the B-cell specific cell surface molecule is CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the nucleic acidfurther comprises a polynucleotide encoding a suicide gene system. Insome alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the cell surface tumor specific molecule is a cancerantigen. In some alternatives, the cell surface tumor specific moleculeis EGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylatedGD2, GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the spacer is an IgG4hinge spacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for the B cell specific cell surfacemolecule is specific for CD19. In some alternatives, the antibody orbinding fragment thereof or scFv specific for the B cell specific cellsurface molecule comprises an amino sequence set forth in SEQ ID NO: 11and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 12. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule is specific forCD20. In some alternatives, the antibody or binding fragment thereof orscFv specific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 13 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 14. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for L1CAM. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38.

A Vector for Expression of a Chimeric Antigen Receptor Specific forPromoting In Vivo Expansion and Activation of B Cells

In some alternatives, a vector for expression of a chimeric antigenreceptor specific for promoting in vivo expansion and activation of Bcells is provided, wherein the vector comprises the nucleic acid of anyone of the alternatives provided herein. In some alternatives, thenucleic acid encoding a chimeric antigen receptor comprises a firstnucleic acid comprising a sequence encoding a leader sequence, a secondnucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface molecule,and wherein the first nucleic acid is covalently attached to a 5′ end ofthe second nucleic acid, a third nucleic acid comprising a sequenceencoding a de-immunized extracellular spacer, wherein the third nucleicacid is covalently attached to a 3′ end of the second nucleic acid, afourth nucleic acid comprising a sequence encoding a transmembranedomain, wherein the fourth nucleic acid is covalently attached to a 3′end of the third nucleic acid, a fifth nucleic acid comprising asequence encoding a signaling domain, wherein the signaling domaincomprises a 4-1BB domain and/or CD3-zeta domain, and wherein the fifthnucleic acid is covalently attached to a 3′ end of the fourth nucleicacid, a sixth nucleic acid comprising a sequence encoding a linker,wherein the sixth nucleic acid is covalently attached to a 3′ end of thefifth nucleic acid, and a seventh nucleic acid comprising a sequenceencoding a marker domain, wherein the seventh nucleic acid is covalentlyattached to a 3′ end of the sixth nucleic acid, thereby having saidnucleic acid encoding a chimeric antigen receptor. In some alternatives,the nucleic acid encoding a chimeric antigen receptor comprises a firstnucleic acid comprising a sequence encoding a leader sequence, a secondnucleic acid comprising a sequence encoding a first promoter inducibleby a drug, wherein the first nucleic acid is covalently attached to a 5′end of the second nucleic acid, a third nucleic acid comprising asequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora B cell specific cell surface molecule, and wherein the third nucleicacid is covalently attached to a 3′ end of the second nucleic acid, afourth nucleic acid comprising a sequence encoding a de-immunizedextracellular spacer, wherein the fourth nucleic acid is covalentlyattached to a 3′ end of the third nucleic acid, a fifth nucleic acidcomprising a sequence encoding a transmembrane domain, wherein the fifthnucleic acid is covalently attached to a 3′ end of the fourth nucleicacid, a sixth nucleic acid comprising a sequence encoding a signalingdomain, wherein the signaling domain comprises a 4-1BB domain and/orCD3-zeta domain, and wherein the sixth nucleic acid is covalentlyattached to a 3′ end of the fifth nucleic acid, a seventh nucleic acidcomprising a sequence encoding a linker, wherein the seventh nucleicacid is covalently attached to a 3′ end of the sixth nucleic acid and aneighth nucleic acid comprising a sequence encoding a marker domain,wherein the eighth nucleic acid is covalently attached to a 3′ end ofthe seventh nucleic acid, thereby having said nucleic acid encoding achimeric antigen receptor. In some alternatives, the linker is aribosome skip sequence or an IRES sequence. In some alternatives, theribosome skip sequence is a P2A, T2A, E2A or F2A sequence. In somealternatives, the ribosome skip sequence is T2A. In some alternatives,the T2A sequence comprises an amino acid sequence set forth in SEQ IDNO: 33 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:34. In some alternatives, the linker further comprises an IRES sequenceat the 5′ end of the linker. In some alternatives, the first promoter isinducible by tamoxifen and/or its metabolites. In some alternatives, thefirst promoter is inducible by a drug. In some alternatives, thesequence encoding the transmembrane domain further comprises an IRESsequence at the 3′ end of the sequence encoding the transmembranedomain. In some alternatives, the B-cell specific cell surface moleculeis CD1d, CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24,CD25/IL-2 R alphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5),CD44, CD45, CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80,CD84/SLAMF5, LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD,B220/CD45R, C1q R1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R,B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14,BLIMP1/PRDM1, CXCR4, DEP-1/CD148, or EMMPRIN/CD147. In somealternatives, the nucleic acid further comprises a polynucleotideencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the drug is a steroid, such as a ligand for theestrogen receptor. In some alternatives, the steroid is tamoxifen and/orits metabolites. In some alternatives, the spacer is an IgG4 hingespacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for the B cell specific cell surfacemolecule is specific for CD19. In some alternatives, the antibody orbinding fragment thereof or scFv specific for the B cell specific cellsurface molecule comprises an amino sequence set forth in SEQ ID NO: 11and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 12. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule is specific forCD20. In some alternatives, the antibody or binding fragment thereof orscFv specific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 13 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 14. In some alternatives, theleader sequence comprises a Granulocyte-macrophage colony-stimulatingfactor signal sequence. In some alternatives, the Granulocyte-macrophagecolony-stimulating factor signal sequence comprises an amino acidsequence set forth in SEQ ID NO: 29 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 30. In some alternatives, the leadersequence comprises an amino acid sequence set forth in SEQ ID NO: 31 andis encoded by a nucleic acid sequence set forth in SEQ ID NO: 32. Insome alternatives, the marker domain comprises Her2tG. In somealternatives, Her2tG comprises an amino acid sequence set forth in SEQID NO: 35 and is encoded by a nucleic acid sequence set forth in SEQ IDNO: 36. In some alternatives, the marker domain comprises EGFRt. In somealternatives, EGFRt comprises an amino acid sequence set forth in SEQ IDNO: 37 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:38. In some alternatives, the vector is a viral vector. In somealternatives, the vector is a lentiviral vector, retroviral vector,gammaretroviral vectors or a foamy viral vector. In some alternatives,the vector is a transposon, integrase vector system, or an mRNA vector.

A Vector for the Expression of a Chimeric Antigen Receptor or TcRSpecific for Targeting a Solid Tumor

In some alternatives, a vector for expression of a chimeric antigenreceptor or TcR specific for targeting a solid tumor is provided,wherein the vector comprises the nucleic acid of any one of alternativesprovided herein. In some alternatives, the nucleic acid encoding achimeric antigen receptor comprises a first nucleic acid comprising asequence encoding a leader sequence, a second nucleic acid comprising asequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora cell surface tumor specific molecule, and wherein the first nucleicacid is covalently attached at a 5′ end of the second nucleic acid, athird nucleic acid comprising a sequence encoding a de-immunizedextracellular spacer, wherein the third nucleic acid sequence iscovalently attached at a 3′ end of the second nucleic acid, a fourthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the fourth nucleic acid is covalently attached at a 3′ end ofthe third nucleic acid, a fifth nucleic acid comprising a sequenceencoding a signaling domain sequence, wherein the signaling domaincomprises a 4-1BB domain, CD3-zeta domain and/or CD28-zeta domain, andwherein the fifth nucleic acid is covalently attached at a 3′ end of thefourth nucleic acid, a sixth nucleic acid comprising a sequence encodinga linker, wherein the sixth nucleic acid is covalently attached at a 3′end of the fifth nucleic acid and a seventh nucleic acid comprising asequence encoding a marker domain, wherein the seventh nucleic acid iscovalently attached at a 3′ end of the sixth nucleic acid, therebyhaving said nucleic acid encoding a chimeric antigen receptor. In somealternatives, the nucleic acid encoding a chimeric antigen receptorcomprises a first nucleic acid comprising a sequence encoding a leadersequence, a second nucleic acid comprising a sequence encoding a firstpromoter inducible by a drug, wherein the first nucleic acid iscovalently attached to a 5′ end of the second nucleic acid, a thirdnucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a cell surface tumor specific molecule,and wherein the third nucleic acid is covalently attached at a 3′ end ofthe second nucleic acid, a fourth nucleic acid comprising a sequenceencoding a de-immunized extracellular spacer, wherein the fourth nucleicacid sequence is covalently attached at a 3′ end of the third nucleicacid, a fifth nucleic acid comprising a sequence encoding atransmembrane domain, wherein the fifth nucleic acid is covalentlyattached at a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a signaling domain sequence, wherein thesignaling domain comprises a 4-1BB domain, CD3-zeta domain and/orCD28-zeta domain, and wherein the sixth nucleic acid is covalentlyattached at a 3′ end of the fifth nucleic acid, a seventh nucleic acidcomprising a sequence encoding a linker, wherein the seventh nucleicacid is covalently attached at a 3′ end of the sixth nucleic acid and aneighth nucleic acid comprising a sequence encoding a marker domain,wherein the eighth nucleic acid is covalently attached at a 3′ end ofthe seventh nucleic acid, thereby having said nucleic acid encoding achimeric antigen receptor. In some alternatives, the linker is aribosome skip sequence or an IRES sequence. In some alternatives, theribosome skip sequence is a P2A, T2A, E2A or F2A sequence. In somealternatives, the ribosome skip sequence is T2A. In some alternatives,the T2A sequence comprises an amino acid sequence set forth in SEQ IDNO: 33 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:34. In some alternatives, the linker further comprises an IRES sequenceat the 5′ end of the linker. In some alternatives, the first promoter isinducible by tamoxifen and/or its metabolites. In some alternatives, thefirst promoter is inducible by a drug. In some alternatives, thesequence encoding the transmembrane domain further comprises an IRESsequence at the 3′ end of the sequence encoding the transmembranedomain. In some alternatives, the nucleic acid further comprises apolynucleotide encoding a suicide gene system. In some alternatives, thesuicide gene system is a Herpes Simplex Virus Thymidine Kinase(HSVTK)/Ganciclovir (GCV) suicide gene system or an inducible Caspasesuicide gene system. In some alternatives, the drug is a steroid, suchas a ligand for the estrogen receptor. In some alternatives, the steroidis tamoxifen and/or its metabolites. In some alternatives, the cellsurface tumor specific molecule is a cancer antigen. In somealternatives, the cell surface tumor specific molecule is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the spacer is an IgG4hinge spacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for a cell surface tumor specificmolecule is specific for L1CAM. In some alternatives, the antibody orbinding fragment thereof or scFv specific for a cell surface tumorspecific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38. In some alternatives, thevector is a viral vector. In some alternatives, the vector is alentiviral vector, retroviral vector, gammaretroviral vectors or a foamyviral vector. In some alternatives, the vector is a transposon,integrase vector system, or an mRNA vector.

A Vector for the Expression of a Bi-Specific Chimeric Antigen Receptor

In some alternatives, a vector for expression of a bi-specific chimericantigen receptor is provided, wherein the bi-specific chimeric antigenreceptor is specific for a B cell specific cell surface molecule and isspecific for a cell surface tumor specific molecule, the vectorcomprising the nucleic acid of any one of the alternatives providedherein. In some alternatives, the nucleic acid encoding a bi-specificchimeric antigen receptor comprises a first nucleic acid sequencecomprising a sequence encoding a leader sequence, a second nucleic acidcomprising a sequence encoding an antibody or binding fragment thereofor scFv, wherein the antibody or binding fragment thereof or scFv isspecific for a B cell specific cell surface molecule or is specific fora cell surface tumor specific molecule, and wherein the first nucleicacid is covalently attached at a 5′ end of the second nucleic acid, athird nucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface moleculeor is specific for a cell surface tumor specific molecule, and whereinthe third nucleic acid is covalently attached at a 3′ end of the secondnucleic acid, a fourth nucleic acid comprising a sequence encoding ade-immunized extracellular spacer, wherein the fourth nucleic acid iscovalently attached at a 3′ end of the third nucleic acid, a fifthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the fifth nucleic acid is covalently attached at a 3′ end of thefourth nucleic acid, a sixth nucleic acid comprising a sequence encodinga signaling domain sequence, wherein the signaling domain comprises aco-stimulatory domain, wherein the co-stimulatory domain comprises a4-1BB domain, CD3-zeta domain and/or CD28-zeta domain and wherein thesixth nucleic acid is covalently attached at a 3′ end of the fifthnucleic acid, a seventh nucleic acid comprising a sequence encoding alinker, wherein the seventh nucleic acid is covalently attached at a 3′end of the sixth nucleic acid, and an eighth nucleic acid comprising asequence encoding a marker domain, wherein the eighth nucleic acid iscovalently attached at a 3′ end of the seventh nucleic acid, therebyhaving said nucleic acid encoding a bi-specific chimeric antigenreceptor. In some alternatives, the nucleic acid encoding a bi-specificchimeric antigen receptor comprises a first nucleic acid comprising asequence encoding a leader sequence, a second nucleic acid comprising asequence encoding a first promoter inducible by a drug, wherein thefirst nucleic acid is covalently attached to a 5′ end of the secondnucleic acid, a third nucleic acid comprising a sequence encoding anantibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B cell specific cellsurface molecule or is specific for a cell surface tumor specificmolecule, and wherein the third nucleic acid is covalently attached at a3′ end of the second nucleic acid, a fourth nucleic acid comprising asequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora B cell specific cell surface molecule or is specific for a cellsurface tumor specific molecule, and wherein the fourth nucleic acid iscovalently attached at a 3′ end of the third nucleic acid, a fifthnucleic acid comprising a sequence encoding a de-immunized extracellularspacer, wherein the fifth nucleic acid is covalently attached at a 3′end of the fourth nucleic acid, a sixth nucleic acid comprising asequence encoding a transmembrane domain, wherein the sixth nucleic acidis covalently attached at a 3′ end of the fifth nucleic acid, a seventhnucleic acid comprising a sequence encoding a signaling domain sequence,wherein the signaling domain comprises a co-stimulatory domain, whereinthe co-stimulatory domain comprises a 4-1BB domain, CD3-zeta domainand/or CD28-zeta domain and wherein the seventh nucleic acid iscovalently attached at a 3′ end of the sixth nucleic acid, an eighthnucleic acid comprising a sequence encoding a linker, wherein the eighthnucleic acid is covalently attached at a 3′ end of the seventh nucleicacid, and a ninth nucleic acid comprising a sequence encoding a markerdomain, wherein the ninth nucleic acid is covalently attached at a 3′end of the eighth nucleic acid, thereby having said nucleic acidencoding a bi-specific chimeric antigen receptor. In some alternatives,the linker is a ribosome skip sequence or an IRES sequence. In somealternatives, the ribosome skip sequence is a P2A, T2A, E2A or F2Asequence. In some alternatives, the ribosome skip sequence is T2A. Insome alternatives, the T2A sequence comprises an amino acid sequence setforth in SEQ ID NO: 33 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 34. In some alternatives, the linker furthercomprises an IRES sequence at the 5′ end of the linker. In somealternatives, the first promoter is inducible by tamoxifen and/or itsmetabolites. In some alternatives, the first promoter is inducible by adrug. In some alternatives, the sequence encoding the transmembranedomain further comprises an IRES sequence at the 3′ end of the sequenceencoding the transmembrane domain. In some alternatives, the B-cellspecific cell surface molecule is CD1d, CD5, CD19, CD20, CD21, CD22,CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32, CD34,CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54 (ICAM-1),CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA, B-cell receptor(BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5, BAFFR/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1,HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, or EMMPRIN/CD147. Insome alternatives, the nucleic acid further comprises a polynucleotideencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the drug is a steroid, such as a ligand for theestrogen receptor. In some alternatives, the steroid is tamoxifen and/orits metabolites. In some alternatives, the cell surface tumor specificmolecule is a cancer antigen. In some alternatives, the cell surfacetumor specific molecule is EGFR, HER2, Mesothelin, cancer testisantigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2, glypican-2(GPC2), HPV antigens, alphafetoprotein, carcinoembryonic antigen,CA-125, MUC-1, epithelial tumor antigen, abnormal products of ras orp53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin, AIM2,ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3,EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In some alternatives, the cancerantigen is L1CAM. In some alternatives, the cancer antigen is ROR1. Insome alternatives, the spacer is an IgG4 hinge spacer. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 1 and is encoded by a nucleic acid sequence set forth in SEQID NO: 2. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 3 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 4. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 39 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 40. In somealternatives, the CD28-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 5 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 6. In some alternatives, the 4-1BB domain comprisesan amino acid sequence set forth in SEQ ID NO: 7 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 8. In some alternatives,the CD3-zeta domain comprises an amino acid sequence set forth in SEQ IDNO: 9 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:10. In some alternatives, the antibody or binding fragment thereof orscFv specific for the B cell specific cell surface molecule is specificfor CD19. In some alternatives, the antibody or binding fragment thereofor scFv specific for the B cell specific cell surface molecule comprisesan amino sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12. In some alternatives, theantibody or binding fragment thereof or scFv specific for the B cellspecific cell surface molecule is specific for CD20. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule comprises an aminosequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. In some alternatives, the antibodyor binding fragment thereof or scFv specific for a cell surface tumorspecific molecule is specific for L1CAM. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38. In some alternatives, thevector is a viral vector. In some alternatives, the vector is alentiviral vector, retroviral vector, gammaretroviral vectors or a foamyviral vector. In some alternatives, the vector is a transposon,integrase vector system, or an mRNA vector.

A Chimeric Antigen Receptor or TcR Specific for a B-Cell Specific CellSurface Molecule

In some alternatives, a chimeric antigen receptor or TcR specific for aB-cell specific cell surface molecule encoded by a nucleic acid orvector of any one of the alternatives is provided. In some alternatives,the vector is for expression of a chimeric antigen receptor specific forpromoting in vivo expansion and activation of B cells, wherein thevector comprises the nucleic acid of any one of the alternativesprovided herein. In some alternatives, the nucleic acid encoding achimeric antigen receptor comprises a first nucleic acid comprising asequence encoding a leader sequence, a second nucleic acid comprising asequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora B cell specific cell surface molecule, and wherein the first nucleicacid is covalently attached to a 5′ end of the second nucleic acid, athird nucleic acid comprising a sequence encoding a de-immunizedextracellular spacer, wherein the third nucleic acid is covalentlyattached to a 3′ end of the second nucleic acid, a fourth nucleic acidcomprising a sequence encoding a transmembrane domain, wherein thefourth nucleic acid is covalently attached to a 3′ end of the thirdnucleic acid, a fifth nucleic acid comprising a sequence encoding asignaling domain, wherein the signaling domain comprises a 4-1BB domainand/or CD3-zeta domain, and wherein the fifth nucleic acid is covalentlyattached to a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a linker, wherein the sixth nucleic acidis covalently attached to a 3′ end of the fifth nucleic acid, and aseventh nucleic acid comprising a sequence encoding a marker domain,wherein the seventh nucleic acid is covalently attached to a 3′ end ofthe sixth nucleic acid, thereby having said nucleic acid encoding achimeric antigen receptor. In some alternatives, the nucleic acidencoding a chimeric antigen receptor comprises a first nucleic acidcomprising a sequence encoding a leader sequence, a second nucleic acidcomprising a sequence encoding a first promoter inducible by a drug,wherein the first nucleic acid is covalently attached to a 5′ end of thesecond nucleic acid, a third nucleic acid comprising a sequence encodingan antibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B cell specific cellsurface molecule, and wherein the third nucleic acid is covalentlyattached to a 3′ end of the second nucleic acid, a fourth nucleic acidcomprising a sequence encoding a de-immunized extracellular spacer,wherein the fourth nucleic acid is covalently attached to a 3′ end ofthe third nucleic acid, a fifth nucleic acid comprising a sequenceencoding a transmembrane domain, wherein the fifth nucleic acid iscovalently attached to a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a signaling domain, whereinthe signaling domain comprises a 4-1BB domain and/or CD3-zeta domain,and wherein the sixth nucleic acid is covalently attached to a 3′ end ofthe fifth nucleic acid, a seventh nucleic acid comprising a sequenceencoding a linker, wherein the seventh nucleic acid is covalentlyattached to a 3′ end of the sixth nucleic acid and an eighth nucleicacid comprising a sequence encoding a marker domain, wherein the eighthnucleic acid is covalently attached to a 3′ end of the seventh nucleicacid, thereby having said nucleic acid encoding a chimeric antigenreceptor. In some alternatives, the linker is a ribosome skip sequenceor an IRES sequence. In some alternatives, the ribosome skip sequence isa P2A, T2A, E2A or F2A sequence. In some alternatives, the ribosome skipsequence is T2A. In some alternatives, the T2A sequence comprises anamino acid sequence set forth in SEQ ID NO: 33 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 34. In some alternatives,the linker further comprises an IRES sequence at the 5′ end of thelinker. In some alternatives, the first promoter is inducible bytamoxifen and/or its metabolites. In some alternatives, the firstpromoter is inducible by a drug. In some alternatives, the sequenceencoding the transmembrane domain further comprises an IRES sequence atthe 3′ end of the sequence encoding the transmembrane domain. In somealternatives, the B-cell specific cell surface molecule is CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the nucleic acidfurther comprises a polynucleotide encoding a suicide gene system. Insome alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the spacer is an IgG4 hinge spacer. In some alternatives,the spacer comprises an amino acid sequence set forth in SEQ ID NO: 1and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 2. Insome alternatives, the spacer comprises an amino acid sequence set forthin SEQ ID NO: 3 and is encoded by a nucleic acid sequence set forth inSEQ ID NO: 4. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 39 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 40. In some alternatives, the CD28-zetadomain comprises an amino acid sequence set forth in SEQ ID NO: 5 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 6. In somealternatives, the 4-1BB domain comprises an amino acid sequence setforth in SEQ ID NO: 7 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 8. In some alternatives, the CD3-zeta domaincomprises an amino acid sequence set forth in SEQ ID NO: 9 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 10. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule is specific for CD19. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 11 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 12. In some alternatives, theantibody or binding fragment thereof or scFv specific for the B cellspecific cell surface molecule is specific for CD20. In somealternatives, the antibody or binding fragment thereof or scFv specificfor the B cell specific cell surface molecule comprises an aminosequence set forth in SEQ ID NO: 13 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 14. In some alternatives, the leadersequence comprises a Granulocyte-macrophage colony-stimulating factorsignal sequence. In some alternatives, the Granulocyte-macrophagecolony-stimulating factor signal sequence comprises an amino acidsequence set forth in SEQ ID NO: 29 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 30. In some alternatives, the leadersequence comprises an amino acid sequence set forth in SEQ ID NO: 31 andis encoded by a nucleic acid sequence set forth in SEQ ID NO: 32. Insome alternatives, the marker domain comprises Her2tG. In somealternatives, Her2tG comprises an amino acid sequence set forth in SEQID NO: 35 and is encoded by a nucleic acid sequence set forth in SEQ IDNO: 36. In some alternatives, the marker domain comprises EGFRt. In somealternatives, EGFRt comprises an amino acid sequence set forth in SEQ IDNO: 37 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:38. In some alternatives, the vector is a viral vector. In somealternatives, the vector is a lentiviral vector, retroviral vector,gammaretroviral vectors or a foamy viral vector. In some alternatives,the vector is a transposon, integrase vector system, or an mRNA vector.

A Chimeric Antigen Receptor or TcR Specific for a Cell Surface TumorSpecific Molecule

In some alternatives, a chimeric antigen receptor or TcR specific for acell surface tumor specific molecule encoded by a nucleic acid or vectorof any one of the alternatives is provided. In some alternatives, thevector is for expression of a chimeric antigen receptor or TcR specificfor targeting a solid tumor, wherein the vector comprises the nucleicacid of any one of alternatives provided herein. In some alternatives,the nucleic acid encoding a chimeric antigen receptor comprises a firstnucleic acid comprising a sequence encoding a leader sequence, a secondnucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a cell surface tumor specific molecule,and wherein the first nucleic acid is covalently attached at a 5′ end ofthe second nucleic acid, a third nucleic acid comprising a sequenceencoding a de-immunized extracellular spacer, wherein the third nucleicacid sequence is covalently attached at a 3′ end of the second nucleicacid, a fourth nucleic acid comprising a sequence encoding atransmembrane domain, wherein the fourth nucleic acid is covalentlyattached at a 3′ end of the third nucleic acid, a fifth nucleic acidcomprising a sequence encoding a signaling domain sequence, wherein thesignaling domain comprises a 4-1BB domain, CD3-zeta domain and/orCD28-zeta domain, and wherein the fifth nucleic acid is covalentlyattached at a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a linker, wherein the sixth nucleic acidis covalently attached at a 3′ end of the fifth nucleic acid and aseventh nucleic acid comprising a sequence encoding a marker domain,wherein the seventh nucleic acid is covalently attached at a 3′ end ofthe sixth nucleic acid, thereby having said nucleic acid encoding achimeric antigen receptor. In some alternatives, the nucleic acidencoding a chimeric antigen receptor comprises a first nucleic acidcomprising a sequence encoding a leader sequence, a second nucleic acidcomprising a sequence encoding a first promoter inducible by a drug,wherein the first nucleic acid is covalently attached to a 5′ end of thesecond nucleic acid, a third nucleic acid comprising a sequence encodingan antibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a cell surface tumorspecific molecule, and wherein the third nucleic acid is covalentlyattached at a 3′ end of the second nucleic acid, a fourth nucleic acidcomprising a sequence encoding a de-immunized extracellular spacer,wherein the fourth nucleic acid sequence is covalently attached at a 3′end of the third nucleic acid, a fifth nucleic acid comprising asequence encoding a transmembrane domain, wherein the fifth nucleic acidis covalently attached at a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a signaling domain sequence,wherein the signaling domain comprises a 4-1BB domain, CD3-zeta domainand/or CD28-zeta domain, and wherein the sixth nucleic acid iscovalently attached at a 3′ end of the fifth nucleic acid, a seventhnucleic acid comprising a sequence encoding a linker, wherein theseventh nucleic acid is covalently attached at a 3′ end of the sixthnucleic acid and an eighth nucleic acid comprising a sequence encoding amarker domain, wherein the eighth nucleic acid is covalently attached ata 3′ end of the seventh nucleic acid, thereby having said nucleic acidencoding a chimeric antigen receptor. In some alternatives, the linkeris a ribosome skip sequence or an IRES sequence. In some alternatives,the ribosome skip sequence is a P2A, T2A, E2A or F2A sequence. In somealternatives, the ribosome skip sequence is T2A. In some alternatives,the T2A sequence comprises an amino acid sequence set forth in SEQ IDNO: 33 and is encoded by a nucleic acid sequence set forth in SEQ ID NO:34. In some alternatives, the linker further comprises an IRES sequenceat the 5′ end of the linker. In some alternatives, the first promoter isinducible by tamoxifen and/or its metabolites. In some alternatives, thefirst promoter is inducible by a drug. In some alternatives, thesequence encoding the transmembrane domain further comprises an IRESsequence at the 3′ end of the sequence encoding the transmembranedomain. In some alternatives, the nucleic acid further comprises apolynucleotide encoding a suicide gene system. In some alternatives, thesuicide gene system is a Herpes Simplex Virus Thymidine Kinase(HSVTK)/Ganciclovir (GCV) suicide gene system or an inducible Caspasesuicide gene system. In some alternatives, the drug is a steroid, suchas a ligand for the estrogen receptor. In some alternatives, the steroidis tamoxifen and/or its metabolites. In some alternatives, the cellsurface tumor specific molecule is a cancer antigen. In somealternatives, the cell surface tumor specific molecule is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the spacer is an IgG4hinge spacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for a cell surface tumor specificmolecule is specific for L1CAM. In some alternatives, the antibody orbinding fragment thereof or scFv specific for a cell surface tumorspecific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38. In some alternatives, thevector is a viral vector. In some alternatives, the vector is alentiviral vector, retroviral vector, gammaretroviral vectors or a foamyviral vector. In some alternatives, the vector is a transposon,integrase vector system, or an mRNA vector.

A Bi-Specific Chimeric Antigen Receptor Specific for a B Cell SpecificCell Surface Molecule and Specific for a Cell Surface Tumor SpecificMolecule

In some alternatives, a bi-specific chimeric antigen receptor specificfor a B cell specific cell surface molecule and specific for a cellsurface tumor specific molecule encoded by a nucleic acid or vector ofany one of the alternatives is provided. In some alternatives, thebi-specific chimeric antigen receptor is specific for a B cell specificcell surface molecule and is specific for a cell surface tumor specificmolecule, the vector comprising the nucleic acid of any one of thealternatives provided herein. In some alternatives, the nucleic acidencoding a bi-specific chimeric antigen receptor comprises a firstnucleic acid sequence comprising a sequence encoding a leader sequence,a second nucleic acid comprising a sequence encoding an antibody orbinding fragment thereof or scFv, wherein the antibody or bindingfragment thereof or scFv is specific for a B cell specific cell surfacemolecule or is specific for a cell surface tumor specific molecule, andwherein the first nucleic acid is covalently attached at a 5′ end of thesecond nucleic acid, a third nucleic acid comprising a sequence encodingan antibody or binding fragment thereof or scFv, wherein the antibody orbinding fragment thereof or scFv is specific for a B cell specific cellsurface molecule or is specific for a cell surface tumor specificmolecule, and wherein the third nucleic acid is covalently attached at a3′ end of the second nucleic acid, a fourth nucleic acid comprising asequence encoding a de-immunized extracellular spacer, wherein thefourth nucleic acid is covalently attached at a 3′ end of the thirdnucleic acid, a fifth nucleic acid comprising a sequence encoding atransmembrane domain, wherein the fifth nucleic acid is covalentlyattached at a 3′ end of the fourth nucleic acid, a sixth nucleic acidcomprising a sequence encoding a signaling domain sequence, wherein thesignaling domain comprises a co-stimulatory domain, wherein theco-stimulatory domain comprises a 4-1BB domain, CD3-zeta domain and/orCD28-zeta domain and wherein the sixth nucleic acid is covalentlyattached at a 3′ end of the fifth nucleic acid, a seventh nucleic acidcomprising a sequence encoding a linker, wherein the seventh nucleicacid is covalently attached at a 3′ end of the sixth nucleic acid, andan eighth nucleic acid comprising a sequence encoding a marker domain,wherein the eighth nucleic acid is covalently attached at a 3′ end ofthe seventh nucleic acid, thereby having said nucleic acid encoding abi-specific chimeric antigen receptor. In some alternatives, the nucleicacid encoding a bi-specific chimeric antigen receptor comprises a firstnucleic acid comprising a sequence encoding a leader sequence, a secondnucleic acid comprising a sequence encoding a first promoter inducibleby a drug, wherein the first nucleic acid is covalently attached to a 5′end of the second nucleic acid, a third nucleic acid comprising asequence encoding an antibody or binding fragment thereof or scFv,wherein the antibody or binding fragment thereof or scFv is specific fora B cell specific cell surface molecule or is specific for a cellsurface tumor specific molecule, and wherein the third nucleic acid iscovalently attached at a 3′ end of the second nucleic acid, a fourthnucleic acid comprising a sequence encoding an antibody or bindingfragment thereof or scFv, wherein the antibody or binding fragmentthereof or scFv is specific for a B cell specific cell surface moleculeor is specific for a cell surface tumor specific molecule, and whereinthe fourth nucleic acid is covalently attached at a 3′ end of the thirdnucleic acid, a fifth nucleic acid comprising a sequence encoding ade-immunized extracellular spacer, wherein the fifth nucleic acid iscovalently attached at a 3′ end of the fourth nucleic acid, a sixthnucleic acid comprising a sequence encoding a transmembrane domain,wherein the sixth nucleic acid is covalently attached at a 3′ end of thefifth nucleic acid, a seventh nucleic acid comprising a sequenceencoding a signaling domain sequence, wherein the signaling domaincomprises a co-stimulatory domain, wherein the co-stimulatory domaincomprises a 4-1BB domain, CD3-zeta domain and/or CD28-zeta domain andwherein the seventh nucleic acid is covalently attached at a 3′ end ofthe sixth nucleic acid, an eighth nucleic acid comprising a sequenceencoding a linker, wherein the eighth nucleic acid is covalentlyattached at a 3′ end of the seventh nucleic acid, and a ninth nucleicacid comprising a sequence encoding a marker domain, wherein the ninthnucleic acid is covalently attached at a 3′ end of the eighth nucleicacid, thereby having said nucleic acid encoding a bi-specific chimericantigen receptor. In some alternatives, the linker is a ribosome skipsequence or an IRES sequence. In some alternatives, the ribosome skipsequence is a P2A, T2A, E2A or F2A sequence. In some alternatives, theribosome skip sequence is T2A. In some alternatives, the T2A sequencecomprises an amino acid sequence set forth in SEQ ID NO: 33 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 34. In somealternatives, the linker further comprises an IRES sequence at the 5′end of the linker. In some alternatives, the first promoter is inducibleby tamoxifen and/or its metabolites. In some alternatives, the firstpromoter is inducible by a drug. In some alternatives, the sequenceencoding the transmembrane domain further comprises an IRES sequence atthe 3′ end of the sequence encoding the transmembrane domain. In somealternatives, the B-cell specific cell surface molecule is CD1d, CD5,CD19, CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the nucleic acidfurther comprises a polynucleotide encoding a suicide gene system. Insome alternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the drug isa steroid, such as a ligand for the estrogen receptor. In somealternatives, the steroid is tamoxifen and/or its metabolites. In somealternatives, the cell surface tumor specific molecule is a cancerantigen. In some alternatives, the cell surface tumor specific moleculeis EGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylatedGD2, GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the spacer is an IgG4hinge spacer. In some alternatives, the spacer comprises an amino acidsequence set forth in SEQ ID NO: 1 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 2. In some alternatives, the spacercomprises an amino acid sequence set forth in SEQ ID NO: 3 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 4. In somealternatives, the spacer comprises an amino acid sequence set forth inSEQ ID NO: 39 and is encoded by a nucleic acid sequence set forth in SEQID NO: 40. In some alternatives, the CD28-zeta domain comprises an aminoacid sequence set forth in SEQ ID NO: 5 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 6. In some alternatives, the 4-1BBdomain comprises an amino acid sequence set forth in SEQ ID NO: 7 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 8. In somealternatives, the CD3-zeta domain comprises an amino acid sequence setforth in SEQ ID NO: 9 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 10. In some alternatives, the antibody or bindingfragment thereof or scFv specific for the B cell specific cell surfacemolecule is specific for CD19. In some alternatives, the antibody orbinding fragment thereof or scFv specific for the B cell specific cellsurface molecule comprises an amino sequence set forth in SEQ ID NO: 11and is encoded by a nucleic acid sequence set forth in SEQ ID NO: 12. Insome alternatives, the antibody or binding fragment thereof or scFvspecific for the B cell specific cell surface molecule is specific forCD20. In some alternatives, the antibody or binding fragment thereof orscFv specific for the B cell specific cell surface molecule comprises anamino sequence set forth in SEQ ID NO: 13 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 14. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for L1CAM. In some alternatives, theantibody or binding fragment thereof or scFv specific for a cell surfacetumor specific molecule is specific for a CE7 epitope on L1CAM. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 15 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 16. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for ROR1. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 17 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 18. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EGFR 806. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 19 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 20. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for Her2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 21 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 22. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for GD2. In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 23 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 24. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (2H4). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 25 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 26. In some alternatives,the antibody or binding fragment thereof or scFv specific for a cellsurface tumor specific molecule is specific for EphA2 (4H5). In somealternatives, the antibody or binding fragment thereof or scFv comprisesan amino acid sequence set forth in SEQ ID NO: 27 and is encoded by anucleic acid sequence set forth in SEQ ID NO: 28. In some alternatives,the leader sequence comprises a Granulocyte-macrophagecolony-stimulating factor signal sequence. In some alternatives, theGranulocyte-macrophage colony-stimulating factor signal sequencecomprises an amino acid sequence set forth in SEQ ID NO: 29 and isencoded by a nucleic acid sequence set forth in SEQ ID NO: 30. In somealternatives, the leader sequence comprises an amino acid sequence setforth in SEQ ID NO: 31 and is encoded by a nucleic acid sequence setforth in SEQ ID NO: 32. In some alternatives, the marker domaincomprises Her2tG. In some alternatives, Her2tG comprises an amino acidsequence set forth in SEQ ID NO: 35 and is encoded by a nucleic acidsequence set forth in SEQ ID NO: 36. In some alternatives, the markerdomain comprises EGFRt. In some alternatives, EGFRt comprises an aminoacid sequence set forth in SEQ ID NO: 37 and is encoded by a nucleicacid sequence set forth in SEQ ID NO: 38. In some alternatives, thevector is a viral vector. In some alternatives, the vector is alentiviral vector, retroviral vector, gammaretroviral vectors or a foamyviral vector. In some alternatives, the vector is a transposon,integrase vector system, or an mRNA vector.

A Cell Comprising a First and Second Chimeric Antigen Receptor or TcR

In some alternatives, a cell comprising a first and second chimericantigen receptor or TcR is provided, wherein the first chimeric antigenreceptor is specific for a ligand on a B cell, which promotes the invivo expansion and activation of an effector cell and, wherein thesecond chimeric antigen receptor or TcR is specific for a ligand on atumor. In some alternatives, the ligand on a B cell is CD1d, CD5, CD19,CD20, CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 RalphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45,CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5,LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1qR1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80,B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4,DEP-1/CD148, or EMMPRIN/CD147. In some alternatives, the ligand on thetumor is a cancer antigen. In some alternatives, the cancer antigen isEGFR, HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2,GD2, neoantigens, Var2, glypican-2 (GPC2), HPV antigens,alphafetoprotein, carcinoembryonic antigen, CA-125, MUC-1, epithelialtumor antigen, abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4,MAGE-C2, PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274,CPSF, cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the first chimeric antigenreceptor and/or the second chimeric antigen receptor or TcR areinducibly expressed in said cell. In some alternatives, expression ofthe first chimeric antigen receptor and/or the second chimeric antigenreceptor or TcR is under the control of a regulatory element. In somealternatives, the first chimeric antigen receptor comprises an antibodyor binding fragment thereof or scFv, a receptor ligand or mutantthereof, peptide, and/or polypeptide affinity molecule or bindingpartner. In some alternatives, the second chimeric antigen receptor orTcR comprises an antibody or binding fragment thereof or scFv, areceptor ligand or mutant thereof, peptide, and/or polypeptide affinitymolecule or binding partner. In some alternatives, a first markerprotein is co-expressed with the first chimeric antigen receptor and asecond marker protein is co-expressed with the second chimeric antigenreceptor or TcR. In some alternatives, the first marker proteinco-expressed with the first chimeric antigen receptor is EGFRt and thesecond marker protein co-expressed with the second chimeric antigenreceptor or TcR is Her2tg or first marker protein co-expressed with thefirst chimeric antigen receptor is Her2tg and the second marker proteinco-expressed with the second chimeric antigen receptor or TcR is EGFRt.In some alternatives, the cell further comprises a nucleic acid encodinga suicide gene system. In some alternatives, the suicide gene system isa Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir (GCV)suicide gene system or an inducible Caspase suicide gene system. In somealternatives, the cell expresses a soluble protein for therapy. In somealternatives, the soluble protein is a homeostatic cytokine, wherein thehomeostatic cytokine is IL2, IL7, IL12 or IL15. In some alternatives,the cell is a CD8+ T cytotoxic lymphocyte cell selected from the groupconsisting of naïve CD8+ T-cells, CD8+ memory T-cells, central memoryCD8+ T-cells, regulatory CD8+ T-cells, IPS derived CD8+ T-cells,effector memory CD8+ T-cells and bulk CD8+ T-cells. In somealternatives, the cell is a CD4+ T helper lymphocyte cell that isselected from the group consisting of naïve CD4+ T-cells, CD4+ memoryT-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells, IPSderived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the first chimeric antigen receptor isspecific for a ligand on a B cell, wherein the ligand on the B cell isCD19, and wherein the second chimeric antigen receptor is specific forL1CAM, and wherein the chimeric antigen receptors further comprises a4-1 BB and CD3-zeta signaling domain. In some alternatives, the firstchimeric antigen receptor is specific for a ligand on a B cell, whereinthe ligand on the B cell is CD19, and wherein the second chimericantigen receptor is specific for ROR1, and wherein the chimeric antigenreceptors further comprises a 4-1 BB and CD3-zeta signaling domain.

A Cell Comprising a Bi-Specific Chimeric Antigen Receptor

In some alternatives, a cell comprising a bi-specific chimeric antigenreceptor is provided, wherein the bi-specific chimeric antigen receptorcomprises two binding domains, wherein a first binding domain isspecific for a ligand on a B cell, which promotes the in vivo expansionand activation of the B cell and a second binding domain, wherein thesecond binding domain is specific for a ligand on a tumor. In somealternatives, the ligand on a B cell is CD1d, CD5, CD19, CD20, CD21,CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32,CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54(ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA,B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5,BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5,ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, orEMMPRIN/CD147. In some alternatives, the ligand on the tumor is a cancerantigen. In some alternatives, the cancer antigen is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the first and secondbinding domain comprises an antibody or portion thereof, a receptorligand or mutant thereof, peptide, and/or polypeptide affinity moleculeor binding partner. In some alternatives, the cell further comprises anucleic acid encoding a suicide gene system. In some alternatives, thesuicide gene system is a Herpes Simplex Virus Thymidine Kinase(HSVTK)/Ganciclovir (GCV) suicide gene system or an inducible Caspasesuicide gene system. In some alternatives, the cell expresses a solubleprotein for therapy. In some alternatives, the soluble protein is ahomeostatic cytokine, wherein the homeostatic cytokine is IL2, IL7, IL12or IL15. In some alternatives, the cell is a CD8+ T cytotoxic lymphocytecell selected from the group consisting of naïve CD8+ T-cells, CD8+memory T-cells, central memory CD8+ T-cells, regulatory CD8+ T-cells,IPS derived CD8+ T-cells, effector memory CD8+ T-cells and bulk CD8+T-cells. In some alternatives, the cell is a CD4+T helper lymphocytecell that is selected from the group consisting of naïve CD4+ T-cells,CD4+ memory T-cells, central memory CD4+ T-cells, regulatory CD4+T-cells, IPS derived CD4+ T-cells, effector memory CD4+ T-cells and bulkCD4+ T-cells. In some alternatives, the first binding domain is specificfor a ligand on a B cell, wherein the ligand on the B cell is CD19, andwherein the second binding domain is specific for L1CAM. In somealternatives, the first binding domain is specific for a ligand on a Bcell, wherein the ligand on the B cell is CD19, and wherein the secondbinding domain is specific for ROR1.

A Method of Making a Cell Having a Chimeric Antigen Receptor

In some alternatives, a method of making a cell having a chimericantigen receptor is provided, wherein the method comprises introducinginto a cell a first nucleic acid or a first vector comprising apolynucleotide sequence encoding a first chimeric antigen receptor thatcomprises a binding domain specific for a ligand on a B cell, whichpromotes the in vivo expansion and activation of the B cell, introducinginto the cell a second nucleic acid or a second vector comprising apolynucleotide sequence encoding a second chimeric antigen receptor orTcR that comprises a binding domain specific for a ligand on a solidtumor, expanding the cell, and isolating the cell. In some alternatives,the first nucleic acid and the second nucleic acid reside on separateviral vectors. In some alternatives, the viral vectors are retroviralvectors, gammaretroviral vectors, foamy viral vector and/or lentiviralvectors. In some alternatives, the viral vectors are co-introduced intothe cell as a composition comprising the viral vectors. In somealternatives, the vectors are a transposon, integrase vector system,and/or an mRNA vector. In some alternatives, expression of the firstchimeric antigen receptor is linked to co-expression of EGFRt andexpression of the second chimeric antigen receptor is linked toco-expression of Her2tg, or wherein expression of the first chimericantigen receptor is linked to co-expression of Her2tg, and expression ofthe second chimeric antigen receptor is linked to co-expression ofEGFRt. In some alternatives, the method further comprises introducing avector comprising a sequence encoding a soluble protein into said cell.In some alternatives, the soluble protein is a homeostatic cytokine. Insome alternatives, the homeostatic cytokine is IL2, IL7, IL12 or IL15.In some alternatives, the viral vectors further comprise a nucleic acidencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the method further comprises introducing a vectorcomprising a sequence encoding a suicide gene system. In somealternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives of themethod, the method further comprises stimulating the cells. In somealternatives, cells are stimulated with interleukin-2 (IL-2) for CD8cells. In some alternatives, cells are stimulated with interleukin-7(IL-7) for CD4 cells. In some alternatives cells are stimulated withanti-CD3/CD28 beads.

A Method of Making a Cell Having a Chimeric Antigen Receptor

In some alternatives, a method of making a cell having a chimericantigen receptor is provided, wherein the method comprises co-deliveringinto a cell two vectors, wherein the first vector comprises a firstnucleic acid sequence encoding a first chimeric antigen receptor thatcomprises a binding domain specific for a ligand on a B cell, whichpromotes the in vivo expansion and activation of the B cell, and asecond vector wherein the second vector comprises a secondpolynucleotide sequence encoding a second chimeric antigen receptor orTcR that comprises a binding domain specific for a ligand on a solidtumor, expanding the cell and isolating the cell. In some alternatives,the vectors are plasmids and/or minicircle transposons. In somealternatives, the first nucleic acid and the second nucleic acid residebetween a first inverted terminal repeat gene sequence and a secondinverted terminal repeat gene sequence. In some alternatives, theinverted terminal repeat gene sequences are inverted repeats of aSleeping Beauty transposon or PiggyBac transposons. In somealternatives, the method further comprises introducing a vector encodingthe Sleeping Beauty transposase or PiggyBac transposase into the cell.In some alternatives of the method, the method further comprisesstimulating the cells. In some alternatives, cells are stimulated withinterleukin-2 (IL-2) for CD8 cells. In some alternatives, cells arestimulated with interleukin-7 (IL-7) for CD4 cells. In some alternativescells are stimulated with anti-CD3/CD28 beads.

A Method of Making a Cell Having a Bi-Specific Chimeric Antigen Receptor

In some alternatives, a method of making a cell having a chimericantigen receptor is provided, wherein the method comprises co-deliveringinto a cell two vectors, wherein the first vector comprises a firstnucleic acid sequence encoding a first chimeric antigen receptor thatcomprises a binding domain specific for a ligand on a B cell, whichpromotes the in vivo expansion and activation of the B cell, and asecond vector wherein the second vector comprises a secondpolynucleotide sequence encoding a second chimeric antigen receptor orTcR that comprises a binding domain specific for a ligand on a solidtumor, expanding the cell, and isolating the cell. In some alternatives,the vectors are plasmids and/or minicircle transposons. In somealternatives, the first nucleic acid and the second nucleic acid residebetween a first inverted terminal repeat gene sequence and a secondinverted terminal repeat gene sequence. In some alternatives, theinverted terminal repeat gene sequences are inverted repeats of aSleeping Beauty transposon or PiggyBac transposons. In somealternatives, the method further comprises introducing a vector encodingthe Sleeping Beauty transposase or PiggyBac transposase into the cell.In some alternatives of the method, the method further comprisesstimulating the cells. In some alternatives, cells are stimulated withinterleukin-2 (IL-2) for CD8 cells. In some alternatives, cells arestimulated with interleukin-7 (IL-7) for CD4 cells. In some alternativescells are stimulated with anti-CD3/CD28 beads.

A Method of Making a Cell Having a Bi-Specific Chimeric Antigen Receptor

In some alternatives, a method of making a cell having a bi-specificchimeric antigen receptor is provided, wherein the method comprisesintroducing into a cell a nucleic acid comprising a polynucleotidesequence encoding a bi-specific chimeric antigen receptor that comprisesa first binding domain specific for a ligand on a B cell, which promotesthe in vivo expansion and activation of the B cell, and a second bindingdomain specific for a ligand on a solid tumor, expanding the cells andisolating the cells. In some alternatives, the polynucleotide resides ona viral vector. In some alternatives, the viral vector is a lentiviral,retroviral vector, foamy viral vector or a gammaretroviral vector. Insome alternatives, the polynucleotide resides on a transposon, integrasevector system, and/or an mRNA vector. In some alternatives, thebi-specific chimeric antigen receptor is co-expressed with a markerprotein. In some alternatives, the marker protein is EGFRt or Her2tg. Insome alternatives, the method further comprises introducing a vectorcomprising a sequence encoding a soluble protein into said cell. In somealternatives, the soluble protein is a homeostatic cytokine. In somealternatives, the homeostatic cytokine is IL2, IL7, IL12 or IL15. Insome alternatives, the viral vector further comprises a nucleic acidencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the method further comprises introducing a vectorcomprising a sequence encoding a suicide gene system. In somealternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives of themethod, the method further comprises stimulating the cells. In somealternatives, cells are stimulated with interleukin-2 (IL-2) for CD8cells. In some alternatives, cells are stimulated with interleukin-7(IL-7) for CD4 cells. In some alternatives cells are stimulated withanti-CD3/CD28 beads.

A Method of Making a Cell Having a Bi-Specific Chimeric Antigen Receptor

In some alternatives, a method of making a cell having a bi-specificchimeric antigen receptor is provided, wherein the method comprisesintroducing into a cell a vector, wherein the vector comprises a firstnucleic acid encoding a bi-specific chimeric antigen receptor thatcomprises a first binding domain specific for a ligand on a B cell,which promotes the in vivo expansion and activation of the B cell, and asecond binding domain wherein the second binding domain comprises abinding domain specific for a ligand on a solid tumor; expanding thecell and isolating the cell. In some alternatives, the vector is aplasmid or minicircle transposon. In some alternatives, the firstnucleic acid resides between a first inverted terminal repeat genesequence and a second inverted terminal repeat gene sequence. In somealternatives, the inverted terminal repeat gene sequences are invertedrepeats of a Sleeping Beauty transposon or PiggyBac transposons. In somealternatives, the method further comprises introducing a vector encodinga Sleeping Beauty transposase or PiggyBac transposase into the cell. Insome alternatives of the method, the method further comprisesstimulating the cells. In some alternatives, cells are stimulated withinterleukin-2 (IL-2) for CD8 cells. In some alternatives, cells arestimulated with interleukin-7 (IL-7) for CD4 cells. In some alternativescells are stimulated with anti-CD3/CD28 beads.

Compositions

In some alternatives, a composition comprising any one or more of thecells of any one or more of the alternatives, is provided. In somealternatives, the cell comprises a first and second chimeric antigenreceptor or TcR, wherein the first chimeric antigen receptor is specificfor a ligand on a B cell, which promotes the in vivo expansion andactivation of an effector cell and, wherein the second chimeric antigenreceptor or TcR is specific for a ligand on a tumor. In somealternatives, the ligand on a B cell is CD1d, CD5, CD19, CD20, CD21,CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32,CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54(ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA,B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5,BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5,ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, orEMMPRIN/CD147. In some alternatives, the ligand on the tumor is a cancerantigen. In some alternatives, the cancer antigen is EGFR, HER2,Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives, the cancer antigen is L1CAM. In some alternatives, thecancer antigen is ROR1. In some alternatives, the first chimeric antigenreceptor and/or the second chimeric antigen receptor or TcR areinducibly expressed in said cell. In some alternatives, expression ofthe first chimeric antigen receptor and/or the second chimeric antigenreceptor or TcR is under the control of a regulatory element. In somealternatives, the first chimeric antigen receptor comprises an antibodyor binding fragment thereof or scFv, a receptor ligand or mutantthereof, peptide, and/or polypeptide affinity molecule or bindingpartner. In some alternatives, the second chimeric antigen receptor orTcR comprises an antibody or binding fragment thereof or scFv, areceptor ligand or mutant thereof, peptide, and/or polypeptide affinitymolecule or binding partner. In some alternatives, a first markerprotein is co-expressed with the first chimeric antigen receptor and asecond marker protein is co-expressed with the second chimeric antigenreceptor or TcR. In some alternatives, the first marker proteinco-expressed with the first chimeric antigen receptor is EGFRt and thesecond marker protein co-expressed with the second chimeric antigenreceptor or TcR is Her2tg or first marker protein co-expressed with thefirst chimeric antigen receptor is Her2tg and the second marker proteinco-expressed with the second chimeric antigen receptor or TcR is EGFRt.In some alternatives, the cell comprises a bi-specific chimeric antigenreceptor, wherein the bi-specific chimeric antigen receptor comprisestwo binding domains, wherein a first binding domain is specific for aligand on a B cell, which promotes the in vivo expansion and activationof the B cell and a second binding domain, wherein the second bindingdomain is specific for a ligand on a tumor. In some alternatives, theligand on a B cell is CD1d, CD5, CD19, CD20, CD21, CD22, CD23/Fc epsilonRII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32, CD34, CD35, CD38, CD40(TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54 (ICAM-1), CD69, CD72, CD79,CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA, B-cell receptor (BCR), IgMs, IgD,B220/CD45R, C1q R1/CD93, CD84/SLAMF5, BAFF R/TNFRSF13C, B220/CD45R,B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5, ENPP-1, HVEM/TNFRSF14,BLIMP1/PRDM1, CXCR4, DEP-1/CD148, or EMMPRIN/CD147. In somealternatives, the ligand on the tumor is a cancer antigen. In somealternatives, the cancer antigen is EGFR, HER2, Mesothelin, cancertestis antigens, L1CAM, o-acetylated GD2, GD2, neoantigens, Var2,glypican-2 (GPC2), HPV antigens, alphafetoprotein, carcinoembryonicantigen, CA-125, MUC-1, epithelial tumor antigen, abnormal products ofras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2, PRAME, SSX2, adipophilin,AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF, cyclin D1, DKK1, ENAH, EpCAM,EphA3, EZH2, FGF5, glypican-3, G250, HLA-DOB, Hepsin, ID01, IGF2B3,IL13Ralpha2, Intestinal carboxylesterase, alpha-foetoprotein,kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2, Meloe, midkine, MMP-2,MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA, RAGE-1, RGS5, RhoC,RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1, survivin, telomerase,TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In some alternatives, the cancerantigen is L1CAM. In some alternatives, the cancer antigen is ROR1. Insome alternatives, the first and second binding domain comprises anantibody or portion thereof, a receptor ligand or mutant thereof,peptide, and/or polypeptide affinity molecule or binding partner. Insome alternatives, the cell further comprises a nucleic acid encoding asuicide gene system. In some alternatives, the suicide gene system is aHerpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir (GCV) suicidegene system or an inducible Caspase suicide gene system. In somealternatives, the cell expresses a soluble protein for therapy. In somealternatives, the soluble protein is a homeostatic cytokine, wherein thehomeostatic cytokine is IL2, IL7, IL12 or IL15. In some alternatives,the cell is a CD8+ T cytotoxic lymphocyte cell selected from the groupconsisting of naïve CD8+ T-cells, CD8+ memory T-cells, central memoryCD8+ T-cells, regulatory CD8+ T-cells, IPS derived CD8+ T-cells,effector memory CD8+ T-cells and bulk CD8+ T-cells. In somealternatives, the cell is a CD4+T helper lymphocyte cell that isselected from the group consisting of naïve CD4+ T-cells, CD4+ memoryT-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells, IPSderived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the first chimeric antigen receptor isspecific for a ligand on a B cell, wherein the ligand on the B cell isCD19, and wherein the second chimeric antigen receptor is specific forL1CAM, and wherein the chimeric antigen receptors further comprises a4-1 BB and CD3-zeta signaling domain. In some alternatives, the firstchimeric antigen receptor is specific for a ligand on a B cell, whereinthe ligand on the B cell is CD19, and wherein the second chimericantigen receptor is specific for ROR1, and wherein the chimeric antigenreceptors further comprises a 4-1 BB and CD3-zeta signaling domain. Insome alternatives, the first binding domain is specific for a ligand ona B cell, wherein the ligand on the B cell is CD19, and wherein thesecond binding domain is specific for L1CAM. In some alternatives, thefirst binding domain is specific for a ligand on a B cell, wherein theligand on the B cell is CD19, and wherein the second binding domain isspecific for ROR1.

A Method of Treating, Ameliorating, or Inhibiting a Non-B Cell RelatedDisease in a Subject

In some alternatives, a method of treating, ameliorating, or inhibitinga non-B cell related disease in a subject is provided, wherein themethod comprises identifying a subject that does not have a B-cellrelated disease for therapy, introducing, providing, or administeringany one or more of the cells of any one or more of the alternativesherein or the cells made by any one or more of the methods of any one ormore of the alternatives herein or the composition of any one or more ofthe alternatives herein into a subject for therapy. In somealternatives, the composition comprises any one or more of the cells ofany one of more of the alternatives herein or the cells made by any oneor more of the methods of any one of the alternatives described herein.In some alternatives, the composition comprises CD8+ T cytotoxiclymphocyte cells and/or CD4+ T helper lymphocyte cells, wherein the CD8+T cytotoxic lymphocyte cells are selected from the group consisting ofnaïve CD8+ T-cells, CD8+ memory T-cells, central memory CD8+ T-cells,regulatory CD8+ T-cells, IPS derived CD8+ T-cells, effector memory CD8+T-cells and bulk CD8+ T-cells and, wherein the CD4+T helper lymphocytecells are selected from the group consisting of naïve CD4+ T-cells, CD4+memory T-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells,IPS derived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the composition has a ratio of CD4+ Thelper lymphocyte cells to CD8+ T lymphocytes of 1:10 to 10:1. In somealternatives, the ratio of CD4+ T helper lymphocyte cells to CD8+ Tlymphocytes is 1:1. In some alternatives, the subject does not have aB-cell related disease. In some alternatives, the subject does not haveB-cell lymphoma, Hodgkin's lymphomas, non-Hodgkins lymphomas, Diffuselarge B cell lymphoma, Follicular lymphoma, marginal zone lymphoma,Mucosa-Associated Lymphatic Tissue lymphoma, small lymphocytic lymphoma,chronic lymphocytic leukemia, mantle cell lymphoma, Burkitt lymphoma,primary mediastinal (thymic) large B cell lymphoma, Lymphoplasmacyticlymphoma, Waldenstrom macroglobulinermia, Nodal marginal zone B celllymphoa, splenic marginal zone lymphoma, intravascular large B celllymphoma, Intravascular large B-cell lymphoma, Primary effusionlymphoma, Lymphomatoid granulomatosis, T cell/histiocyte-rich largeB-cell lymphoma, Primary central nervous system lymphoma, Primarycutaneous diffuse large B-cell lymphoma (leg type), EBV positive diffuselarge B-cell lymphoma of the elderly, Diffuse large B-cell lymphomaassociated with inflammation, Intravascular large B-cell lymphoma,ALK-positive large B-cell lymphoma, ALK-positive large B-cell lymphoma,Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associatedmulticentric Castleman's disease, B-cell lymphoma, unclassifiable withfeatures intermediate between diffuse large B-cell lymphoma and Burkittlymphoma, B-cell lymphoma, unclassifiable with features intermediatebetween diffuse large B-cell lymphoma and classical Hodgkin lymphoma, ornodular lymphocyte predominant Hodgkin's lymphoma. In some alternatives,the disease is a cancer. In some alternatives, the disease is aninfection, wherein the infection is a bacterial or viral infection. Insome alternatives, the cancer is a solid tumor. In some alternatives,the solid tumor is selected from the group consisting of a breastcancer, brain cancer, lung cancer, liver cancer, stomach cancer, spleencancer, colon cancer, renal cancer, pancreatic cancer, prostate cancer,uterine cancer, skin cancer, head cancer, neck cancer, sarcomas,neuroblastomas and ovarian cancer. In some alternatives, the subject hasrefractory and relapsed neuroblastoma. In some alternatives, the subjectis identified or selected to receive a non-B cell related diseasetherapy, anti-cancer therapy, anti-infection therapy, antibacterialtherapy, anti-viral therapy, or anti-tumoral therapy. In somealternatives, the method further comprises measuring or evaluating aninhibition of said non-B cell related disease, cancer, infection,bacterial infection, viral infection, or tumor. In some alternatives,the method further comprises introducing, providing, or administering tosaid subject an additional therapeutic agent, such as a chemotherapeuticagent, an antiviral agent, or an antibacterial agent or an adjuncttherapy such as radiation therapy and/or surgery before, during, orafter introducing, providing, or administering any one or more of thecells of any one of the alternatives described herein or the cells madeby any one or more of the methods of any one of the alternativesdescribed herein or the composition of any one of the alternativesdescribed herein into the subject for therapy. In some alternatives, thecomposition comprises any one or more of the cells of any one of thealternatives described herein or the cells made by any one or more ofthe methods of any one of the alternatives described herein. In somealternatives, the composition comprises CD8+ T cytotoxic lymphocytecells and/or CD4+ T helper lymphocyte cells, wherein the CD8+ Tcytotoxic lymphocyte cells are selected from the group consisting ofnaïve CD8+ T-cells, CD8+ memory T-cells, central memory CD8+ T-cells,regulatory CD8+ T-cells, IPS derived CD8+ T-cells, effector memory CD8+T-cells and bulk CD8+ T-cells and, wherein the CD4+T helper lymphocytecells are selected from the group consisting of naïve CD4+ T-cells, CD4+memory T-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells,IPS derived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the composition has a ratio of CD4+ Thelper lymphocyte cells to CD8+ T lymphocytes of 1:10 to 10:1. In somealternatives, the ratio of CD4+ T helper lymphocyte cells to CD8+ Tlymphocytes is 1:1. In some alternatives, the composition comprises anyone or more of the cells of any one or more of the alternatives. In somealternatives, the cell comprises a first and second chimeric antigenreceptor or TcR, wherein the first chimeric antigen receptor is specificfor a ligand on a B cell, which promotes the in vivo expansion andactivation of an effector cell and, wherein the second chimeric antigenreceptor or TcR is specific for a ligand on a tumor. In somealternatives, the ligand on a B cell is CD1d, CD5, CD19, CD20, CD21,CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7, CD32,CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54(ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA,B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5,BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5,ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, orEMMPRIN/CD147. In some alternatives of the cell, the ligand on the tumoris a cancer antigen. In some alternatives, the cancer antigen is EGFR,HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives of the cell, the cancer antigen is L1CAM. In somealternatives, the cancer antigen is ROR1. In some alternatives of thecell, the first chimeric antigen receptor and/or the second chimericantigen receptor or TcR are inducibly expressed in said cell. In somealternatives of the cell, expression of the first chimeric antigenreceptor and/or the second chimeric antigen receptor or TcR is under thecontrol of a regulatory element. In some alternatives of the cell, thefirst chimeric antigen receptor comprises an antibody or bindingfragment thereof or scFv, a receptor ligand or mutant thereof, peptide,and/or polypeptide affinity molecule or binding partner. In somealternatives of the cell, the second chimeric antigen receptor or TcRcomprises an antibody or binding fragment thereof or scFv, a receptorligand or mutant thereof, peptide, and/or polypeptide affinity moleculeor binding partner. In some alternatives of the cell, a first markerprotein is co-expressed with the first chimeric antigen receptor and asecond marker protein is co-expressed with the second chimeric antigenreceptor or TcR. In some alternatives, the first marker proteinco-expressed with the first chimeric antigen receptor is EGFRt and thesecond marker protein co-expressed with the second chimeric antigenreceptor or TcR is Her2tg or first marker protein co-expressed with thefirst chimeric antigen receptor is Her2tg and the second marker proteinco-expressed with the second chimeric antigen receptor or TcR is EGFRt.In some alternatives of the cell, the cell comprises a bi-specificchimeric antigen receptor, wherein the bi-specific chimeric antigenreceptor comprises two binding domains, wherein a first binding domainis specific for a ligand on a B cell, which promotes the in vivoexpansion and activation of the B cell and a second binding domain,wherein the second binding domain is specific for a ligand on a tumor.In some alternatives, the ligand on a B cell is CD1d, CD5, CD19, CD20,CD21, CD22, CD23/Fc epsilon RII, CD24, CD25/IL-2 R alphaCD27/TNFRSF7,CD32, CD34, CD35, CD38, CD40 (TNFRSF5), CD44, CD45, CD45.1, CD45.2, CD54(ICAM-1), CD69, CD72, CD79, CD80, CD84/SLAMF5, LFA-1, CALLA, BCMA,B-cell receptor (BCR), IgMs, IgD, B220/CD45R, C1q R1/CD93, CD84/SLAMF5,BAFF R/TNFRSF13C, B220/CD45R, B7-1/CD80, B7-2/CD86, TNFSF7, TNFRSF5,ENPP-1, HVEM/TNFRSF14, BLIMP1/PRDM1, CXCR4, DEP-1/CD148, orEMMPRIN/CD147. In some alternatives of the cell, the ligand on the tumoris a cancer antigen. In some alternatives, the cancer antigen is EGFR,HER2, Mesothelin, cancer testis antigens, L1CAM, o-acetylated GD2, GD2,neoantigens, Var2, glypican-2 (GPC2), HPV antigens, alphafetoprotein,carcinoembryonic antigen, CA-125, MUC-1, epithelial tumor antigen,abnormal products of ras or p53, EphA2, MAGE-A3, MAGE-A4, MAGE-C2,PRAME, SSX2, adipophilin, AIM2, ALDH1A1, BCLX, EpCAM, CS274, CPSF,cyclin D1, DKK1, ENAH, EpCAM, EphA3, EZH2, FGF5, glypican-3, G250,HLA-DOB, Hepsin, ID01, IGF2B3, IL13Ralpha2, Intestinal carboxylesterase,alpha-foetoprotein, kallikrein4, KIF20A, Lengsin, M-CSF, MCSP, mdm-2,Meloe, midkine, MMP-2, MMP-7, MUC1, MUC5AC, p53, PAX5, PBF, PRAME, PSMA,RAGE-1, RGS5, RhoC, RNF43, RUF43, FU2AS, secernin 1, SOX10, STEAP1,survivin, telomerase, TPBG, VEGF, WT1, NY-ESO-1 or ROR1. In somealternatives of the cell, the cancer antigen is L1CAM. In somealternatives, the cancer antigen is ROR1. In some alternatives, thefirst and second binding domain comprises an antibody or portionthereof, a receptor ligand or mutant thereof, peptide, and/orpolypeptide affinity molecule or binding partner. In some alternatives,the cell further comprises a nucleic acid encoding a suicide genesystem. In some alternatives of the cell, the suicide gene system is aHerpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir (GCV) suicidegene system or an inducible Caspase suicide gene system. In somealternatives, the cell expresses a soluble protein for therapy. In somealternatives of the cell, the soluble protein is a homeostatic cytokine,wherein the homeostatic cytokine is IL2, IL7, IL12 or IL15. In somealternatives, the cell is a CD8+ T cytotoxic lymphocyte cell selectedfrom the group consisting of naïve CD8+ T-cells, CD8+ memory T-cells,central memory CD8+ T-cells, regulatory CD8+ T-cells, IPS derived CD8+T-cells, effector memory CD8+ T-cells and bulk CD8+ T-cells. In somealternatives, the cell is a CD4+T helper lymphocyte cell that isselected from the group consisting of naïve CD4+ T-cells, CD4+ memoryT-cells, central memory CD4+ T-cells, regulatory CD4+ T-cells, IPSderived CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+T-cells. In some alternatives, the first chimeric antigen receptor isspecific for a ligand on a B cell, wherein the ligand on the B cell isCD19, and wherein the second chimeric antigen receptor is specific forL1 CAM, and wherein the chimeric antigen receptors further comprises a4-1 BB and CD3-zeta signaling domain. In some alternatives of the cell,the first chimeric antigen receptor is specific for a ligand on a Bcell, wherein the ligand on the B cell is CD19, and wherein the secondchimeric antigen receptor is specific for ROR1, and wherein the chimericantigen receptors further comprises a 4-1 BB and CD3-zeta signalingdomain. In some alternatives of the cell, the first binding domain isspecific for a ligand on a B cell, wherein the ligand on the B cell isCD19, and wherein the second binding domain is specific for L1CAM. Insome alternatives of the cell, the first binding domain is specific fora ligand on a B cell, wherein the ligand on the B cell is CD19, andwherein the second binding domain is specific for ROR1. In somealternatives, the method of making a cell having a chimeric antigenreceptor comprises introducing into a cell a first nucleic acid or afirst vector comprising a polynucleotide sequence encoding a firstchimeric antigen receptor that comprises a binding domain specific for aligand on a B cell, which promotes the in vivo expansion and activationof the B cell, introducing into the cell a second nucleic acid or asecond vector comprising a polynucleotide sequence encoding a secondchimeric antigen receptor or TcR that comprises a binding domainspecific for a ligand on a solid tumor, expanding the cell, andisolating the cell. In some alternatives, the first nucleic acid and thesecond nucleic acid reside on separate viral vectors. In somealternatives, the viral vectors are retroviral vectors, gammaretroviralvectors, foamy viral vector and/or lentiviral vectors. In somealternatives, the viral vectors are co-introduced into the cell as acomposition comprising the viral vectors. In some alternatives, thevectors are a transposon, integrase vector system, and/or an mRNAvector. In some alternatives, expression of the first chimeric antigenreceptor is linked to co-expression of EGFRt and expression of thesecond chimeric antigen receptor is linked to co-expression of Her2tg,or wherein expression of the first chimeric antigen receptor is linkedto co-expression of Her2tg, and expression of the second chimericantigen receptor is linked to co-expression of EGFRt. In somealternatives, the method further comprises introducing a vectorcomprising a sequence encoding a soluble protein into said cell. In somealternatives, the soluble protein is a homeostatic cytokine. In somealternatives, the homeostatic cytokine is IL2, IL7, IL12 or IL15. Insome alternatives, the viral vectors further comprise a nucleic acidencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the method further comprises introducing a vectorcomprising a sequence encoding a suicide gene system. In somealternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives the methodof making a cell having a chimeric antigen receptor comprisesco-delivering into a cell two vectors, wherein the first vectorcomprises a first nucleic acid sequence encoding a first chimericantigen receptor that comprises a binding domain specific for a ligandon a B cell, which promotes the in vivo expansion and activation of theB cell, and a second vector wherein the second vector comprises a secondpolynucleotide sequence encoding a second chimeric antigen receptor orTcR that comprises a binding domain specific for a ligand on a solidtumor, expanding the cell and isolating the cell. In some alternatives,the vectors are plasmids and/or minicircle transposons. In somealternatives, the first nucleic acid and the second nucleic acid residebetween a first inverted terminal repeat gene sequence and a secondinverted terminal repeat gene sequence. In some alternatives, theinverted terminal repeat gene sequences are inverted repeats of aSleeping Beauty transposon or PiggyBac transposons. In somealternatives, the method further comprises introducing a vector encodingthe Sleeping Beauty transposase or PiggyBac transposase into the cell.In some alternatives, the method of making a cell having a chimericantigen receptor comprises co-delivering into a cell two vectors,wherein the first vector comprises a first nucleic acid sequenceencoding a first chimeric antigen receptor that comprises a bindingdomain specific for a ligand on a B cell, which promotes the in vivoexpansion and activation of the B cell, and a second vector wherein thesecond vector comprises a second polynucleotide sequence encoding asecond chimeric antigen receptor or TcR that comprises a binding domainspecific for a ligand on a solid tumor, expanding the cell, andisolating the cell. In some alternatives, the vectors are plasmidsand/or minicircle transposons. In some alternatives, the first nucleicacid and the second nucleic acid reside between a first invertedterminal repeat gene sequence and a second inverted terminal repeat genesequence. In some alternatives, the inverted terminal repeat genesequences are inverted repeats of a Sleeping Beauty transposon orPiggyBac transposons. In some alternatives, the method further comprisesintroducing a vector encoding the Sleeping Beauty transposase orPiggyBac transposase into the cell. In some alternatives, the method ofmaking a cell having a bi-specific chimeric antigen receptor comprisesintroducing into a cell a nucleic acid comprising a polynucleotidesequence encoding a bi-specific chimeric antigen receptor that comprisesa first binding domain specific for a ligand on a B cell, which promotesthe in vivo expansion and activation of the B cell, and a second bindingdomain specific for a ligand on a solid tumor, expanding the cells andisolating the cells. In some alternatives, the polynucleotide resides ona viral vector. In some alternatives, the viral vector is a lentiviral,retroviral vector, foamy viral vector or a gammaretroviral vector. Insome alternatives, the polynucleotide resides on a transposon, integrasevector system, and/or an mRNA vector. In some alternatives, thebi-specific chimeric antigen receptor is co-expressed with a markerprotein. In some alternatives, the marker protein is EGFRt or Her2tg. Insome alternatives, the method further comprises introducing a vectorcomprising a sequence encoding a soluble protein into said cell. In somealternatives, the soluble protein is a homeostatic cytokine. In somealternatives, the homeostatic cytokine is IL2, IL7, IL12 or IL15. Insome alternatives, the viral vector further comprises a nucleic acidencoding a suicide gene system. In some alternatives, the suicide genesystem is a Herpes Simplex Virus Thymidine Kinase (HSVTK)/Ganciclovir(GCV) suicide gene system or an inducible Caspase suicide gene system.In some alternatives, the method further comprises introducing a vectorcomprising a sequence encoding a suicide gene system. In somealternatives, the suicide gene system is a Herpes Simplex VirusThymidine Kinase (HSVTK)/Ganciclovir (GCV) suicide gene system or aninducible Caspase suicide gene system. In some alternatives, the methodof making a cell having a bi-specific chimeric antigen receptorcomprises introducing into a cell a vector, wherein the vector comprisesa first nucleic acid encoding a bi-specific chimeric antigen receptorthat comprises a first binding domain specific for a ligand on a B cell,which promotes the in vivo expansion and activation of the B cell, and asecond binding domain wherein the second binding domain comprises abinding domain specific for a ligand on a solid tumor; expanding thecell and isolating the cell. In some alternatives, the vector is aplasmid or minicircle transposon. In some alternatives, the firstnucleic acid resides between a first inverted terminal repeat genesequence and a second inverted terminal repeat gene sequence. In somealternatives, the inverted terminal repeat gene sequences are invertedrepeats of a Sleeping Beauty transposon or PiggyBac transposons. In somealternatives, the method further comprises introducing a vector encodinga Sleeping Beauty transposase or PiggyBac transposase into the cell.

What is claimed is:
 1. A method of treating, ameliorating, or inhibitinga non-B cell cancer in a human subject, wherein the cancer comprises anEGFR+ cell, the method comprising administering to the subject a human Tcell comprising: a first chimeric antigen receptor (CAR) capable ofspecifically binding to CD19, wherein the first CAR comprises a firstligand binding domain encoded by a sequence having at least 95% identitywith the nucleotide sequence of SEQ ID NO: 12; and a second CAR capableof specifically binding to EGFR, wherein the second CAR comprises asecond ligand binding domain encoded by a sequence having at least 95%identity with the nucleotide sequence of SEQ ID NO: 20, and wherein thefirst CAR is different from the second CAR and wherein the first CAR andsecond CAR each comprises an IgG4 hinge spacer domain, a CD28transmembrane domain, an intracellular signaling domain, and a cellsurface selectable marker.
 2. The method of claim 1, wherein the firstligand binding domain comprises the amino acid sequence of SEQ ID NO:11.3. The method of claim 1, wherein the second ligand binding domaincomprises the amino acid sequence of SEQ ID NO:19.
 4. The method ofclaim 1, wherein the first CAR and the second CAR each comprise anintracellular signalling domain comprising a 4-1BB domain and a CD3 zetadomain.
 5. The method of claim 1, wherein the cell comprises a firstpolynucleotide encoding the first CAR and a first cell surfaceselectable marker.
 6. The method of claim 5, wherein the cell comprisesa second polynucleotide encoding the second CAR and a second cellsurface selectable marker.
 7. The method of claim 6, wherein the firstor the second cell surface selectable marker is selected from atruncated HER2 (Her2tG) polypeptide or a truncated EGFR (EGFRt)polypeptide.
 8. The method of claim 6, further comprising administeringan antibody or antigen binding fragment thereof capable of binding tothe first or the second cell surface selectable marker.
 9. The method ofclaim 8, wherein the antibody or antigen binding fragment thereof isselected from cetuximab (ERBITUX) or trastuzumab (HERCEPTIN).
 10. Themethod of claim 1, wherein the cell is a CD4+ T cell or a CD8+ T cell.11. The method of claim 10, wherein the cell is a CD4+ helper Tlymphocyte selected from the group consisting of a naïve CD4+ T cell, acentral memory CD4+ T cell, an effector memory CD4+ T cell, and a bulkCD4+ T cell.
 12. The method of claim 10, wherein the cell is a CD8+cytotoxic T lymphocyte cell selected from the group consisting of anaïve CD8+ T cell, a central memory CD8+ T cell, an effector memory CD8+T cell, and a bulk CD8+ T cell.
 13. The method of claim 1, wherein thecell comprises a CD4+ T cell, and is administered in combination with aCD8+ T cell comprising the first CAR and the second CAR.
 14. The methodof claim 1, wherein the non-B cell cancer comprises a solid tumor. 15.The method of claim 1, wherein the non-B cell cancer is a breast cancer,a brain cancer, a lung cancer, a liver cancer, a stomach cancer, aspleen cancer, a colon cancer, a renal cancer, a pancreatic cancer, aprostate cancer, a uterine cancer, a skin cancer, a head cancer, a neckcancer, a sarcoma, an ovarian cancer, a neuroblastoma, a refractoryneuroblastoma, or a relapsed neuroblastoma.
 16. The method of claim 1,wherein the subject is a pediatric subject.